method for particle imaging using a particle analysis system configured for geometric hydro-focusing

专利摘要:
"FLOW CELL, WRAP FLUID AND AUTOMATIC FOCUS SYSTEMS AND METHODS FOR PARTICULATE ANALYSIS IN URINE SAMPLES" This disclosure relates to apparatus, systems, compositions and methods for analyzing a sample containing particles. An imaging system or particle analyzer may include a flow cell through which a urine sample containing particles is induced to flow, and a high resolution optical imaging device that captures images for image analysis. A contrast pattern for autofocus is provided in the flow cell. The image processor assesses the accuracy of focus from the contrast of pixel data. A positioning motor moves the microscope and / or flow cell along the optical geometric axis for automatic focusing on the contrast pattern target. The processor then moves the microscope and the flow cell a known distance between the contrast pattern and the sample stream, thus focusing on the sample stream. Cell or particle images are collected from that position until autofocus is reset, periodically, by input signal, or when changes in temperature or inaccuracy of focus are detected in the image data.
公开号:BR112015020255B1
申请号:R112015020255-1
申请日:2014-03-18
公开日:2021-02-23
发明作者:Bart J. Wanders；Eric Chapoulaud；Brett Jordan
申请人:Iris International, Inc；
IPC主号:

专利说明:

CROSS REFERENCES TO RELATED ORDERS
[0001] This application is a non-provisional application and claims priority benefit from US provisional patent application No. 61 / 799,014, filed on March 15, 2013, the content of which is incorporated herein by reference. This application is also related to US patent application No. 14 / 216,562 and international patent application No. (contrast agent), both filed on March 17, 2014. The content of each of these deposits is hereby incorporated, by way of of reference. BACKGROUND OF THE INVENTION
[0002] This disclosure refers to the field of systems, analyzers, compositions and methods for particle analysis, including imaging of particles in fluid samples, such as urine samples, with the use of fully or partially automated devices to discriminate and quantify particles in the sample. The present disclosure also relates to an intracellular organelle and / or particle alignment liquid (PIOAL - particle and / or intracellular organelle alignment liquid) useful for analyzing particles in an individual's urine sample, methods for producing the liquid, and methods to use the liquid to detect and analyze particles in the urine. Compositions and methods useful for conducting image-based urine sample analysis are also disclosed. The compositions and methods of the present disclosure are also useful for detecting, counting and characterizing particles in the urine, such particles may comprise, for example, fat cells, calculations, crystals or bodies for counting, categorizing, sub-categorizing, characterizing and / or analyzing image-based particles and in morphological form.
[0003] Urinary sediment analysis is one of the most commonly performed diagnostic tests to provide an overview of a patient's health status. A urine sample can be obtained from a patient's body and stored in a test tube for further processing and analysis. The appearance of certain characteristic sediments also called elements formed in a urine sample can be clinically significant and / or indicative of pathological conditions in an individual.
[0004] In general, abnormal urine may contain a variety of elements formed, such as blood cells, epithelial cells, crystals, stones or microorganisms. For example, urine samples may contain cells of hematological origin. Red blood cells or red blood cells (RBCs) may be present in the urine as a result of bleeding (hematuria) at any point in the urogenital system from the glomerulus to the urethra. The presence of leukocytes or WBCs, neutrophils, eosinophils may be of clinical importance. Glowing cells are a type of neutrophil seen in hypotonic urine of specific gravity of 1.010 or less. The presence of lymphocytes has been used as an early indicator of renal rejection after transplantation. Eosinophils are associated with drug-induced interstitial nephritis, mucus filaments that originate from the kidney or lower urinary tract may be present.
[0005] Urine samples may also contain cells of epithelial origin. Some renal epithelial cells, also called renal tubular cells, can be found in the urine of healthy individuals due to normal exfoliation. However, the presence of excessive renal tubular cells is indicative of active kidney disease or tubular injury. Among the different types of epithelial cells found in urine (renal, transitional or urothelial, and squamous), renal epithelial cells are the most clinically significant. They are associated with acute tubular necrosis, viral infections (such as cytomegalovirus), and kidney transplant rejection. Its presence is also increased with fever, chemical toxins, drugs (specifically aspirin), heavy metals, inflammation, infection and neoplasms. In addition, the presence of inclusion bodies can be seen in viral infections, such as rubella and herpes, and specifically with cytomegalovirus.
[0006] Urine may also contain transitional epithelial cells or urothelial cells. Transitional epithelial cells are the multilayer of epithelial cells that line the urinary tract from the renal pelvis to the distal part of the male urethra and to the base of the bladder (trigone) in females. They can be difficult to distinguish from renal epithelial cells, but they are usually larger and more spherical. Some transitional cells are present in the urine of healthy individuals. The increased numbers are associated with the infection. Large nodules or leaves of these cells can be seen with transitional cell carcinoma.
[0007] Urine may also contain squamous epithelial cells. Squamous epithelial cells line the urethra in females and the distal portion of the male urethra. The presence of large numbers of squamous cells in female individuals generally indicates vaginal contamination.
[0008] Urine may also contain indicator cells. Indicator cells are another type of squamous cell of vaginal origin, they can be seen contaminating urinary sediment. This squamous epithelial cell is covered or encrusted with a bacterium, Gardnerella vaginalis, the presence of which is indicative of bacterial vaginitis.
[0009] Urine may also contain oval fat bodies, renal tubular fat or renal tubular fat bodies. These bodies are renal epithelial cells (or macrophages) that have been filled with droplets of fat or lipid. The fat can be neutral fat (triglyceride) or cholesterol; have the same clinical importance. The presence of oval fat bodies in urine is indicative of disease abnormality and should not be disregarded. They are often seen with fatty stones and fat droplets in the urine sediment and are associated with massive proteinuria, as seen in nephrotic syndrome.
[00010] Urine may also contain microorganisms, such as bacteria and yeast. Normally, urine is sterile or free of bacteria. However, certain bacteria are typically seen in urine at an alkaline pH. Findings of associated sediment may include the presence of WBCs (neutrophils) and stones (WBC, cellular, granular or bacterial). Although infections are most often due to gram-negative rods of enteric origin, infectious organisms can also be gram-positive cocci.
[00011] In addition, yeast can be seen in urine, specifically as a result of vaginal contamination, such as contamination from female patients with yeast infections. It is also associated with diabetes mellitus due to the presence of urinary glucose. Yeast is a common contaminant, from the skin and the environment, and infections are a problem in debilitated, immunosuppressed or immunosuppressed patients.
[00012] Traditionally, urine sediment analysis has been performed by visual inspection using a microscope in a general laboratory. With these approaches, a urine sample is first subjected to centrifugal separation and enriched. The sediments thus obtained are, in some cases, stained and then loaded on a microscope slide, and are subjected to determination and manual counting under the microscope.
[00013] Sample preparation steps may include concentrating urine sediment by centrifugation and sometimes applying a microscopic stain to accentuate the contrast, for example, between sediment types, such as RBCs, WBCs and epithelial cells . In a manual count, the technician visualizes the exam slide fresh, distinguishing between the types of cells visible or by their appearance using professional judgment, and manually counts the number of urine sediments of different types observed within an area predetermined.
[00014] The use of urine analysis systems is generally described in US Patent No. 4,473,530 by Villa-Real, entitled "Compact Sanitary Urinalysis Unit"; US patent No. 3,894,845, entitled "Urine Collection and Analysis Device" and US patent No. 3,988,209, entitled "Microorganism Analysis Device", both by McDonald; US patent No. 4,973,450 by Schluter, entitled "Device for Urinalysis"; US Patent No. 4,622,298 to Mansour, et al., entitled "Detection and Quantitation of Microorganisms, Leukocytes and Squamous Epithelial Cells in Urine"; and US patent No. 5,132,232 by Parker, entitled "Method and Apparatus for Preparation of Liquids for Examination". US patent No. 4,612,614 by Deindoerfer, et al., Entitled "Method of Analyzing Particles in a Fluid Sample", reports a method for analyzing urinary sediments by distributing a sample over an extended area, such as a microscope slide or a flow cell. Deindoerfer, et al. reports the use of a plurality of optical still images from the sample that are converted into electronic images that are displayed in a matrix ordered by classes of visually discernible characteristics. However, many of these previously developed urine analysis systems generally lack the yield rate, accuracy and / or general applicability required for adaptation across all targets / individuals for all intended purposes.
[00015] For the automation of urine sediment determination, an automated flow microscope can be used (for example, flow automatic microscope - iQ®200, Iris Diagnostics). With these types of devices, a urine sample is introduced into a flat type flow cell without preconcentration and images are taken and stored, while the sample is flowing through the flow cell. However, urinary sediments are diverse in their morphology and many sediments are being damaged and, therefore, the determination of images taken with good accuracy is difficult to achieve. It is particularly difficult to determine sediments with small size, such as erythrocytes (specifically dysmorphic erythrocytes), bacteria and crystals with good accuracy without external validation from the user.
[00016] Although currently known particle analysis systems and methods, along with related medical diagnostic techniques, can provide real benefits for doctors, clinicians and patients, further improvements are still desirable. The embodiments of the present invention provide solutions to at least some of these existing needs. BRIEF SUMMARY OF THE INVENTION
[00017] The present disclosure relates to analyzer, systems, compositions and methods for analyzing a prepared sample that contains particles, such as a urine sample. In some ways, the system includes an analyzer that can be an isual analyzer. In some ways, the analyzer contains a visual analyzer (for example, imaging) and a processor. In one aspect, this disclosure refers to an automated particle imaging system in which a urine sample containing particles of interest is induced to flow through a flow cell that has a viewing port through which an imaging device high-resolution optical captures an image. In some respects, the high-resolution optical imaging device comprises a camera, such as a digital camera. In one aspect, the high-resolution optical imaging device comprises an objective lens.
[00018] The flow cell is coupled to a sample fluid source, such as a prepared sample, and to a source of intracellular organelle and / or particle alignment liquid (PIOAL). The system allows the capture of focused images of particles in a flowing sample. In some embodiments, the images can be used in automated high-throughput processes to categorize and sub-categorize particles.
[00019] In one embodiment, the analyzer is configured to detect particles in the sample that have one or more visual distinctions and determine the exact concentration or particle count of different categories or subcategories of particles in the sample.
[00020] Samples can be obtained using any conventional method, for example, a urine sample collection. The sample may be from an individual considered healthy, for example, a sample collected as part of a control group or routine physical examination. The sample may also be from an individual who has, is at risk, or is suspected of having a disorder. The disorder can be the result of an illness, a genetic abnormality, an infection, an injury, or unknown causes. Alternatively or in addition, the methods may be useful for monitoring an individual during the course of treatment for a disorder. Where there are signs of a lack of responsiveness to treatment, a doctor may choose an alternative or adjunctive treatment. Depending on the condition of the individual and the particular disorder, if any, samples can be collected when (or twice, three times, etc.) daily, weekly, monthly or annually. The sample can be prepared by contacting a particle contrast agent composition as described in the present invention.
[00021] The particles may vary depending on the sample. The particles can be biological cells, for example, epithelial cells or blood cells. In some embodiments, the particles can be an infectious agent, for example, a bacterium, protist, protozoan, fungus or parasite.
[00022] In one aspect, the modalities of the present invention encompass methods for particle imaging with the use of a particle analysis system. In some cases, the system is configured for geometric hydro-focusing. The particles can be included within a sample of body fluid. Exemplary methods include injecting a wrap fluid along a flow path of a particle analyzer flow cell, injecting the body fluid sample from a sample fluid injection tube at a flow rate in the wrap fluid circulating within the flow cell in order to provide a sample stream that has a first thickness adjacent to the injection tube, the flow path of the flow cell having a decrease in size of the flow path such that the sample stream thickness decreases from the initial thickness to a second thickness adjacent to an image capture site, focusing an image capture device by imaging an imaging target that has a fixed position in relation to the imaging cell flow, where the imaging target and the sample stream define a predetermined displacement distance along the geometry axis of the imaging, and acquire a focused image of a first plurality of particles from the first sample along the geometric axis of imaging at the image capture site of the flow cell, suitable for characterization and particle counting, within the stream with the image capture device, wherein the image capture device is focused on the sample stream using the focusing step and the predetermined displacement distance. The decrease in size of the flow path can be defined by a portion of the proximal flow path that has a proximal thickness and a portion of the distal flow path that has a distal thickness less than the proximal thickness. One end downstream of the sample fluid injection tube can be positioned distal to the proximal flow path portion. A speed difference between blood fluid and envelope samples, in combination with the decrease in flow path size and sample flow rate, can be effective in releasing cells in the sample from the sample fluid injection tube. to the image capture site in four seconds or less. In some cases, the body fluid sample is a urine fluid sample. In some cases, the image capture site has a field of view of about 800 μm x 800 μm. In some cases, the sample fluid has a volume of about 900 μl. In some cases, the sample fluid moves from an outlet port of the sample fluid injection tube to the geometry axis of the imaging at the image capture site in about 1.5 seconds. In some cases, the decrease in flow path size is defined by the opposite walls of the flow path angulation radially inward along the generally symmetrical flow path over a transverse plane that bisects the first and second thickness of the flow fluid. sample. In some cases, the flow cell is configured to receive the wrapping fluid from a wrapping fluid source in the flow path in a first flow direction that is perpendicular to the second flow direction of the wrapping fluid along the flow path. at the imaging site. In some cases, the flow cell includes an autofocus target for the image capture device. In some cases, the autofocus target may be in a fixed position in relation to the flow cell. In some cases, the body fluid sample has a sample viscosity, and the wrap fluid has a wrap fluid viscosity that is different from the sample viscosity.
[00023] In another aspect, the modalities of the present invention include a particle analysis system that performs geometric hydrofocusing for particle imaging in a body fluid sample. Exemplary systems can include a flow cell that has a flow path configured to transmit a flow of envelope fluid, a sample fluid injection system in fluid communication with the flow path and configured to inject the sample into the circulating envelope fluid inside the flow cell in order to provide a stream of sample fluid that has a first thickness adjacent to the injection tube, where the flow path of the flow cell has a decrease in size of the flow path so that the thickness of the sample fluid stream decreases from the initial thickness to a second thickness adjacent to an image capture site. The systems may also include an image capture device aligned with the image capture site, in order to image a plurality of particles from the sample fluid at the flow cell image capture site, a configured focusing mechanism to adjust a focal state of the image capture device in relation to the flow cell, wherein an imaging target has a fixed position in relation to the flow cell. The imaging target and the sample stream can define a travel distance along the geometry axis. The systems may also include a processor, a focusing module that has a tangible medium that incorporates machine-readable code executed in the processor to operate the focusing mechanism to adjust the focal state of the image capture device, suitable for characterization and counting of particles, using the displacement distance. In some cases, the sample fluid injection system is configured to release the sample fluid in such a way that the sample fluid has a transit time through the flow cell within a range from about 2 to 4 seconds. In some cases, the body fluid sample is a urine fluid sample. In some cases, the image capture site has a field of view of about 800 μm x 800 μm. In some cases, the sample fluid has a volume of about 900 μl. In some cases, the decrease in size of the flow path is defined by the opposite walls of the flow path positioned at an angle radially inward along the flow path generally symmetrical on a transverse plane that bisects the first and second thickness of the fluid stream of sample. In some cases, the flow cell is configured to receive the wrapping fluid from a wrapping fluid source in the flow path in a first flow direction that is perpendicular to the second flow direction of the wrapping fluid along the flow path. at the imaging site. In some cases, the flow cell includes an autofocus target for the image capture device. In some cases, the autofocus target has a fixed position in relation to the flow cell. In some cases, the body fluid sample has a sample viscosity, and the wrap fluid has a wrap fluid viscosity that is different from the sample viscosity.
[00024] In another aspect, the modalities of the present invention encompass methods for imaging particles in a body fluid sample using a particle analysis system configured for geometric hydro-focusing. The particles can be included in the fluid sample, where the fluid sample has a sample fluid viscosity. Exemplary methods include injecting the fluid sample into a flow cell so that the fluid sample flows into a sample stream with a stream width greater than a stream thickness, where the sample stream flows through a decrease in flow path size and across a geometric imaging axis, focus on an image capture device by imaging an imaging target that has a fixed position in relation to the flow cell, and acquire a focused image of the particles, suitable for the characterization and counting of particles, within the stream with the image capture device, in which the image capture device is focused on the sample stream using a displacement distance. In some cases, the body fluid sample is a urine sample.
[00025] In another aspect, the modalities of the present invention encompass particle analysis systems that perform geometric hydro-focusing for particle imaging in a body fluid sample. Exemplary systems may include a flow cell that has a flow path with an injection tube and an imaging window with a geometry axis of imaging through it, where the flow path of the flow cell has a decrease in size flow path, a fluid inlet in fluid communication with the infection tube, the fluid inlet configured to inject the fluid sample into a flow cell, so that the fluid sample flows into a sample stream with a current width greater than a current thickness, an image capture device, a focusing mechanism configured to adjust a focal state of the image capture device in relation to the flow cell, in which an imaging target has a fixed position relative to the flow cell, where the imaging target and the sample stream define a displacement distance along the imaging axis, a processor, and a m focusing module that has a tangible medium that incorporates machine-readable code executed in the processor to operate the focusing mechanism to adjust the focal state of the image capture device, suitable for characterization and particle counting, using the displacement distance . In some embodiments, the body fluid sample is a urine sample.
[00026] In another aspect, the modalities of the present invention encompass methods for imaging a plurality of particles using a particle analysis system configured for geometric hydro-focusing. The particles can be included in a sample of body fluid that has a sample fluid viscosity. Exemplary methods include flowing a wrapping fluid along a flow path of a flow cell, where the wrapping fluid has a wrapping fluid viscosity that differs from the sample fluid viscosity by a difference in viscosity over a range of predetermined viscosity difference, and inject the body fluid sample into the circulating envelope fluid within the flow cell in order to provide a sample fluid stream surrounded by the envelope fluid. Methods may also include flowing the sample fluid stream and the wrapping fluid through a reduction in size of the flow path toward an imaging site, such that a viscosity-induced hydro-focusing effect interaction between the wrapping fluid and the sample fluid stream associated with the difference in viscosity, in combination with a geometric hydro-focusing effect induced by an interaction between the wrapping fluid and the sample fluid stream associated with the reduction in trajectory size flow rate, is effective to provide a target imaging state on at least part of the plurality of particles at the imaging site, while a viscosity agent in the envelope fluid retains the viability of cells in the sample fluid stream outlet structure and intact cell content when cells extend from the sample fluid stream in the circulating envelope fluid. In addition, the methods may include imaging the plurality of particles at the imaging site. In some embodiments, the body fluid sample is a urine sample.
[00027] In yet another aspect, the embodiments of the present invention encompass systems for imaging a plurality of particles in a sample of body fluid that has a sample fluid viscosity. The systems can be configured for use with a wrapping fluid that has a wrapping fluid viscosity that differs from the sample fluid viscosity by a difference in viscosity in a range of predetermined viscosity difference. Exemplary systems may include a flow cell that has a flow path and a sample fluid injection tube, where the flow path has a reduction in flow path size, a wrap fluid inlet in fluid communication with the flow path of the flow cell in order to transmit a flow of the surrounding fluid along the flow path of the flow cell, and a sample of body fluid in fluid communication with the flow cell injection tube, in order to inject a sample flow of body fluid into the circulating envelope fluid within the flow cell, such that as the envelope fluid and the sample fluid flow through the reduction in size of the flow path and toward to an imaging site, a viscosity hydro-focusing effect induced by an interaction between the wrapping fluid and the sample fluid associated with the viscosity difference, in combination with an effect that of geometric hydro-focusing induced by an interaction between the envelope fluid and the sample fluid associated with the reduction in flow path size, provide a target imaging state in at least part of the plurality of particles at the imaging site, while a viscosity agent in the envelope fluid retains the viability of cells in the sample fluid stream outlet structure and the content of the cells intact when the cells extend from the sample fluid stream in the circulating envelope fluid. The systems may also include an imaging device that images the plurality of particles at the imaging site. In some embodiments, the body fluid sample is a urine sample.
[00028] The present features and advantages described above and many other of the modalities of the present invention will become evident and additionally understood by reference to the following detailed description, when considered in conjunction with the attached drawings. BRIEF DESCRIPTION OF THE DRAWINGS
[00029] Figure 1 is a schematic illustration, partly in section and not in scale, showing operational aspects of an exemplary flow cell, and autofocus system and high resolution optical imaging device for sample image analysis with the use of digital image processing.
[00030] Figures 1A and 1B show an optical bench arrangement according to the modalities of the present invention.
[00031] Figure 1C is a block diagram of a urinalysis analyzer according to the modalities of the present invention.
[00032] Figure 1D shows a flow chart of a process according to the modalities of the present invention.
[00033] Figure 1E represents aspects of a module system according to the modalities of the present invention.
[00034] Figure 2 is a perspective illustration of a flow cell according to an exemplary embodiment.
[00035] Figure 3 is a median longitudinal sectional view along lines 3-3 of the flow cell shown in Figure 2.
[00036] Figures 3A and 3B provide additional cross-sectional views of flow cells according to the modalities of the present invention.
[00037] Figure 4 represents aspects of an imaging system according to the modalities of the present invention.
[00038] Figures 4A, 4B-1 and 4B-2 represent aspects of flow cells according to the modalities of the present invention.
[00039] Figures 4A-1 and 4A-2 represent cross-sectional views of sample fluid stream dimensions and envelope fluid envelope (eg PIOAL) within a flow cell in a cannula outlet port and a image capture site, respectively, according to the modalities of the present invention.
[00040] Figures 4C-4G, 4C-1 and 4D-1 represent aspects of cannula configurations according to the modalities of the present invention.
[00041] Figure 4H shows a portion of a cannula according to the modalities of the present invention.
[00042] Figures 4I and 4J represent flow cells according to the modalities of the present invention.
[00043] Figures 4K and 4L show a sample stream flowing through a flow cell image capture site in accordance with the modalities of the present invention.
[00044] Figures 4K-1 and 4K-2 show a target imaging site according to the modalities of the present invention.
[00045] Figure 4K-3 represents a particle alignment aspect in a sample stream, according to the modalities of the present invention.
[00046] Figure 4L-1 represents aspects of fluid flow velocity profiles within a flow path of a flow cell, according to the modalities of the present invention.
[00047] Figures 4M and 4N show exemplary intracellular particle alignment features, in accordance with the modalities of the present invention.
[00048] Figures 4O and 4P show images that demonstrate the comparison between the images obtained with the use of a PIOAL versus a conventional wrapping fluid, according to the modalities of the present invention.
[00049] Figure 4Q shows the resulting images obtained with the use of systems and methods according to the modalities of the present invention.
[00050] Figure 5 represents a schedule corresponding to the injection of one or more sample fluids in a flow cell, according to the modalities of the present invention.
[00051] Figure 6 represents aspects of an exemplary method for imaging particles in a urine fluid sample, according to the modalities of the present invention.
[00052] Figures 7 and 8 represent aspects of current stress rates present within a flow path of a flow cell according to the modalities of the present invention.
[00053] Figure 9A represents an exemplary autofocus target, according to the modalities of the present invention.
[00054] Figure 9B shows a captured image, according to the modalities of the present invention.
[00055] Figures 10 and 11 represent exemplary autofocus targets, according to the modalities of the present invention.
[00056] Figure 12A represents an exemplary autofocus target, according to the modalities of the present invention.
[00057] Figure 12B shows a close view of the central portion of the autofocus target, in accordance with the modalities of the present invention.
[00058] Figures 13A, 13B and 13C represent views of flow cell temperature sensors, according to the modalities of the present invention.
[00059] Figure 13D represents aspects of flow cell bubble removal techniques, in accordance with the modalities of the present invention.
[00060] Figures 14A and 14B provide lateral cross-sectional views that illustrate aspects of focusing systems and methods, in accordance with the modalities of the present invention.
[00061] Figure 14C represents a cross-sectional side view of a flow cell that illustrates aspects of focusing systems and methods, in accordance with the modalities of the present invention.
[00062] Figure 14D provides a cross-sectional side view illustrating aspects of focusing systems and methods, in accordance with the modalities of the present invention.
[00063] Figure 15 represents aspects of focusing techniques and autofocus pattern, according to the modalities of the present invention.
[00064] Figures 16A and 16B show aspects of focusing systems and methods, in accordance with the modalities of the present invention. DETAILED DESCRIPTION OF THE INVENTION
[00065] The present disclosure relates to analyzer, systems, compositions and methods for analyzing a urine sample that contains particles. In one embodiment, the invention relates to an automated particle imaging system that can comprise a visual analyzer. In some embodiments, the visual analyzer may additionally comprise a processor to facilitate automated analysis of the images. Exemplary urine particles can include urine sediment particles. Exemplary urine sediment particles may include erythrocytes (RBCs), dysmorphic erythrocytes, leukocytes (WBCs), neutrophils, lymphocytes, phagocytic cells, eosinophils, basophils, squamous epithelial cells, transitional epithelial cells, decoy cells, renal tubular epithelial cells, stones crystals, bacteria, yeast, parasites, oval fat bodies, fat droplets, sperm, mucus, trichomonas, cell nodules and cell fragments. Exemplary cells can include red blood cells, white blood cells and epithelial cells. Exemplary calculations can include acellular pigment calculations, unclassified calculations (for example, granular calculations). Exemplary acellular calculations may include, for example, waxy calculations, broad calculations, fatty calculations and crystal calculations. Exemplary cell calculations may include, for example, RBC calculations, WBC calculations and cell calculations. Exemplary crystals may include, for example, calcium oxalate, triple phosphate, calcium phosphate, uric acid, calcium carbonate, leucine, cystine, tyrosine and amorphous crystals. Exemplary non-squamous epithelial cells may include, for example, renal epithelial cells and transitional epithelial cells. Exemplary yeast can include, for example, germinating yeast and yeast with pseudo-hyphae. The exemplary urine sediment particle can also include RBC nodules, fat, oval fat bodies and trichomonas.
[00066] According to this disclosure, a system is provided that comprises an analyzer for obtaining images of a sample that comprises particles suspended in a liquid. The system can be useful, for example, in the characterization of particles in biological fluids, such as in the detection and quantification of erythrocytes (RBCs), dysmorphic erythrocytes, leukocytes (WBCs), neutrophils, lymphocytes, phagocytic cells, eosinophils, basophils, epithelial cells squamous cells, transitional epithelial cells, decoy cells, renal tubular epithelial cells, stones, crystals, bacteria, yeast, parasites, oval fat bodies, fat droplets, sperm, mucus, trichomonas, cell nodules and cell fragments, categorization and subcategorization , counting and analysis. Other similar uses, such as characterizing cells and particles from other fluids, are also contemplated.
[00067] The discrimination of urine sediment particles in a urine sample is an exemplary application for which the subject is particularly well suited. The sample is prepared by automated techniques and presented to a high-resolution optical imaging device as a thin ribbon-shaped sample stream to be imaged periodically, while the ribbon-shaped sample stream flows through a field of view. . Particle images (such as in urine) can be distinguished from each other, categorized, subcategorized and counted, using programmed processing techniques for pixel image data, exclusively automatically or with limited human assistance, to identify and counting cells and / or particles. In addition to the cell images, which can be stored and made available in the case of unusual or critical particle traces, the output data includes a count of the occurrences of each particular cell and / or subcategory distinguished in the sample images registered.
[00068] The counts of the different particles found in each image can be further processed, for example, used to accumulate exact and statistically significant ratios of cell counts for each category and / or subcategory distinguished in the sample as a whole. The sample used for image-based discrimination (for example, visual) can be diluted, but the ratio of cell counts in each category and / or subcategory are proportionally represented in the diluted sample, particularly after a series of images has been processed . Urinalysis - Particle Analysis System
[00069] Again with reference to the drawings, Figure 1 schematically shows an exemplary flow cell 22 for transporting a sample fluid through a viewing zone 23 of a high resolution optical imaging device 24 in a particle imaging configuration. microscopic microscopes in a sample stream 32 using digital image processing. The flow cell 22 is coupled to a source 25 of sample fluid that may have undergone processing, such as contact with a particle contrast and heating agent composition. Flow cell 22 is also coupled to one or more sources 27 of envelope fluid or an intracellular organelle and / or particle alignment liquid (PIOAL), such as a clear glycerol solution that has a viscosity that is greater than viscosity of the sample fluid.
[00070] The sample fluid is injected through a flattened opening at a distal end 28 of a sample feed tube 29, and into the flow cell 22 at a point where the flow of PIOAL has been substantially established resulting in in a symmetrical and stable laminar flow of the PIOAL above and below (or opposite sides) of the ribbon-shaped sample stream. The sample and PIOAL streams can be supplied by precision metering pumps that move the PIOAL with the injected sample fluid along a substantially narrowing flow path. PIOAL wraps and compresses the sample fluid in zone 21 where the flow path narrows. Therefore, the decrease in the thickness of the flow path in zone 21 can contribute to a geometric focus of the sample stream 32. The sample fluid strip 32 is wrapped and loaded together with the PIOAL downstream of the narrowing zone 21, passing in front or otherwise via the viewing zone 23 of the high-resolution optical imaging device 24, where images are collected, for example, using a CCD 48. Processor 18 can receive data as input pixel from CCD 48. The sample fluid strip flows together with the PIOAL for a flush 33.
[00071] As shown here, the narrowing zone 21 can have a proximal flow path portion 21a that has a proximal thickness PT and a distal flow path portion 21b that has a distal thickness DT, such that the thickness distal DT is less than the proximal thickness PT. The sample fluid can therefore be injected through the distal end 28 of the sample tube 29 at a location that is distal to the proximal portion 21a and proximal to the distal portion 21b. Therefore, the sample fluid can enter the PIOAL envelope as the PIOAL stream is compressed by zone 21.
[00072] The digital high-resolution optical imaging device 24 with objective lens 46 is directed along an optical geometric axis that crosses the sample stream in ribbon format 32. The relative distance between the objective lens 46 and the imaging cell flow 33 is variable by operating a motor drive 54, to separate and collect a scanned image focused on a photosensor matrix.
[00073] The present disclosure presents a technique to automatically achieve a correct working position of the high-resolution optical imaging device 24 to focus on the ribbon-shaped sample stream 32. The flow cell structure 22 can be configured in such a way so that the strip-shaped sample stream 32 has a fixed and reliable location within the flow cell that defines the sample fluid flow path, on a thin strip between layers of PIOAL, passing through a viewing zone 23 in the flow cell 22. In certain flow cell modalities, the cross section of the flow path to the PIOAL narrows symmetrically at the point where the sample is inserted through a flattened orifice, such as a tube 29 with a rectangular lumen in the orifice, or cannula. The narrowing flow path (for example, which narrows geometrically in the area in cross section for a ratio of 20: 1, or for a ratio between 20: 1 to 70: 1) together with a differential viscosity between the PIOAL and the Sample fluids and, optionally, a difference in linear velocity of the PIOAL compared to the sample flow, cooperate to compress the cross section of the sample by a ratio between about 20: 1 to 70: 1. In some embodiments, the thickness ratio in cross section can be 40: 1.
[00074] In one aspect, the symmetrical nature of the flow cell 22 and the way of injecting the sample fluid and PIOAL provide a repeatable position within the flow cell 22 for the ribbon-shaped sample stream 32 between the two layers of PIOAL. As a result, variations in the process, such as the specific linear velocities of the sample and the PIOAL; they do not tend to displace the ribbon-shaped sample stream from its location in the stream. With respect to the structure of the flow cell 22, the location of the ribbon-shaped sample stream 32 is stable and repeatable.
[00075] However, the relative positions of the flow cell 22 and the optical high resolution imaging device 24 of the optical system may be subject to change and may benefit from occasional position adjustments to maintain an ideal or desired distance between the device high resolution optical imaging 24 and the ribbon-shaped sample stream 32, thus providing a quality focus image of the enveloped particles in the ribbon-shaped sample stream 32. According to some modalities, there may be a ideal or desired distance between the high-resolution optical imaging device 24 and the ribbon-shaped sample stream 32 to obtain focused images of the enveloped particles. The optics can first be precisely positioned relative to the flow cell 22 by autofocus or other techniques to locate the high-resolution optical imaging device 24 at the ideal or desired distance from an autofocus target 44 with a fixed position in relation to to the flow cell 22. The travel distance between the autofocus target 44 and the ribbon-shaped sample stream 32 is known precisely, for example, as a result of initial calibration steps. After autofocusing on the autofocus target 44, the flow cell 22 and / or high-resolution optical imaging device 24 is then moved over the known travel distance between the autofocus target 44 and the current. ribbon-shaped sample 32. As a result, the objective lens of the optical high-resolution imaging device 44 is precisely focused on the ribbon-shaped sample stream 32 that contains the enveloped particles.
[00076] The exemplary modalities of the present invention involve automatic focusing on the imaging target or focus 44, which is a high contrast figure that defines a known location along the optical geometric axis of the high resolution optical imaging device or the digital image capture device 24. Target 44 may have a known displacement distance from the location of the sample stream in ribbon format 32. A contrast measurement algorithm can be employed specifically on the target strokes. In one example, the position of the optical high resolution imaging device 24 can be varied along a line parallel to the optical geometric axis of the optical high resolution imaging device or digital image capture device, to find the depth or distance at which one or more maximum differential amplitudes are found between the pixel luminance values that occur along a line of pixels in the image that are known to cross an edge of the contrast figure. In some cases, the autofocus pattern has no variation along the line parallel to the optical geometric axis, which is also the line along which a motorized control operates to adjust the position of the high-resolution optical imaging device 24 to provide the travel distance recorded.
[00077] Thus, it may not be necessary to focus automatically or depend on an aspect of image content that is variable between different images, that is, less highly defined as contrast, or that could be located somewhere in a range of positions , as the basis for determining a distance location for reference. Having found the ideal or desired focus location on the autofocus target 44, the relative positions of the objective of the high-resolution optical imaging device 24 and the flow cell 22 can be shifted by the travel distance recorded to provide the position of ideal or desired focus for the particles in the ribbon-shaped sample stream 32.
[00078] According to some modalities, the high resolution optical imaging device 24 can resolve an image of the sample stream in ribbon format 32 as backlit by a light source 42 applied through a lighting aperture (window ) 43. In the modalities shown in Figure 1, the perimeter of the lighting aperture 43 forms an autofocusing target 44. However, the objective is to collect a precisely focused image of the tape-shaped sample stream 32 through the optics of the scanning device high-resolution optical imaging 46 in a matrix of photosensitive elements, such as an integrated load-coupled device.
[00079] The optical high resolution imaging device 24 and its optical 46 are configured to separate an image of the particles in the sample stream in ribbon format 32 that is in focus at distance 50, such distance may be a result of the dimensions of the optical system, the shape of the lenses and the refractive indices of their materials. In some cases, the ideal or desired distance between the high-resolution optical imaging device 24 and the ribbon-shaped sample stream 32 does not change, but the distance between the flow cell 22 and the high-resolution imaging device optics and its 46 optics can be changed. The movement of the high-resolution optical imaging device 24 and / or flow cell 22 closer or further away from each other (for example, by adjusting the distance 51 between the imaging device 24 and the imaging cell flow 22), moves the location of the focus point at the end of the distance 50 from the flow cell.
[00080] In accordance with the modalities of the present invention, a focus target 44 may be located at a distance from the strip-shaped sample stream 32, in this case, fixed directly to the flow cell 22 at the edges of the opening 43 for light from light source 42. Focus target 44 is at a constant travel distance 52 from the ribbon-shaped sample stream 32. Often, travel distance 52 is constant due to the fact that the location of the ribbon-shaped sample stream 32 in the flow cell can remain constant.
[00081] An exemplary autofocus procedure involves adjusting the relative positions of the optical high resolution imaging device 24 and flow cell 22 using a motor 54 to cause the optical high resolution imaging device 24 to focus on the autofocus target 44. In this example, autofocus target 44 is behind the ribbon-shaped sample stream 32 in the flow cell. Then, the high-resolution optical imaging device 24 and / or flow cell 22 are moved towards each other until the autofocus procedures establish that the separate image on the photosensor is an accurately focused image of the autofocus target. 44. Then, the motor 54 is operated to shift the relative positions of the optical high resolution imaging device 24 and flow cell 22 to cause the optical high resolution imaging device to focus on the ribbon-shaped sample stream 32 , that is, by moving the high-resolution optical imaging device 24 and / or flow cell 22 away from each other, precisely by the amplitude of the displacement distance 52.
[00082] These directions of movement would certainly be reversed if the focus target 44 was located in the front viewing window as opposed to the back lighting window 43. In that case, the travel distance would be the amplitude between the sample current in ribbon format 32 and a target 44 on the front viewport (not shown).
[00083] The offset distance 52, which is equal to the distance between the ribbon-shaped sample stream 32 and the autofocus target 44 along the optical geometric axis of the optical high-resolution imaging device 24, can be established in a factory calibration step. Typically, when established, the travel distance 52 does not change. Vibrations and variations in thermal expansion can cause the precise position of the high-resolution optical imaging device 24 and flow cell 22 to vary from one another, thus necessitating the restart of the autofocus process. However, autofocusing on target 44 provides a position reference that is fixed in relation to the flow cell 22 and thereby fixed in relation to the ribbon-shaped sample stream 32. Similarly, the travel distance is constant. Therefore, by automatically focusing on target 44 and moving the optical high-resolution imaging device 24 and flow cell 22 across the range of the displacement distance, the result is that the optical high-resolution imaging device focuses on the sample stream in ribbon format 32.
[00084] According to some modalities, the focus target is provided as a high-contrast circle printed or applied around the lighting aperture 43. Alternative focus target configurations are discussed elsewhere in this document. When a square or rectangular image is collected in focus on target 44, a high contrast margin appears around the center of illumination. The search for the position in which the greatest contrast is obtained in the image at the inner edges of the aperture automatically focuses the high-resolution optical imaging device on the target's workplace 44. According to some modalities, the term "working distance" may refer to the distance between the objective and its focal plane and the term "workplace" may refer to the focal plane of the imaging device. The largest contrast measurement of an image is where the pixels measured in darker black and brighter white are adjacent to each other along a line through an inner border. Larger contrast measurement can be used to assess whether the focal plane of the imaging device is in the desired position in relation to target 44. Other autofocus techniques can also be used, such as integrating differences in amplitude between adjacent pixels and search for the largest sum of differences. In one technique, the sum of differences is calculated over three distances covering working positions on either side of the target 44 and corresponding values resulting with a characteristic curve, where the ideal distance is the peak value on the curve. Correspondingly, exemplary autofocus techniques may involve collecting images of the flow cell target in different positions and analyzing the images to find the best focus position using a measurement that is larger when the target image is more sharp. During a first stage (thick), the autofocus technique can operate to find a better preliminary position from a set of images collected at 2.5 μm intervals. From that position, the autofocus technique can then involve collecting a second set of (thin) images at 0.5 μm intervals and calculating the best final focus position on the target.
[00085] In some cases, the focus target (auto focus pattern) may be on the periphery of the viewing area in which the sample is to appear. It is also possible that the focus target can be defined by contrasting the shapes that are in the field of view, such as those shown in Figure 15. Typically, the autofocus target is mounted on the flow cell or fixed rigidly in a fixed position in relation to the flow cell. Under the power of a positioning motor controlled by a detector responsive to maximizing the image contrast of the autofocusing target, the device automatically focuses on the target as opposed to the stranded sample stream. Then, by displacing the flow cell and / or the high-resolution optical imaging device in relation to each other, by the displacement distance known as the distance between the autofocus target and the tape-shaped sample stream, the working position of the high-resolution optical imaging device is shifted from the autofocus target to the ribbon-shaped sample stream. As a result, the stranded sample stream appears in focus on the collected digital image.
[00086] In order to distinguish particle types by means of data processing techniques, such as categories and / or subcategories of red blood cells and white blood cells, it is advantageous to register microscopic pixel images that have sufficient resolution and clarity to reveal the aspects that distinguish one category or subcategory from the others. It is an objective of the invention to facilitate the autofocus techniques as described.
[00087] In a practical embodiment, the apparatus may be based on an optical bench arrangement, as shown in Figure 1A and as enlarged in Figure 1B, which has an illumination source 42 directed towards a flow cell 22 mounted on a cardan support 55, which backlights the contents of the flow cell 22 in an image obtained by a high-resolution optical imaging device 24. The flow cell support 55 is mounted on a motor drive so that it is mobile accurately towards and away from the optical high resolution imaging device 24. Cardan support 55 also allows for precise alignment of the flow cell with the optical axis of the optical high resolution imaging device or the digital image capture device, so that the ribbon-shaped sample stream flows in a plane orthogonal to the viewing axis in the zone where the sample stream in f tape format is imaged, that is, between the lighting opening 43 and the viewing door 57, as shown in Figure 1. Focus target 44 can help in adjusting the cardan support 55, for example, to establish the plane of the sample stream in an orthogonal format to the optical geometric axis of the optical high resolution imaging device or the digital image capture device.
[00088] Therefore, the support or flow cell support 55 provides very precise linear and angular adjustment of the position and orientation of the flow cell 22, for example, in relation to the image capture device 24 or the lens of the device image capture. As shown here, support 55 includes two pivot points 55a, 55b to facilitate angular adjustment of the support and flow cell in relation to the image capture device. The angular adjustment pivot points 55a, 55b are located on the same plane and centered for the flow cell channel (for example, at the image capture site). This allows adjustment of the angles without causing any linear translation of the flow cell position. The support 55 can be rotated about a geometric axis of the pivot point 55a or about a geometric axis of the pivot point 55b or about both geometric axes. Such rotation can be controlled by a processor and a flow cell movement control mechanism, such as processor 440 and flow cell control mechanism 442 shown in Figure 4.
[00089] Again with reference to Figure 1B, it can be seen that any one of or both the image capture device 24 and the support 55 (together with the flow cell 22) can be rotated or translated along several geometric axes (for example, X, Y, Z) in three dimensions. Therefore, an exemplary technique for adjusting the focus of the image capture device may include deploying the axial rotation of the image capture device 24 about the geometry axis, for example, by rotating the device 24 around the axis geometric X. Focus adjustment can also be achieved by the axial rotation of the flow cell 22 and / or support 55 around a geometric axis that extends along the geometric axis of imaging, for example, around the geometric axis X , and within the field of view of the imaging device. In some cases, the focus adjustment may include the tip rotation (for example, rotation about the geometric Y axis) of the image capture device. In some cases, the focus adjustment may include the tip rotation (for example, rotation around the geometric Y axis, or around the pivot point 55a) of the flow cell. As shown here, pivot point 55a corresponds to a geometric axis Y that extends along and within the flow path of the flow cell. In some cases, the focus adjustment may include the tilt rotation (for example, rotation around the geometric Z axis) of the image capture device. In some cases, the focus adjustment may include the tilt rotation (for example, rotation around the geometric axis Z, or around the pivot point 55b) of the flow cell. As shown here, pivot point 55b corresponds to a geometric axis Z that crosses the flow path and the geometric axis of imaging. In some cases, the image capture device can be focused on the sample stream by implanting a rotation of the flow cell (for example, around the geometric X axis), such that the rotation is centered in the field of view image capture device. The three-dimensional rotational adjustments described in this document can be implemented in order to account for the positional deviation in one or more components of the analyzer system. In some cases, three-dimensional rotational adjustments can be implemented to account for temperature fluctuations in one or more components of the analyzer system. In some cases, the adjustment of an analyzer system may include translating the imaging device 24 along the X axis. In some cases, the adjustment of the analyzer system may include translating the support 55 or flow cell 22 along the geometric axis. X.
[00090] According to some modalities, a visual analyzer for obtaining images of a sample containing particles suspended in a liquid includes the flow cell 22, coupled to a source 25 of the sample and a source 27 of wrapping fluid or material of PIOAL, as shown in Figure 1. As seen in the sectional view of Figure 3, flow cell 22 defines an internal flow path that narrows symmetrically in the flow direction (right to left in Figure 3 or bottom to top in Figure 1). The flow cell 22 is configured to direct a flow 32 of the sample enveloped with the PIOAL through a viewing zone in the flow cell, i.e., behind the viewing port 57.
[00091] With reference again to Figure 1, the digital high-resolution optical imaging device 24 with objective lens 46 is directed along an optical geometric axis that crosses the sample stream in ribbon format 32. The relative distance between the objective 46 and the flow cell 33 is variable by operating a motor drive 54, to separate and collect a scanned image focused on a photosensor matrix.
[00092] The autofocus pattern 44, which has a position that is fixed in relation to the flow cell 22, is located at an offset distance 52 from the plane of the sample stream in ribbon format 32. In the mode shown , the autofocus pattern (target 44) is applied directly to the flow cell 22 at a location that is visible in the image collected by the high-resolution optical imaging device 24. In another embodiment, the target can be loaded in one part which is rigidly fixed in position with respect to the flow cell 22 and the ribbon-shaped sample stream 32 therein, if not applied directly to the flow cell body in an integral manner.
[00093] Light source 42, which can be a stationary source or can be a strobe that is shone in due time with the operation of the optical high resolution imaging device photosensor, is configured to illuminate the sample stream in ribbon format 32 and also to contribute to the contrast of target 44. In the represented mode, the lighting is from the back lighting.
[00094] Figure 1C provides a block diagram showing additional aspects of an exemplary urinalysis analyzer. As shown here, analyzer 100c includes at least one digital processor 18 coupled to operate motor drive 54 and to analyze the scanned image from the photosensor matrix, as collected at different focus positions in relation to the target autofocus pattern 44. Processor 18 is configured to determine a focus position from the autofocus pattern 44, that is, to automatically focus on the target autofocus pattern 44 and thereby establish an ideal distance between the high resolution imaging device optics 24 and the autofocus pattern 44. This can be accomplished by image processing steps, such as applying an algorithm to assess the level of contrast in the image at a first distance, which can apply to the entire image or at least at an edge of the autofocus pattern 44. The processor moves the engine 54 to another position and evaluates the contrast at that position or edge, and after two or more this iterations determines an ideal distance that maximizes the accuracy of the focus over the autofocus pattern 44 (or that would optimize the accuracy of the focus if moved to that position). The processor depends on the fixed spacing between the autofocus pattern 44 of the autofocus target and the sample stream in ribbon form, processor 18 then controls motor 54 to move the high resolution optical imaging device 24 to the correct distance to focus on the sample stream in ribbon format 32. More particularly, the processor operates the motor to shift the distance between the high resolution optical imaging device and the sample stream in ribbon format 32 by the distance of offset 52 (for example, as shown in Figure 1) whereby the ribbon-shaped sample stream is shifted from the target autofocus pattern 44. In this way, the high-resolution optical imaging device is focused on the stream sample in tape format.
[00095] Motor 54 may comprise a stepper motor with gears with slightly less precision than the distinctive features imaged by the high-resolution optical imaging device or by the digital image capture device, specifically the aspects of blood cells. As long as the location of the optical high resolution imaging device 24 is adjusted to locate the position of the optical lens within the width of the ribbon-shaped sample stream, the view of the cell / particle in the ribbon-shaped sample stream is in focus. An autofocus pattern 44 may be situated at an edge of a field of view of the high-resolution optical imaging device or digital image capture device, and will not interfere with the view for that reason.
[00096] Additionally, when the high resolution optical imaging device is moved over the displacement distance and the autofocus pattern does not go out of focus, the strokes that appear in focus are the blood cells as opposed to the autofocus pattern. In the modality of Figure 15, for example, the autofocus pattern is defined by formats in the field of view. The shapes are relatively thin discrete shapes of a limited size, and therefore, after movement by the displacement distance, the shapes become substantially invisible in the scanned image when focused on the ribbon-shaped sample stream. A typical travel distance can be, for example, 50 to 100 μm in a flow cell sized for urinalysis imaging applications. In some embodiments, the autofocus feature keeps the high resolution optical imaging device within 1 μm. the ideal focus distance.
[00097] The internal contour of the flow cell and the flow rates of PIOAL and sample can be adjusted in such a way that the sample is formed in a ribbon-shaped stream. The stream may be approximately as thin as, or even finer than, the particles that are enveloped in the tape-shaped sample stream. White blood cells can have a diameter around 10 μm, for example. By providing a ribbon-shaped sample stream less than 10 μm thick, cells can be oriented when the ribbon-shaped sample stream is extended by the wrapping fluid, or PIOAL. Surprisingly, stretching the ribbon-shaped sample stream along a narrowing flow path within layers of PIOAL of a different viscosity from the ribbon-shaped sample stream, such as higher viscosity, tends to advantageously align non-spherical particles. on a plane substantially parallel to the direction of flow, and apply forces on the cells, perfecting the focused contents of intracellular cell structures. The optical geometric axis of the optical high resolution imaging device 24 is substantially orthogonal (perpendicular) to the plane of the ribbon-shaped sample stream. The linear speed of the ribbon-shaped sample stream at the imaging point can be, for example, from 20 to 200 mm / second. In some embodiments, the linear velocity of the ribbon-shaped sample stream can be, for example, 50 to 150 mm / second. Another embodiment of the wrapping fluid can be the LAMINA ™ solution (IRIS International, Inc.). LAMINA ™ can have a pH of around 7.0 and a specific gravity of 1.007 at 20 ° C. In a related embodiment, a wrap fluid can be supplied as a saline solution. In some embodiments, the wrapping fluid is an aqueous salt composition. In some embodiments, the viscosity of the wrapping fluid is equal to or similar to the viscosity of the sample fluid.
[00098] The sample stream in tape format thickness can be affected by the relative viscosities and flow rates of the sample fluid and the PIOAL. Again with reference to Figure 1, the source 25 of the sample and / or source 27 of the wrapping fluid or PIOAL, for example, which comprises precision displacement pumps, can be configured to deliver the sample and / or the PIOAL at rates of controllable flows to optimize the dimensions of the sample stream in ribbon format 32, that is, as a thin ribbon at least as wide as the field of view of the high-resolution optical imaging device 24.
[00099] In one embodiment, the source 27 of the wrapping fluid or PIOAL is configured to supply the PIOAL at a predetermined viscosity. This viscosity can be different from the viscosity of the sample and can be greater than the viscosity of the sample. The viscosity and density of the PIOAL, the viscosity of the sample material, the flow rate of the PIOAL and the flow rate of the material sample are coordinated to maintain the tape-shaped sample stream at the travel distance from the pattern of autofocus, and with predetermined dimensional characteristics, such as an advantageous tape-shaped sample stream thickness.
[000100] In a practical modality, the PIOAL has a linear speed greater than the sample and a viscosity greater than the sample, thus stretching the sample on the flat tape. In some cases, the PIOAL viscosity can be up to 10 centipoise.
[000101] In the modality shown in Figure 1C, the same digital processor 18 that is used to analyze the digital pixel image obtained from the photosensor matrix is also used to control the autofocus engine 54. However, typically the scanning device high optical resolution imaging 24 is not automatically focused for each captured image. The autofocus process can be performed periodically (at the beginning of the day or at the beginning of a shift) or, for example, when the temperature or other changes in the process are detected by suitable sensors, or when the image analysis detects a potential need refocusing. In some cases, an automated autofocusing process can be performed within a time span of about 10 seconds. In some cases, an autofocus procedure may be performed before processing a sample rack (for example, 10 samples per rack). It is also possible, in other modalities, to have the image analysis of the urine sample carried out by a processor and to have a separate processor, optionally associated with its own photosensor matrix, willing to handle the steps of automatic focusing on a fixed target 44.
[000102] The digital processor 18 can be configured to autofocus at programmed times or under programmed conditions or on user demand, and is also configured to perform categorization and subcategorization based on the image of the particles. Exemplary particles include cells, white blood cells, red blood cells and the like.
[000103] In one embodiment, digital processor 18 in Figure 1 or Figure 1C is configured to detect an auto-focus reset signal. The autofocus reset signal can be triggered by a detected change in temperature, a decrease in focus quality, as discerned by parameters of the pixel image date, time passing, or user input. Advantageously, it is not necessary to recalibrate in order to measure the travel distance 52 shown in Figure 1 to be recalibrated. Optionally, autofocus can be programmed to recalibrate at certain frequencies / intervals between runs for quality control and / or to maintain focus.
[000104] The travel distance 52 varies slightly from one flow cell to another, but remains constant for a given flow cell. According to a configuration process, when an image analyzer is equipped with a flow cell, the displacement distance is first estimated and then, during the calibration steps in which the aspects of imaging and autofocus are exercised, the distance of exact displacement for the flow cell is determined and inserted as a constant in the programming of the processor 18.
[000105] Consequently, as shown in the form of a flowchart in Figure 1D, and with reference to the urinalysis analyzer in Figure 1 and / or Figure 1C, the process performed according to the disclosed methods and apparatus may involve calibration once or rarely . Calibration can include focusing on the contrast target 44, focusing on the ribbon-shaped sample stream 32 and observing the shift along the optical geometric axis between these two locations, as indicated in step 110d. This displacement can be observed as a constant. Subsequently, by controlling engine 54 and analyzing image data from the photosensor matrix, processor 18 automatically focuses on target 44 and moves the high-resolution optical imaging device 24 and / or flow cell 22 one by one. relation to the other by the observed displacement distance, as indicated in step 120d. The stranded sample stream 32 is then in focus and its image can be collected (as indicated in step 130d) and processed (as indicated in step 140d) at regular intervals, specifically at intervals sufficient to collect substantially adjacent views overlapping portions of the tape-shaped sample stream that pass through the display zone on the display port 57. When self-monitoring (as indicated in step 150d) reveals a data abnormality or a temperature change that could have altered the relative positions of the high resolution optical imaging device 24 and flow cell 22 due to differences in thermal expansion, then the autofocus (as indicated in step 160d) is initiated, after which regular operation resumes. Therefore, an autofocusing process may include detecting an autofocus reset signal and repeating the autofocusing and image acquisition steps in response to the autofocus reset signal. In some embodiments, the auto-focus reset signal may include or be based on a change in temperature, a decrease in focus quality, a time lag, or a user input.
[000106] The linear speed of the sample stream in tape format can be sufficiently limited to avoid obscurity of movement of the scanned image in the time of exposure of the image of the photosensor matrix. The light source can optionally be a strobe light that shines to apply high incident amplitude for a short time. As the autofocus pattern 44 and the image are in the same field of view, the light source is configured to illuminate the ribbon-shaped sample stream and the autofocus pattern simultaneously. However, in other modalities, the field of view for imaging and auto focus may be different, for example, illuminated and / or imaged separately.
[000107] The present developments have aspects of the method, as well as of the apparatus. One method of focusing a visual analyzer comprises focusing a high-resolution optical imaging device 24, which can be a high-resolution digital optical imaging device or the digital image capture device, in an autofocus pattern 44 fixed at relative to a flow cell 22, where the autofocus pattern 44 is located at a displacement distance 52 from a ribbon-shaped sample stream 32. The digital optical high-resolution imaging device 24 has a lens with an optical geometric axis that crosses the sample stream in ribbon format 32. A relative distance between the objective and the flow cell 22 is varied by the operation of a motor drive 54, while the distance along the optical geometric axis between the high resolution optical imaging device and the ideal focus point is known. The high-resolution digital optical imaging device is configured to separate and collect a scanned image in a photosensor matrix. The motor drive is operated to focus on the autofocus pattern in an autofocus process. The motor drive is then operated over the travel distance, thus focusing the high-resolution optical imaging device on the sample stream in a ribbon format.
[000108] It is possible to use automatic focusing on the target and displacement by the displacement distance to obtain an adequate distance to focus on the sample stream in tape format. Advantageously, however, autofocusing is not required or repeated for each image capture. However, autofocusing is started under certain conditions. An autofocus reset signal can be detected or generated, leading to the steps of refocusing on the autofocus pattern, operating the motor drive over the travel distance and refocusing the high resolution optical imaging device on the sample stream in ribbon format. The autofocus reset signal can be caused by the detection of a change, for example, in temperature, a decrease in focus quality, the passage of time, other process parameters or user input.
[000109] Figure 1E is a simplified block diagram of an example module system that broadly illustrates how the individual elements of the system for a module 100e system can be deployed in a separate or more integrated manner. The module system 100e can be part of or in connectivity with a particle analysis system for imaging particles in a body fluid sample, such as a urine sample, according to the modalities of the present invention. The 100e module system is well suited for producing data or instructions related to focusing and imaging techniques, receiving input related to focusing and imaging techniques and / or processing information or data related to focusing and imaging techniques, as described elsewhere in this document. In some cases, the module system 100e includes hardware elements that are electrically coupled through a bus subsystem 102e, including one or more processors 104e, one or more input devices 106e, such as user interface input devices and / or one or more output devices 108e, such as user interface output devices. In some cases, system 100e includes a network interface 110e and / or an imaging system interface 140e that can receive signals from and / or transmit signals to an imaging system 142e. In some cases, the 100e system includes software elements, for example, shown here as currently being located within a working memory 112e of a memory 114e, an operating system 116e and / or other code 118e, such as a configured program to deploy one or more aspects of the techniques revealed in this document.
[000110] In some embodiments, the module system 100e may include a storage subsystem 120e that can store the data constructs and basic programming that provide the functionality of the various techniques disclosed in this document. For example, software modules that implement the functionality of aspects of the method, as described here, can be stored in storage subsystem 120e. These software modules can be run by one or more 104e processors. In a distributed environment, software modules can be stored in a plurality of computer systems and run by processors from the plurality of computer systems. The storage subsystem 120e can include memory subsystem 122e and file storage subsystem 128e. The memory subsystem 122e can include multiple memories that include a main random access memory (RAM) 126e for storing instructions and data during program execution and a read-only memory (ROM) 124e in which fixed instructions are stored . The 128e file storage subsystem can provide persistent (non-volatile) storage for data and program files and can include tangible storage media that can optionally incorporate sample, patient, treatment, evaluation or other data. The 128e file storage subsystem can include a hard disk drive, a floppy drive along with associated removable media, a compact digital read-only memory (CD-ROM), an optical disc, DVD, CD-R, CD RW, removable solid state memory, other disks or cartridges of removable media and the like. One or more of the units may be located at remote locations on other computers connected to other sites attached to the 100e module system. In some cases, systems may include a computer-readable storage medium or another tangible storage medium that stores one or more sequences of instructions that, when executed by one or more processors, can cause one or more processors to perform any aspect of the techniques or methods disclosed in this document. One or more modules that implement the functionality of the techniques disclosed in this document can be stored by the file storage subsystem 128e. In some embodiments, the software or code will provide a protocol to allow the module system 100e to communicate with the communication network 130e. Optionally, these communications can include communications by dial-up connection or Internet connection.
[000111] It is understood that the 100e system can be configured to carry out various aspects of the methods of the present invention. For example, the processor component or module 104e may be a microprocessor control module configured to receive temperature parameter signals and / or flow cell operating parameters from a 132e sensor input module or device, from of a user interface input module or device 106e and / or from an imaging system 142e, optionally via an imaging system interface 140e and / or a network interface 110e and a communication network 130e. In some cases, the sensor input device (s) may include or be part of a particle analysis system that is equipped to image body fluid samples, such as urine samples. In some cases, the user interface input device (s) 106e and / or network interface 110e can be configured to receive image parameter signals generated by a particle analysis system that is equipped to obtain parameters of image. In some cases, the 142e imaging system may include or be part of a particle analysis system that is equipped to obtain imaging parameters related to body fluid samples, such as urine samples.
[000112] Processor component or module 104e may also be configured to transmit particle analysis parameter signals or image parameter signals, optionally processed according to any of the techniques disclosed in this document, to the module or device sensor output 136e, for the user interface output module or device 108e, for the network interface module or device 110e, for the imaging system interface 140e, or any combination thereof. according to the modalities of the present invention it may include one or more software modules in a computer-readable medium that is processed by a processor, or hardware modules, or any combination thereof. Any of a variety of commonly used platforms, such as Windows, MacIntosh and Unix, along with any of a variety of commonly used programming languages, can be used to implement modalities of the present invention.
[000113] User interface input devices 106e can include, for example, a touchpad, a keyboard, pointing devices such as a mouse, a trackball, a graphic tablet computer, a scanning device, a control joystick type, a touchscreen built into a display, audio input devices such as speech recognition systems, microphones, and other types of input devices. User input devices 106e may also download executable code from a computer from a tangible storage medium or from communication network 130e, where the code incorporates any of the methods or aspects thereof disclosed herein document. It will be understood that the terminal software can be updated from time to time and downloaded to the terminal, as appropriate. In general, the use of the term "input device" is intended to include a variety of conventional and unique devices and ways to enter information into the 100e module system.
[000114] User interface output devices 106e may include, for example, a display subsystem, a printer, a fax machine or non-visual displays, such as audio output devices. The display subsystem can be a cathode ray tube (TRC), a flat panel device, such as a liquid crystal display (LCD), a projection device, or the like. The display subsystem can also provide a non-visual display, such as through audio output devices. In general, the use of the term "output device" is intended to include a variety of conventional and unique devices and ways to deliver information from the 100e module system to a user.
[000115] The bus subsystem 102e provides a mechanism to allow the various components and subsystems of the module system 100e to communicate with each other as intended or desired. The various subsystems and components of the 100e module system do not need to be in the same physical location, but can be distributed to multiple locations within a distributed network. Although the bus subsystem 102e is shown schematically as a single bus, the alternative modalities of the bus subsystem can use multiple buses.
[000116] The network interface 110e can provide an interface to an external network 130e or other devices. The external communication network 130e can be configured to communicate, as needed or desired, with other parties. It can thus receive an electronic packet from the 100e module system and transmit any information, as needed or desired, back to the 100e module system. As depicted here, communication network 130e and / or imaging system interface 142e can transmit information to or receive information from an imaging system 142e that is equipped to obtain images or image parameters that correspond to body fluid samples , such as urine samples.
[000117] In addition to providing such infrastructure communications links internal to the system, the communications network system 130e can also provide a connection to other networks, such as the internet, and may comprise a wireless, wired modem and / or other type of interface connection.
[000118] It will be apparent to the person skilled in the art that considerable variations can be used according to specific requirements. For example, custom hardware may also be used and / or specific elements may be implemented in the hardware, software (including portable software, such as applets), or both. In addition, the connection to other computing devices, such as network input / output devices, can be used. The module terminal system 100e itself can be of various types that include a computer terminal, a personal computer, a portable computer, a workstation, a network computer, or any other data processing system. Due to the constantly evolving nature of computers and networks, the description of the module system 100e depicted in Figure 1E is intended only as a specific example for the purposes of illustrating one or more embodiments of the present invention. Many other configurations of the 100e module system are possible with more or less components than the module system shown in Figure 1E. Any of the modules or components of the 100e module system, or any combination of such modules or components, may be coupled to, integrated into or otherwise configured to be in connectivity with any of the particle analysis system modalities and / or imaging system disclosed in the present invention. Correspondingly, any of the hardware and software components discussed above can be integrated with or configured to interface with another medical assessment or treatment system used elsewhere.
[000119] In some embodiments, the module system 100e can be configured to receive one or more image parameters of a sample of body fluid, such as a urine sample, in an input module. The image parameter data can be transmitted to an evaluation module, where the diagnosis or other results can be predicted or determined based on the analysis of the image data. The image or diagnostic data can be sent to a system user via an output module. In some cases, the 100e module system can determine diagnostic results for a body fluid sample, such as a urine sample, for example, using a diagnostic module. Diagnostic information can be issued to a user of the system via an output module. Optionally, certain aspects of the diagnosis can be determined by an output device, and transmitted to a diagnostic system or a sub-device of a diagnostic system. Any of a variety of data related to body fluid samples, such as urine samples, or patients from whom samples are obtained, can be entered into the module system, including age, weight, sex, treatment history, medical history and the like. The parameters of treatment regimens or diagnostic assessments can be determined based on this data.
[000120] Correspondingly, in some cases, a system includes a processor configured to receive the image data as input. Optionally, a processor, storage medium, or both, can be incorporated into a urinalysis or particle analysis machine. In some cases, the urinalysis machine can generate image data or other information for input to the processor. In some cases, a processor, a storage medium, or both, can be incorporated into a computer, and the computer can be in communication with a urinalysis machine. In some cases, a processor, a storage medium, or both, can be incorporated within a computer, and the computer can be remotely communicating with a urinalysis machine over a network. Flow cell
[000121] A practical embodiment of the flow cell 22 is further represented in Figures 2 and 3. As shown here, the flow cell 22 can be coupled to a sample source 25 and a source 27 of wrapping fluid or PIOAL material. . Sample fluid is injected into flow cell 22 through cannula 29, for example, through a distal outlet port 31 from cannula 29. Typically, PIOAL wrap fluid is not in a laminar flow state as it travels through a curved channel section 41 in the flow cell from the source 27 towards the viewing zone 23. However, the flow cell 22 can be configured so that the PIOAL wrapping fluid is or becomes laminar, or present a flat velocity profile as it flows past the distal outlet port 31, in which the sample fluid is introduced into the circulating envelope fluid. The sample fluid and the PIOAL can flow along the flow cell 22 in a direction usually indicated by arrow A, and then out of the flow cell 22 through the discharge 33. The flow cell 22 defines a flow path. internal flow 20 that narrows symmetrically (for example, in the transition zone 21) in the direction of flow A. The symmetry of the flow path contributes to a robust and centralized flow of the sample stream. The flow cell 22 is configured to direct a flow 32 of the sample enveloped with the PIOAL through a viewing zone 23 in the flow cell, that is, behind the viewing port 57. Associated with the viewing port 57 is a pattern of auto focus 44. Flow cell 22 also has a rounded or recessed seat 58 that is configured to accept or receive a microscope objective (not shown).
[000122] According to some modalities, the autofocus pattern 44 can have a position that is fixed in relation to the flow cell 22, and that is located at a distance of displacement from the plane of the sample stream in tape format 32 In the modality shown here, the autofocus pattern (target 44) is applied directly to flow cell 22 at a location that is visible in an image collected through viewport 57 by a high resolution optical imaging device (not shown). The flow cell 22 may be constructed of a first layer or section or layer or upper section 22a and a second layer or section or layer or lower section 22b. As shown here, a glass or transparent window panel 60 is attached to or integral with the first section 22a. Panel 60 can define at least a portion of the sample flow path within the flow cell. The light from the light source 42 can travel through an aperture or passage of the autofocus pattern 44 in order to illuminate sample particles that flow into the stream 32.
[000123] In some cases, the thickness of the panel 60 can have a value within a range from about 150 μm to about 170 μm. As noted above, panel 60 can define or form part of the flow path or envelope channel (for example, PIOAL). Using a thin panel 60, it is possible to place the microscope objective very close to the sample fluid strip and therefore obtain highly enlarged images of particles that flow along the flow path.
[000124] Figure 3A represents aspects of a flow cell modality, in which a distance between the imaging axis 355 and the distal transition zone portion 316 is about 8.24 mm. A distance between the distal transition zone portion 316 and the cannula outlet port 331 is about 12.54 mm. A distance between the cannula outlet port 331 and the inlet fluid inlet 301 is about 12.7 mm. A distance between the cannula outlet port 331 and a portion of the proximal transition zone 318 is about 0.73 mm. Figure 3B represents aspects of a flow cell modality in which the cannula outlet port has been moved to a more distal location in relation to the transition zone, as compared with the modality of Figure 3A. As shown here, the distal end of the cannula is advanced to the narrowing transition zone of the flow cell, and a distance between the imaging axis 355 and the distal transition zone portion 316 is in a range from about 16 mm to about 26 mm. In some case, the distance between the imaging axis 355 and the distal transition zone portion 316 is about 21 mm.
[000125] Again with reference to Figure 1, the internal contour of the flow cell (for example, in the transition zone 21) and the flow rates of PIOAL and sample can be adjusted in such a way that the sample is formed in a current in tape format 32. The stream can be approximately as thin as or even finer than the particles that are enveloped in the tape-shaped sample stream. White blood cells can have a diameter around 10 μm, for example. By providing a ribbon-shaped sample stream less than 10 μm thick, cells can be oriented when the ribbon-shaped sample stream is extended by the wrapping fluid, or PIOAL. Surprisingly, stretching the ribbon-shaped sample stream along a narrowing flow path within layers of PIOAL of a different viscosity from the ribbon-shaped sample stream, such as higher viscosity, tends to advantageously align non-spherical particles. in a plane substantially parallel to the direction of flow, and apply forces on the cells, perfecting the focused contents of the cell's intracellular structures. The optical geometric axis of the optical high resolution imaging device 24 is substantially orthogonal (perpendicular) to the plane of the ribbon-shaped sample stream. The linear speed of the ribbon-shaped sample stream at the imaging point can be, for example, from 20 to 200 mm / second. In some embodiments, the linear velocity of the ribbon-shaped sample stream can be, for example, 50 to 150 mm / second.
[000126] With reference also to Figures 2 and 3, the internal flow path of the flow cell narrows downstream of the injection point of the ribbon-shaped sample stream in the PIOAL, to produce a thickness of the sample-shaped stream of tape, for example, up to 7 μm, and / or the internal flow path produces a tape-shaped sample stream width of 500 to 3,000 μm. In exemplary modalities, as shown in Figure 1, the internal flow path of the flow cell begins in a narrowing transition zone upstream of the injection point of the sample stream in the PIOAL.
[000127] In another embodiment, the internal flow path narrows to produce a tape-shaped sample stream thickness of 2 to 4 μm and / or the internal flow path results in the 2,000 tape-shaped sample stream μm in width. In some cases, the sample stream has a width of about 2,190 μm. The thickness of the chain in this case is less than the diameter of some particles, such as red blood cells in their relaxed state. Consequently, those particles can become reoriented in their widest dimension towards the geometric axis of imaging, which is useful in the disclosure of distinctive features.
[000128] The method may additionally include forming the sample stream in a tape format into a tape format. The ribbon format is presented in such a way that the optical geometric axis of the optical high resolution imaging device is substantially perpendicular to the ribbon-shaped sample stream, that is, orthogonal to the plane of the ribbon-shaped stream.
[000129] Figure 4 represents aspects of a 400 system for imaging particles in a urine sample. As shown here, system 400 includes a sample fluid injection system 410, a flow cell 420, and an image capture device 430, and a processor 440. Flow cell 420 provides a flow path 422 that transmits a flow of the wrapping fluid, optionally in combination with the sample fluid. According to some embodiments, the sample fluid injection system 410 may include or be coupled to a tube or cannula 412. The sample fluid injection system 410 may be in fluid communication with the flow path 422, and may operate to inject sample fluid 424 through a distal outlet port 413 of the cannula 412 and into a circulating envelope fluid 426 within the flow cell 420 to provide a stream of sample fluid 428. For example, processor 440 may include or be operationally associated with a storage medium that has a computer application that, when run by the processor, is configured to cause the sample fluid injection system 410 to inject sample fluid 424 into the circulating envelope fluid 426 As shown here, wrap fluid 426 can be introduced into flow cell 420 by a wrap fluid injection system 450. For example, processor 440 can include or car in operational association with a storage medium that has a computer application which, when run by the processor, is configured to cause the sample fluid injection system 450 to inject wrap fluid 426 into flow cell 420.
[000130] The sample fluid stream 428 has a first thickness T1 (see, for example, Figure 4A) adjacent to the injection tube 412. The flow path 422 of the flow cell that has a decrease in the path length of flow such that the thickness of the sample fluid stream 428 decreases from the initial thickness T1 to a second thickness T2 adjacent to an image capture site 432. Image capture device 430 is aligned with the image capture site image 432 in order to image a first plurality of particles from the first sample fluid at the image capture site 432 of flow cell 420.
[000131] Processor 440 is coupled to the sample fluid injector system 410, image capture device 430 and, optionally, to the fluid injection system 450. Processor 440 is configured to stop the injection of the first fluid sample into the circulating envelope fluid 426 and starting the injection of the second sample fluid into the circulating envelope fluid 426 in such a way that sample fluid transients are initiated. For example, processor 440 may include or be in operational association with a storage medium that has a computer application that, when run by the processor, is configured to cause the sample fluid injection system 410 to inject the second fluid samples in the circulating envelope fluid 426 in such a way that sample fluid transients are initiated.
[000132] Additionally, processor 440 is configured to start capturing an image of a second plurality of particles from the second sample fluid at image capture site 432 of flow cell 420 after the sample fluid transients and within 4 seconds of imaging the first plurality of particles. For example, the 440 processor may include or remain in operational association with a storage medium that has a computer application that, when run by the processor, is configured to cause the image capture device 430 to start capturing an image of a second plurality of particles from the second sample fluid at the image capture site 432 of the flow cell 420 after the sample fluid transients and within four seconds of imaging the first plurality of the particles.
[000133] In some embodiments, the 440 processor may include or remain in operational association with a storage medium that has a computer application that, when run by the processor, is configured to cause a cell motion control mechanism flow 442 adjust the position of the flow cell 420, for example, in relation to the image capture device 430. In some embodiments, the processor 440 may include or be in operational association with a storage medium that has a computer application that , when executed by the processor, it is configured to cause an image capture device movement control mechanism 444 to adjust the position of the image capture device 430, for example, in relation to flow cell 420. The control mechanisms movement 442, 444 can include motors, cardan suspensions and other mechanical features that facilitate and produce movement in the flow cell and device image capture, respectively. In some cases, the flow cell control mechanism 442 and / or the image capture device control mechanism 444 may include a high precision stepper motor control that provides motorized and automated focusing of the image capture device image in relation to the flow cell. As shown in Figure 1, a processor can control the movement of the image capture device 24. Similarly, as shown in Figure 1B, a processor can control the movement of a flow cell holder 55.
[000134] Therefore, the modalities of the present invention encompass particle analysis systems that perform geometric hydro-focusing and combined viscosity for imaging particles in a urine sample. Exemplary systems can include a flow cell that has a flow path with an injection tube and an imaging window with a geometrical imaging axis through it. The flow path of the flow cell may have a decrease in the size of the flow path. In addition, analyzer systems may include a wrap fluid inlet in fluid communication with the flow path, and a urine inlet in fluid communication with the injection tube. The urine inlet can be configured to inject the urine sample into the circulating envelope fluid within the flow cell, so that the urine sample flows in a sample stream with a stream width greater than a stream thickness. The wrapping fluid may have a viscosity that is greater than a viscosity of the urine sample. In addition, the analyzer system may include an image capture device, and a focusing mechanism that defines a focal state of the image capture device in relation to the flow cell. In addition, the system can include an imaging target that has a fixed position in relation to the flow cell, where the imaging target and the sample stream define a displacement distance along the imaging geometry axis. The system can also include a processor and a focusing module that has a tangible medium that incorporates machine-readable code executed in the processor to operate the focusing mechanism to adjust the focal state of the image capture device, suitable for characterization and counting of particles, using the displacement distance. The difference in viscosity between the wrapping fluid and the urine sample, in combination with the decrease in flow path size, can be effective for hydro-focusing the first and second sample fluid on the geometrical imaging axis, while retaining the viability of cells in the urine sample. In some cases, the focusing mechanism may include a drive motor configured to adjust a distance between the image capture device and the flow cell.
[000135] In some cases, an analyzer system 400 may include a thermal or temperature sensor 448 that is thermally coupled to the flow cell 420, as shown in Figure 4. A focusing module, which can be operationally associated with the processor, may include a tangible medium that incorporates machine-readable code that runs on the processor to operate a focusing mechanism (for example, 442 flow cell control mechanism or 444 image capture device control mechanism) in order to to adjust the focal state or focal plane of the image capture device, suitable for the characterization and counting of particles, in response to a change in temperature detected by the temperature sensor and a known relationship between temperature and a desired focus.
[000136] Consequently, the embodiments of the present invention encompass a system 400 for imaging a plurality of particles in a urine sample 424 that has a sample fluid viscosity. System 400 can be used with a wrap fluid 426 that has a wrap fluid viscosity that differs from the sample fluid viscosity by a difference in viscosity in a range of predetermined viscosity difference. The system 400 may include a flow cell 420 which has a flow path 422 and a sample fluid injection tube 412. Flow path 422 may have a reduction in size of the flow path or narrowing transition zone. In addition, the system 400 may include an envelope fluid inlet 401 in fluid communication with flow path 422 of flow cell 420 in order to transmit a flow of envelope fluid along flow path 422 of flow cell 420. The system 400 may also include a urine sample inlet 402 in fluid communication with the injection cell 412 of the flow cell 420 in order to inject a stream or stream 428 of the urine sample into the circulating envelope fluid 428 within the flow cell 420 For example, the sample fluid 424 can exit the distal outlet port 423 of the cannula 412 and into an envelope of the circulating envelope fluid 426 to form a sample strip 428 therein.
[000137] As the wrapping fluid 426, along with the sample fluid strip 428 formed from the sample fluid 424, flows through a reduction 419 in flow path size and toward an imaging site 432 , a viscosity hydro-focusing effect induced by an interaction between envelope fluid 426 and sample fluid 424 associated with the difference in viscosity, in combination with a geometric hydro-focusing effect induced by an interaction between envelope fluid 426 and the sample fluid 424 associated with the reduction in flow path size, provides a target imaging state in at least part of the plurality of particles at the imaging site 432. As shown here, system 400 also includes an imaging device 430 that image the plurality of particles at the 432 imaging site.
[000138] As shown in the flow cell embodiment shown in Figure 4A, a decrease in flow path size (for example, in the transition zone 419a) can be defined by opposite walls 421a, 423a of the flow path 422a. Opposite walls 421a, 423a can be angled radially inward along the flow path 422a, generally symmetrical over a transverse plane 451a that bisects the sample fluid stream 428a. The plane 451a can bisect the sample stream 428a, where the sample stream has a first thickness T1, at a location where the sample stream 428a exits a distal portion 427a of the sample cannula or injection tube 412a. Similarly, the plane 451a can bisect the sample stream 428a, where the sample stream has a second thickness T2, at a location where the sample stream 428a passes the image capture site 432a. According to some modalities, the first thickness T1 has a value of about 150 μm and the second thickness T2 has a value of about 2 μm. In such cases, the compression ratio of the sample tape stream is 75: 1. According to some modalities, the first thickness T1 has a value within a range from about 50 μm to about 250 μm and the second thickness T2 has a value within a range from about 2 μm to about 10 μm. As the fluid in the sample stream flows through the flow cell, the tape becomes thinner as it accelerates and is stretched. Two traces of the flow cell can contribute to the thinning of the sample fluid strip. First, a speed difference between the envelope fluid envelope and the sample fluid strip can operate to reduce the thickness of the strip. Second, the tapered geometry of the transition zone can operate to reduce the thickness of the tape. As shown in Figure 4A, the distal outlet port 413a of the cannula 412a can be positioned centrally along the length of the narrowing transition zone 419a. In some cases, the distal outlet port may be positioned closer to the beginning (proximal portion 415a) of the transition zone 419a. In some cases, the distal outlet port may be positioned closer to the end (distal portion 416a) of the transition zone 419a. In some cases, the distal outlet port 413a can be positioned entirely outside the transition zone 419a, for example, as shown in Figure 3A (where the distal outlet port 331 is arranged proximal to the narrowing transition zone).
[000139] As shown in Figure 4A (as well as in Figures 4 and 4B-1), the transition zone 419a can be defined by angular transitions in the proximal (415a) and distal (416a) portions. It should also be understood that the transition zone 419a may instead have curved or smooth transitions in the proximal (415a) and distal (416a) portions, similar to the curved or smooth transitions as shown in Figures 1, 3, 3A, 3B and 4B-2).
[000140] Typically, the first thickness T1 is much larger than the size of the sample particles and, therefore, the particles are contained entirely within the sample strip stream. However, the second thickness T2 may be less than the size of certain sample particles and, therefore, those particles may extend out of the sample fluid and into the surrounding envelope fluid. As shown in Figure 4A, the sample tape stream can generally flow along the same plane as it exits the cannula and travels towards the image capture site.
[000141] The flow cell can also provide a separation distance 430a between the distal cannula portion 427a and the imaging site 432a. According to some embodiments, the distal portion 427a of the sample fluid injection tube 412a can be positioned at an axial separation distance 430a from the image capture site 432a, where the axial separation distance 432a has a value of about 21 mm. According to some embodiments, the axial separation distance 430a has a value within a range from about 16 mm to about 26 mm.
[000142] The axial separation distance 430a between the cannula outlet port and the imaging site can impact the transition time for the sample fluid as the fluid moves from the outlet port to the site image capture. For example, a relatively shorter axial separation distance 430a can contribute to a shorter transition time, and a relatively longer axial separation distance 430a can contribute to a longer transition time.
[000143] The position of the outlet port in the distal cannula portion 427a in relation to the flow path transition zone 419a, or in relation to the proximal portion 415a of the flow path transition zone 419a, can also interfere with time transition to the sample fluid as the fluid moves from the outlet port to the image capture site. For example, the wrapping fluid may have a relatively lower velocity in the proximal portion 415a, and a relatively greater velocity in a location between the proximal portion 415a and the distal portion 416a. Therefore, if the cannula outlet port in the distal portion 427a is positioned in the proximal portion 415a, it will take a longer amount of time for the sample fluid to reach the image capture site, not only due to the fact that the The path is longer, but also due to the fact that the initial velocity of the sample fluid, after it leaves the distal portion of the cannula, is lower (due to the lower envelope fluid velocity). Otherwise, the longer the sample fluid is present in the thickest part (for example, close to the proximal portion 415a) of the flow cell, the longer the sample will take to reach the image capture site. Conversely, if the cannula outlet port on the distal portion 427a is positioned distal to the proximal portion 415a (for example, in a central location between the proximal portion 415a and the distal portion 416a, as shown in Figure 4A), it will take an amount of less time for the sample fluid to reach the image capture site, not only due to the fact that the travel distance is shorter, but also due to the fact that the initial velocity of the sample fluid after it leaves of the distal portion of the cannula, is greater (due to the greater wrapping fluid velocity). As discussed elsewhere in this document, the wrapping fluid is accelerated as it flows through transition zone 419a, due to the cross-sectional area of zone 419a.
[000144] According to some modalities, with a shorter transition time, more time is available for image collection on the image capture site. For example, as the duration of the transition time from the distal tip of the cannula to the imaging area decreases, it is possible to process more samples in a specific amount of time and, correspondingly, it is possible to obtain more images in one specific amount of time (for example, images per minute).
[000145] Although there are advantages associated with positioning the outlet port of the distal cannula portion 427a closer to the image capture site 432a, it is also desirable to maintain a certain distance between the port and the capture site. For example, as shown in Figure 3, a front lens or optical objective of an imaging device can be positioned on the seat 58 of the flow cell 22. If the outlet port 31 of the cannula is too close to the seat 58, then the Sample fluid may not be sufficiently stabilized after it is injected into the envelope fluid to provide desired imaging properties at the image capture site. Similarly, it may be desirable to keep the tapered transition region 21 at a distance from the viewing area 23, so that the tapered region does not interfere with the positioning of the seat 58, which receives the lens from the image capture device.
[000146] Again with reference to Figure 4A, the downstream end 427a of the sample fluid injection tube 412a can be positioned distal to a proximal portion 415a of the flow path transition zone 419a. Correspondingly, the downstream end 427a of the sample fluid injection tube 412a can be positioned proximal to a distal portion 416a of the flow path transition zone 419a. Therefore, according to some embodiments, the sample fluid can be injected from the injection cannula 412a and into the flow cell at a location within the transition zone 419a.
[000147] According to some modalities, the symmetry in the decrease in flow path size (for example, in the flow path transition zone 419a) operates to limit the particle misalignment in the urine sample. For example, such symmetry can be effective in limiting the misalignment of red blood cell imaging orientation in the urine sample to less than about 20%.
[000148] According to some modalities, the methods disclosed in this document are operable for the signaling rate during blood test analysis at below 30%, 29%, 28%, 27%, 26%, 25%, 24%, 23%, 22%, 21%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8% , 7%, 6% or 5% of samples.
[000149] According to some modalities, the image capture site 432a has a field of view 433a between about 800 μm x 800 μm. In some cases, the image capture site 432a has a field of view 433a of about 275 μm x 275 μm. In some cases, the field of view can be defined in terms of length by width. If expressed as a surface area, a field of view of 275 μm x 275 μm has an area of 75,625 μm2. According to some modalities, the field of view can be determined by the lens of the imaging device and its magnification. In some cases, the field of view may correspond to the extension of the field (area) that is imaged by the collection optics (for example, objective, tube lens and camera). In some cases, the field of view is much smaller than the viewing area of the transparent area at the image capture site.
[000150] Figures 4A-1 and 4A-2 illustrate the effects of hydrofocusing on the sample stream as it moves from the cannula outlet port to the image capture site. As shown in Figure 4A-1, the sample stream can have a height H (S) of about 150 μm and a width W (S) of about 1,350 μm. In some cases, the width W (S) is about 1,600 μm. In some cases, the width W (S) is about 2,000 μm. In some cases, the sample stream has a width of about 2,190 μm. In some cases, the W (S) width has a value within a range from about 1,350 μm to about 2,200 μm. The sample stream dimensions shown here may correspond to the dimensions of the cannula outlet port, for example, as shown in Figure 4E. In addition, the PIOAL wrap current can have a height H (P) of about 6,000 μm and a width W (P) of about 4,000 μm. Subsequent to hydro-focusing, as shown in Figure 4A-2, the sample stream can have a height H (S) of about 2 μm and a width W (S) of about 1,350 μm. In some cases, the width W (S) is about 1,600 μm. In some cases, the width W (S) is about 2,000 μm. In some cases, the sample stream has a width of about 2,190 μm. In some cases, the W (S) width has a value within a range from about 1,350 μm to about 2,200 μm. In addition, the PIOAL wrap current can have a height H (P) of about 150 μm and a width W (P) of about 4,000 μm. In one embodiment, the cross-sectional area of the PIOAL wrap current at the cannula outlet is 40 times greater than the cross-sectional area close to the image capture site.
[000151] According to some modalities, it may be useful to determine the cross section of the flow cell channel at the image capture site. This can correspond to the height H (P) of PIOAL wrap current of about 150 μm and a width W (P) of about 4,000 μm, as shown in Figure 4A-2. It may also be useful to determine the volumetric flow rate of the combined sample and envelope fluid through the flow cell at the image capture site. When the cross-sectional area and flow rate are known, it is possible to determine the speed of the combined sample and envelope fluid at the image capture site.
[000152] According to some modalities, the flow of the sample and envelope fluids through the flow cell can be approximated to a parallel plate profile model. Correspondingly, the flow rate at the center of the sample fluid stream (for example, as shown in Figure 4A-2), can be about 1.5 times the average flow rate of the combined sample stream and wrap fluid .
[000153] According to some modalities, the cross-sectional area of the sample flow at the cannula outlet (for example, W (S) x H (S) in Figure 4A-1) is 40 times larger than the section area section of the sample flow at the imaging site (for example, W (S) x H (S) in Figure 4A-2). The volumetric flow rate of the wrapping fluid in the imaging area can be about 45 μl / second. The volumetric flow rate of the sample fluid in the imaging area can be about 0.232 μl / second. In some cases, the cross-sectional area of the combined sample and envelope streams at the imaging site is 600,000 μm2. In some cases, the average current speed at the imaging site is 75 mm / second.
[000154] The rate of flow or speed can be determined as the rate that results in clear and focused cellular images. The flow rates and exemplary speeds were revealed based on the flow rates of the two samples that were observed by reaching certain characteristics or formats of sample current strips at the imaging site. For example, at a flow rate of about 75 mm / second (or within a range from 20 to 200 mm / second), cells do not flow too slowly so that there are overlapping cells in consecutive images, and the cells do not flow too fast so that the effects of ghosting are created (blurry image). Correspondingly, by avoiding excessively high flow rates, it is possible to conserve more reagent and sample. According to some modalities, an ideal or desired linear speed can be achieved by changing the volumetric flow (pump rate) or the shape of the cannula.
[000155] The flow rate of the sample stream through the image capture zone may also be related to the performance of the image capture device in relation to the function of the flow cell. For example, if the sample stream is flowing too fast, it can be difficult to obtain clear images of particles contained in the sample (for example, the shutter speed of the image capture device may be too small, thus producing a blurry image. ). Similarly, if the sample stream is flowing too slowly, the image capture device can take consecutive images of the same particle (for example, the same particle remains in the capture frame for two image captures). In some embodiments, the speed of the sample tape can be modulated (for example, by adjusting any of a variety of flow cell operating parameters) in relation to the image capture rate, so that there is minimal flow between captures and, therefore, a high percentage of the sample is imagined.
[000156] According to some modalities, the particle analysis system and associated components can be configured so that, as the wrapping fluid and fluid sample flow through the flow cell, the wrapping fluid can flow in a envelope fluid volumetric rate of 45 μl / s and the fluid sample can flow at a fluid sample volumetric flow rate of 0.232 μl / s (or within a range from 0.2 to 0.35 μl / s) . In some cases, a sample fluid flow rate can have a value within a range from 0.2 μl / s to 1 μl / s. In some cases, the wrapping fluid can have a flow rate of around 40 μl / s. In some cases, the sample fluid may have a flow rate of around 0.56 μl / s. In some case, for an imaging duration of about 19 seconds, a volume of sample fluid flowing through the flow cell may have a value within a range from about 8 μl to about 12 μl. In some cases, the ratio between the wrap fluid flow rate and the sample fluid flow rate is about 200. In some cases, the ratio between the wrap fluid flow rate and the fluid flow rate sample size has a value within the range of about 70 to 200. In some cases, the ratio between the wrapping fluid flow rate and the sample fluid flow rate is around 193. In some cases , the ratio between the wrapping fluid flow rate and the sample fluid flow rate is about 70. In some cases, a ratio between the wrapping fluid volume and the sample fluid volume flowing inside the cell flow can be in a range from 25: 1 to 250: 1.
[000157] According to some modalities, the system and associated components can be configured so that, as the wrapping fluid and the fluid sample flow through the flow cell 420, the wrapping fluid can flow at a fluid speed 75 mm / second wrap before the imaging area and the fluid sample can flow at a fluid sample speed of 130 mm / second before the imaging area. In some cases, a ratio between the volume of envelope fluid and the volume of fluid sample flowing within the flow cell can range from 100: 1 to 200: 1.
[000158] In some cases, a flow cell may have a minimum compression ratio of about 50: 1 and a maximum compression ratio of about 125: 1. In some cases, the minimum compression ratio can be around 30: 1 or 20: 1. This compression ratio refers to the flow current ratio H (S): H (S) when comparing Figure 4A-1 with Figure 4A-2. This compression ratio can be influenced by a combination of geometric compression (for example, the ratio between the thicknesses of wrap fluid H (P): H (P) when comparing Figure 4A-1 with Figure 4A-2, the which can also generally correspond to the dimensions of the flow cell narrowing tapered transition zone 419a shown in Figure 4A) and a hydrodynamic compression (for example, which also corresponds to a difference in speed). According to some modalities, the geometric compression ratio is about 40: 1.
[000159] The decrease in size of the flow path, which corresponds to the transition zone, can be defined by a portion of the proximal flow path that has a proximal height or thickness and a portion of the distal flow path that has a height or distal thickness that is less than the height or proximal thickness. For example, as shown in the partial views of Figures 4B-1 and 4B-2, the transition zone 419b of the flow path may have a length L between a proximal portion 415b and a distal portion 416b, where the proximal portion 415b has a proximal height 417b, and the distal portion 416b has a distal height 418b. As shown in Figure 4B-2, and as noted elsewhere in this document, the shape or contour of the transition zone can be curved or smooth and, for example, can be provided in the shape of an S curve, a sigmoid curve , or a tangent curve. According to some modalities, the proximal height 417b has a value of about 6,000 μm. In some cases, the proximal height 417b has a value within a range from about 3,000 μm to about 8,000 μm. According to some modalities, the distal height 418b has a value of about 150 μm. In some cases, the distal height 418b has a value within a range from about 50 μm to about 400 μm.
[000160] The geometry of the transition zone 419a can provide a first angle α1 between the first flow path limit 403b and the bisector transverse plane 451b, and a second angle α2 between the second flow path limit 404b and the transverse plane bisector 451b. In some cases, angle α1 is about 45 degrees and angle α2 is about 45 degrees. In some cases, the angle α1 has a value within a range from about 10 degrees to about 60 degrees. In some cases, the angle α2 has a value within a range from about 10 degrees to about 60 degrees. According to some modalities, the angles α1 and α2 have the same value. Angles α1 and α2 can be selected to maintain laminar flow or to minimize turbulence of the sample fluid as it moves from the proximal portion 415b to the distal portion 416b, which, in turn, can enhance the alignment of particles within the sample along the transverse plane 451b. As noted above with reference to Figure 4A, the distal and proximal portions or boundaries of the transition zone can be curved or smooth, rather than angular.
[000161] Figure 4C represents traces of an exemplary cannula or sample feeding tube 400c according to the modalities of the present invention, in which the cannula is of length L. Figure 4D represents a longitudinal cross section of the cannula 400d. As shown here, the cannula 400d includes a flattened distal section 410d, a central tapered section 420d and a proximal tubular portion 430d. As shown in Figure 4C-1, an exemplary 400c-1 sample feeding tube or cannula may have a distal portion 410c-1 and a proximal portion 430c- 1. In some cases, the distal portion 410c-1 has a length of about 1.359 mm and a width of about 1.43 mm. In some cases, the outlet port at the distal end has an outlet width W (E) of about 1.359 mm. According to some modalities, a cannula may have an internal flow path geometry that is different from that shown in Figures 4C and 4D. For example, as illustrated in Figure 4D-1, the cannula 400d-1 does not include a tapered center section that has an expanded flow area cross section. As shown in Figure 4D-1, the cannula 400d-1 has a distal section 410d-1, a central tapered section 420d-1 that has a tapered internal diameter, and a proximal section 430d-1. Corresponding to the tapered internal diameter of the central section 420d-1, the internal area in cross section of 410d-1 is smaller than the internal area in cross section of 430d-1.
[000162] A urinalysis system according to the modalities of the present invention can process a urine sample that has a volume of about 900 μl. The cannula or injection tube 400d shown in Figure 4D has an internal volume of about 13 µl. According to some modalities, the cannula or injection tube has an internal volume of less than about 30 ul.
[000163] Figure 4E illustrates a cross section of a flattened distal section 410e. As shown here, the distal section 410e has an internal width W (I) and an internal height H (I), through which a sample stream flows. Additionally, the distal section 410e has an outer width W (O) and an outer height H (O). As shown in Figures 4D and 4E taken in combination, the distal portion 410e of the sample fluid injection tube has an outlet port P that has a height H (I) and a width W (I), where the height H (I) is less than the width W (I). According to some modalities, the height H (I) of the exit port P of the distal portion 410e (or the internal height of the distal portion 410d) can have a value of about 150 μm. In some cases, height H (I) can be in a range from about 50 μm to about 250 μm. According to some modalities, the width W (I) of the exit port P of the distal portion 410e (or the internal width of the distal portion 410d) can have a value of about 1,350 μm. In some cases, the width is about 1,194 μm. In some cases, the width W (I) can have a value within a range from about 500 μm to about 3,000 μm. In some cases, the height H (I) can be about 150 μm and the width W (I) can be about 1,350 μm. In some cases, the width W (I) is about 1,600 µm. In some cases, the width W (I) is about 2,000 μm. In some cases, the width W (I) is about 2,190 μm. In some cases, the width W (I) has a value within a range from about 1,350 μm to about 2,200 μm. As discussed elsewhere in this document, the value for width W (I) can determine the width of the sample stream at the imaging site. In some cases, the distal flat section 410d can be produced by applying a clamping force to a pipe or conduit. In some cases, the cannula may have a length of about 3.12 cm (about 1.23 inches) and an internal diameter of about 0.140 cm (about 0.055 inches). In some cases, the cannula may have an internal volume of about 48 μl.
[000164] Figure 4F illustrates a cross section of a central tapered section 420f. As shown here, the central tapered section 420f has an internal diameter D (I) through which a sample stream flows. Additionally, the central tapered section 420f has an outer diameter D (O). Figure 4G illustrates a cross section of a 430g proximal section. As shown here, the proximal section 430g has an internal diameter D (I) through which a sample stream flows. Additionally, the distal section 430g has an outer diameter D (O).
[000165] As shown in Figure 4D, the injection tube or cannula 400d may have a proximal portion 430d that has a first flow cross-sectional area (for example, π * (D / 2) 2 shown in Figure 4G), a distal portion 410d that has a second flow cross-sectional area (for example, W (I) * H (I) shown in Figure 4E) which is smaller than the first flow cross-sectional area and a third portion 420d arranged between the proximal portion 430d and the distal portion 410d. The third portion 420d may have a third flow cross section (for example, π * (D / 2) 2 shown in Figure 4F) that is larger than the first and second flow cross sections. In some cases, the outer diameter D (O) of the proximal portion 430g is about 1,067 μm and the inner diameter D (I) of the proximal portion 430g is around 813 μm.
[000166] According to some modalities, a proximal portion of an injection tube can be coupled to a sample port of a sample inlet fitting. For example, as shown in Figure 4H, a proximal portion 405h of a cannula 400h can be coupled directly to a sample port 410h on an outlet of a sample inlet fitting 420h.
[000167] A flow cell of a particle imaging system in a urine sample can be oriented in any desired direction or angle in relation to the direction of the force of gravity. For example, a flow cell can be oriented in an upward direction, so that the fluid flowing inside the flow cell (for example, wrapping fluid, optionally in combination with the sample fluid) can move in one direction upwards, against the force of gravity. Similarly, a flow cell can be oriented in a downward direction, so that the fluid flowing within the flow cell (for example, wrapping fluid, optionally, in combination with the sample fluid) can move in a downward direction against the force of gravity. Figure 4I represents a flow cell 420i oriented in an upward direction, so that the sample fluid 424i and envelope fluid 426i that flow within the flow cell 420i flow against gravity G. Figure 4J represents a flow cell. flow 420j oriented in a downward direction, so that sample fluid 424j and envelope fluid 426j flowing within flow cell 420j do not flow against gravity G, but preferably flow with gravity G.
[000168] As shown in Figure 4K, a sample stream ribbon R flowing through a 432k image capture site of a 420k flow cell can have a T thickness of about 2 μm. In some cases, the thickness T of the sample stream strip can be up to about 3 μm. Typically, cells or particles that are less than the thickness of the sample stream will be contained within the tape. An exemplary red blood cell (RBC) can be present as a biconcave disk and can have a diameter D between about 6.2 μm and about 8.2 μm. In addition, an exemplary red blood cell can have a maximum thickness T1 between about 2 μm and about 2.5 μm and a minimum thickness T2 between about 0.8 μm and about 1 μm. In some cases, red blood cells can be up to about 3 μm thick. Exemplary human platelets may vary in size and may also have a thickness or diameter of about 2 μm. Although not shown in scale here, the flow cell can define a flow path thickness H that has a value of about 150 μm, at the image capture site. In some cases, the flow path thickness F has a value between 50 μm and 400 μm. This flow path thickness F may also correspond to the distal height 418b of the distal portion 461b shown in Figures 4B-1 and 4B-2.
[000169] As shown in Figure 4K, the ratio between the thickness T of the sample fluid stream and the thickness of the particle (red blood cell) is about 1: 1. According to some modalities, a ratio between the thickness T of the sample fluid stream at the image capture site and a particle size is in a range from 0.25 to 25. In some cases, the T thickness can have a value within a range from 0.5 μm to 5 μm.
[000170] As discussed elsewhere in this document, as well as in copending US patent application no., Differences in viscosity between the sample tape fluid R and the wrapping fluid can operate to align or orient the particles in the stream sample, for example, red blood cells, along the flow direction. When so aligned, as shown in Figure 4K, the imaging device or camera can take images of the red blood cells, they appear round, due to the fact that the larger surface of the blood cell is facing the camera. In this way, the red blood cell assumes an alignment that presents a low resistance in relation to the flow. Therefore, the relative viscosity characteristics of the wrapping fluid and the sample fluid can contribute to a high percentage or number of red blood cells facing the camera, thus enhancing the evaluation capacity of the particle analysis system.
[000171] According to some modalities, the viscosity characteristics of the surrounding fluid operate to limit the particle misalignment in the urine sample. For example, viscosity differentials can be effective in limiting the misalignment of red blood cell imaging orientation in the urine fluid sample to less than about 10%. That is, 90 or more red blood cells out of 100 red blood cells in a sample can be aligned so that their larger surfaces face the imaging device. A symmetric narrowing transition zone can provide a value of 20%. An image of a urine sample processed using a flow cell without a viscous wrap fluid is shown in Figure 4O, and in comparison, an image of a urine sample processed using a flow cell with a fluid viscous envelope is shown in Figure 4P. As shown here, the use of a viscous wrap fluid can limit the misalignment of particles within the sample fluid stream. According to some modalities, the wrapping fluid has a refractive index similar to that of water (that is, n = 1.3330). In some cases, the wrapping fluid has a water content of around 89%. In addition to the alignment effects observed as a result of the viscosity differential, the alignment effects are also observed as a result of a bilateral tapered transition zone. In some cases, it is observed that a bilateral tapered transition zone (that is, symmetrical) is twice as effective in aligning particles as compared to an asymmetric tapered transition zone design.
[000172] The efficient alignment of red blood cells can contribute to the improved diagnosis. In some cases, the shape of the imaged red blood cells can be used to determine whether a patient from whom the sample is obtained has a particular physiological condition or disease. For example, patients with sickle cell anemia have blood cells that have an abnormal shape (that is, the shape of a sickle). Therefore, by obtaining high quality images of aligned red blood cells, it is possible to ensure an accurate diagnosis. Other shape variations in red blood cells, for example, red blood cells that have a thin peripheral area and a large, flat central area, so that the red blood cell appears to have the profile of a bicycle tire, can be imagined effectively with use of the present alignment techniques. Similarly, red blood cells with a small central portion and a thick peripheral area, so that the red blood cell appears to have the profile of a truck tire, can be imaged for diagnostic purposes. The improved imaging techniques disclosed in this document are also useful for evaluating other characteristics of red blood cells, such as hemoglobin content, iron content and the like.
[000173] Without sticking to any particular theory, it is believed that a viscosity differential between the viscosity of the wrapping fluid and the viscosity of the sample fluid produces a modified parabolic profile, in which the profile is generally parabolic and has a central boss which corresponds to a central area of the flow in which the acceleration is increased, and the central boss contributes to the alignment of sample particles or intraparticle organelles. According to some modalities, the difference in speed between the sample tape and wrap and the difference in viscosity generate shear forces to increase the alignment of organelles or intracellular particles. Exemplary aspects of the wrapper fluid parabolic profile are discussed in copending US patent application no., The content of which is incorporated herein by way of reference.
[000174] White blood cells are typically larger than red blood cells and platelets. For example, exemplifying neutrophils and eosinophils can have a diameter between about 10 μm and about 12 μm. Exemplary basophils can have a diameter between about 12 μm and about 15 μm. Example lymphocytes (small) can have a diameter between about 7 μm and about 8 μm, and example lymphocytes (large) can have a diameter between about 12 μm and about 15 μm. Exemplary monocytes can have a diameter between about 12 μm and about 20 μm. The configuration of the particle analysis system, including the interaction between the wrapping fluid and the fluid sample tape, as they pass through the flow cell, can operate to compress the white blood cells as they move through the image capture site 432l, as shown in Figure 4L. Therefore, for example, a central portion of the white blood cell (WBC) can be positioned within the sample fluid strip R, and the peripheral portions of the white blood cell can be positioned within the envelope fluid. Therefore, as the white blood cell is transported through the flow cell by the ribbon, the sides of the white blood cell may extend into the surrounding fluid.
[000175] According to some modalities, differences in viscosity between the wrapping fluid and the sample fluid can operate to align the organelles or other intracellular traces that are present within the cells, such as white blood cells. Without sticking to any particular theory, it is believed that the shear forces associated with the viscosity differential between the envelope fluid and the sample fluid can act on the white blood cells to align the intracellular traces. In some cases, the shear forces associated with speed differentials between the envelope fluid and the sample fluid can contribute to such an alignment. These alignment effects can be impacted by a size differential between the particles and the sample fluid strip as well. For example, where the portions of the particles extend out of the sample fluid strip and into the surrounding envelope fluid, the shear forces associated with the difference in viscosity can have a considerable effect on intracellular trace alignment.
[000176] As shown in Figure 4L, portions of a cell, such as a white blood cell, can extend into the envelope fluid. The embodiments of the present invention encompass envelope fluid compositions that do not cause lysis or fragment the cell, or otherwise compromise the integrity of the outer cell membrane, when the cell is exposed to the envelope fluid. A viscosity agent in the wrapping fluid can operate to retain the viability of cells in the sample fluid stream, in order to leave the structure (eg, shape) and content (eg, nucleus) of the cells intact when the wall or cell membrane crosses an interface between the sample fluid strip and the envelope fluid envelope, or otherwise extends from the sample fluid stream in the circulating envelope fluid.
[000177] Often, there are compressive forces that act under the cells or particles as they flow into the sample fluid strip along the flow cell. Consequently, cells can come in contact with the envelope fluid, while cells are in a compressed state or are otherwise subjected to compressive forces as a result of a narrowing transition zone. The wrapping fluid viscosity agent can operate to protect the compressed cells from being fragmented or destroyed when they emerge from the thin sample fluid strip and are exposed to the viscous wrap fluid, at least until the cells reach the capture site of image. Therefore, the viscosity agent composition of the wrapping fluid can operate as a cell protector, while also enhancing the alignment of particles or intraparticle content.
[000178] With reference to Figures 4K and 4L, in some cases, the cell or particle portions may extend out of the thin sample fluid strip R and into the surrounding envelope fluid. As discussed in copending US patent application no., The wrapping fluid may contain cell protectors that inhibit or prevent the wrapping fluid from breaking or causing lysis of the cells or particles. For example, the wrapping fluid may contain cell protectors that preserve the structural integrity of the cell walls as cells are exposed to the chemical environment of the wrapping fluid. Similarly, cell protectors can also operate to preserve the structural integrity of cell walls as cells experience any shear forces induced by the flow cell's geometry and a difference in speed and / or viscosity between the sample fluid and the wrap fluid. Correspondingly, guards can protect cells or particles against forces that result from the difference in speed between the sample fluid and the wrapping fluid. In this way, the cells retain their viability as they reach the image capture site.
[000179] Shear forces can be significant at the interface between the sample fluid strip and the envelope fluid envelope. According to some modalities, the flow within the flow path of the flow cell can be characterized by a parabolic flow profile. Figure 4L-1 represents exemplifying aspects of parabolic flow profiles 400l-1a and 400l-1b. The 400l-1a parabolic profile on the top panel is a typical velocity profile found in flows within certain flow cell modalities of the present invention (for example, where there is little or no viscosity differential between a sample stream fluid that is enveloped within a fluid flow envelope). As can be seen, a higher linear velocity is observed in the middle of the fluid stream and slower linear velocities are observed near the flow cell wall. The 400l-1a profile can also be seen in a fluid stream with a slight difference in viscosity between the wrapping and sample fluids. In a case in which there is a high viscosity differential between the fluid and envelope streams, a central boss is observed as shown in the profile 400l-1b, in which there is an area located with amplified linear velocities. According to some modalities, particles that are large enough in size will be subjected to some amount of shear force, to the extent that such particles are completely contained within a single fluid phase (i.e., within the envelope fluid or envelope envelope). , alternatively, inside the sample fluid strip).
[000180] In some cases, the speed of the wrapping fluid may be different from the speed of the sample fluid. For example, the wrapping fluid may be moving at 80 mm / second and the sample fluid may be moving at 60 mm / second. Therefore, in some cases, the sample fluid leaves the distal cannula port at a sample fluid rate that is less than the envelope fluid rate of the surrounding envelope. Therefore, the wrapping fluid can operate to drag the sample fluid along the flow path of the cannula, thereby accelerating the sample fluid and reducing the thickness of the sample fluid strip. The sample fluid tape maintains total mass and volume, as it moves faster it becomes thinner. According to some modalities, both the wrapping fluid and the sample fluid have a speed between about 20 and 200 mm / second at the image capture site.
[000181] Typically, the velocity of the sample fluid increases as the sample fluid moves from the cannula outlet port to the image capture site. In some cases, the speed of the sample fluid at the imaging site is 40 times the speed of the sample fluid as it exits the cannula port in the distal portion of the cannula. According to some modalities, the decrease in cross-sectional area of the sample tape is linear to the increase in speed. According to some modalities, if the wrap speed at the cannula outlet is greater than the sample tape speed, this will also increase the final sample tape speed in the imaging area.
[000182] The wrapping fluid can operate to apply significant shear forces on the sample fluid strip and on particles within the sample fluid strip. Some forces are parallel to the flow direction, and particles can also encounter forces that are perpendicular to the flow direction. Often, as the wrapping fluid and sample fluid get closer to the image capture zone or site, the wrapping and sample fluids are moving at almost or the same speed. Therefore, the boundary or interface between the wrapping and sample fluids, as they pass from the image capture site, may exhibit less shear forces compared to the boundary or interface on the distal cannula outlet port or in the tapered transition zone. For example, in the tapered transition zone, the boundary or interface between the envelope fluid envelope and the sample fluid strip may be in transition, such that the sample strip that is initially slower and thicker becomes more thinner, and the particles in the sample fluid become more aligned. Otherwise, the shear forces may be prominent in the tapered transition zone, and may dissipate towards the image capture site. The shear forces at the image capture site can be represented by a parabolic profile and can be much less than the shear forces in the tapered transition zone. Therefore, cells or particles may experience greater shear forces as they pass through the transition zone, and lesser shear forces as they pass through the image capture site. According to some modalities, the difference in viscosity between the wrapping and sample fluids can put the red blood cells in alignment and, thus, in focus. According to some modalities, the difference in viscosity between the envelope and sample fluids can put the white blood cells in alignment and, thus, in focus. Correspondingly, enhanced imaging results can be obtained for the cellular components and organelles that are aligned and brought into focus, which results from the geometric narrowing of the current and the difference in speed between the envelope and sample fluids.
[000183] As noted elsewhere in this document, and with reference to Figures 4K and 4L, as the wrapping fluid and sample fluid R flow through a reduction in the size of the flow path or transition zone of a flow cell, and towards a 432k or 432l imaging site, a viscosity hydro-focusing effect induced by an interaction between the wrapping fluid and the sample fluid R associated with a viscosity difference between the wrapping fluid viscosity and the sample fluid viscosity, in combination with a geometric hydro-focusing effect induced by an interaction between the envelope fluid and the sample fluid R associated with the reduction in size of the flow path or transition zone, provides a state of targeting at least part of the plurality of particles at the 432k or 432l imaging site.
[000184] In some cases, the target imaging state is a target orientation relative to a focal plane F at the imaging site. For example, as shown in Figure 4K-1, the particle (RBC) can be displaced a distance from the focal plane F. In some cases, a target orientation involves an orientation of the target particle in relation to the focal plane F at the imaging site. 432k-1. The particle can be a blood cell, such as a red blood cell, a white blood cell or a platelet. As shown here, the flow path at the 432k-1 imaging site can define a plane P that is substantially parallel to or coplanar with the focal plane F. In some cases, a portion of the particle may be positioned along the focal plane F furthermore, the central portion of the particle may be otherwise displaced from the focal plane F. In some cases, the target orientation involves a target position in relation to the focal plane F at the 432k-1 imaging site. For example, the target position may involve positioning the particle so that at least a portion of the particle is arranged along the focal plane F. In some cases, the target position may involve positioning the particle so that a distance between the particle and the focal plane F does not exceed a certain threshold. In some cases, the target position involves a target particle position that is relative to the focal plane F at the 432k-1 imaging site. In some cases, the target position is equal to or less than a distance D from the focal plane F, where the distance D corresponds to a positional tolerance. A viscosity differential between the wrapping fluid and the sample fluid can be selected in order to achieve a desired positioning of the ribbon sample stream within the flow cell (for example, in relation to the flow path plane P and / or focal plane F). In some cases, the viscosity differential can be selected in order to achieve a target particle position that is equal to or less than positional tolerance D.
[000185] In some cases, the focal plane F has a thickness or depth of field as indicated in Figure 4K-2, and the particle (RBC) has a target imaging state in relation to the thickness of the focal plane. For example, the target position for the particle may be within the focal plane F or at least partially within the focal plane F. In some cases, a high-resolution optical imaging device or camera may have a depth of field or plane thickness focal length of about 7 μm. In some cases, the depth of field or focal plane thickness has a value with a range from about 2 μm to about 10 μm. In some cases, the depth of field of the camera is similar to or equal to the thickness of the sample tape at the image capture site.
[000186] In some cases, the target orientation may involve target alignment in relation to the focal plane F at the imaging site. For example, the target alignment may indicate that a plane defined by the particle is aligned with the focal plane F, not to exceed a certain angle α in relation to the focal plane F at the 432k-3 image capture site as shown in Figure 4K- 3. In some cases, the target imaging state may involve a limitation on the number or percentage of misaligned particles in a sample. For example, a difference in viscosity between the wrapping fluid and the sample fluid R can be effective in limiting the misalignment of red blood cell imaging orientation in the urine sample to less than about 10%. That is, 90 or more red blood cells out of 100 red blood cells in a sample can be aligned so that their larger surfaces face the imaging device (as shown in Figures 4K-1 and 4K-2) or so that the alignment of those 90 or more RBCs is within 20 degrees of a plane substantially parallel to the direction of flow (for example, RBC α alignment angle is 20 degrees or less). As discussed elsewhere in this document, in some cases, at least 92% of non-spherical particles, such as RBCs, can be aligned in a plane substantially parallel to the direction of flow. In some cases, at least between 75% and 95% of non-spherical particles, such as RBCs, can be substantially aligned, that is, within 20 degrees of a plane substantially parallel to the direction of flow (for example, angle of alignment α is 20 degrees or less). According to some modalities, 90% or more of certain particles (for example, red blood cells and / or platelets) can be oriented across the geometrical axis of the imaging device.
[000187] In some cases, the embodiments of the present invention include compositions for use with a urinalysis system, as described in the present invention, such as a particle or wrapping fluid and intracellular organelle alignment fluid (PIOAL). Such wrapping fluids or PIOALs are suitable for use in a visual analyzer of geometric hydro-focusing and combined viscosity. The PIOAL can operate to direct or facilitate the flow of a urine sample fluid of a given viscosity through a narrowing flow cell transition zone of the visual analyzer. The PIOAL can include a fluid that has a viscosity greater than the viscosity of the sample. A viscosity hydro-focusing effect induced by an interaction between the PIOAL fluid and the sample fluid associated with the difference in viscosity, in combination with a geometric hydro-focusing effect induced by an interaction between the PIOAL fluid and the fluid of the sample associated with the narrowing flow cell transition zone, can be effective in providing a target imaging state in at least part of the plurality of particles at a visual analyzer imaging site, while retaining cell viability in the urine sample fluid.
[000188] Figure 4M represents an exemplary 400 m neutrophil (a type of white blood cell) that has internal organelles, such as lobes 410 m. As a result of the viscosity differential between the sample fluid and the surrounding fluid, the internal organelles can line up within the cell, as indicated by Figure 4N. Therefore, intracellular organelles can be imaged effectively with a 430m image capture device, without the organelles overlapping each other. That is, instead of the lobes being stacked on top of each other, as shown in Figure 4M, when viewed from the optical or imaging geometric axis of the image capture device, the lobes are aligned and seated side by side, as shown in Figure 4N. Therefore, the lobes can be viewed in the captured image more effectively. The alignment of the internal organelle is a surprising and unexpected result of the viscosity differential between the sample and envelope fluids.
[000189] As noted elsewhere in this document, and with reference to Figures 4M and 4N, as the wrapping fluid and sample fluid R flow through a reduction in the size of the flow path or transition zone of a flow cell, and towards an imaging site of a 430m or 430n image capture device, a viscosity hydro-focusing effect induced by an interaction between the wrapping fluid and the sample fluid R associated with a difference in viscosity between the envelope fluid viscosity and the sample fluid viscosity, in combination with a geometric hydro-focusing effect induced by an interaction between the envelope fluid and the sample fluid R associated with the reduction in size of the flow path or zone transition, provides a target imaging state in at least part of the plurality of particles at the imaging site. According to some modalities, the target imaging state may correspond to a distribution of imaging states.
[000190] In some cases, the target imaging state may involve an orientation of the target intraparticle structure (eg, alignment and / or position) in relation to a focal plane at the imaging site. For example, as shown in Figure 4N, the internal structures 410m (for example, intracellular structure, organelle, lobe, or the like) can be oriented in relation to the F focal plane. In some cases, the target alignment involves a structural alignment target intraparticle in relation to a focal plane F at the imaging site, similar to the particle alignment relationship shown in Figure 4K-3. In some cases, the target position involves a position of the target intraparticle structure in relation to a focal plane at the imaging site, similar to the particle position relationship represented in Figure 4K-1. In some cases, the target orientation of the intraparticle structure may include both a target alignment in relation to the focal plane and a target position in relation to the focal plane. In some cases, the target imaging state may involve a target deformation at the imaging site. For example, as shown in Figure 4N, the 400m particle has a compressed shape compared to the particle shape shown in Figure 4M. Therefore, it can be seen that the operation of the flow cell can produce a side compression effect on the particle shapes. Correspondingly, the intraparticle traces can be oriented positionally or directionally (for example, aligned in relation to the focal plane F and / or the ribbon flow plane), as the particle itself is compressed in shape. According to some modalities, a difference in speed between the sample and envelope fluids can produce friction within the stream, and a difference in viscosity between the sample and envelope fluids can amplify this hydrodynamic friction. EXAMPLES
[000191] Any of a variety of urinalysis or urine particle analysis techniques can be performed using images of sample fluid flowing through the flow cell. Image analysis can often involve determining certain cell or particle parameters, or measuring, detecting or evaluating certain cell or particle traits. For example, image analysis may involve evaluating cell or particle size, cell nucleus traits, cell cytoplasm traits, intracellular organelle traits and the like. Correspondingly, analysis techniques may cover certain methods of counting or grading or diagnostic tests. Correspondingly, with reference to Figure 4, processor 440 may include or remain in operational association with a storage medium that has a computer application that, when run by the processor, is configured to make the system 400 differentiate different types. of cells or particles based on images obtained from the image capture device. For example, diagnostic or testing techniques can be used to differentiate between various particles present in the urine (for example, red blood cells, white blood cells, squamous epithelial cells, stones, crystals and yeast).
[000192] The examples provided in this document are for the purpose of illustration only, and the invention is not limited to these Examples, but preferably covers all variations that are evident as a result of the instruction provided in this document.
[000193] Before the experiments described here, there was no published protocol that allowed the development and methods of use that comprise PIOAL to align particles in urine and reposition the intracellular content, as revealed here. This is useful for image-based analysis and differential categorization and sub-categorization of particles in body fluid samples (eg, urine). The methods and compositions disclosed in this document can optionally stain and / or lyse the particles in a manner suitable to achieve staining of white blood cells, epithelial cells, staining of bacteria, which accentuate the differential visualization on the microscope slide. Correspondingly, before the experiments described in this document, there was no published protocol that allowed the development and methods of use that comprise PIOAL for image-based analysis and to perform the differential particle / cell categorization and sub-categorization in urine samples. and methods for using such compositions, while maintaining viable or substantially intact cells, with the option of staining and permeabilization steps that occur during flow, to achieve the staining of white blood cells, epithelial cells, bacteria, which enhance visualization microscope slide differential.
[000194] The exemplary compositions described in this document allow staining to occur at a relatively low blood-to-reagent dilution and staining can occur quickly (for example, within 30 seconds). If desired, the example method can employ the use of a surfactant in combination with heat to achieve red blood cell lysis. Exemplary formulations can be modified to maintain RBC integrity and still achieve WBC, reticulocyte and platelet staining efficacy.
[000195] The aspects and modalities of the present disclosure are based on the surprising and unexpected discovery that certain PIOAL compositions have unexpected properties that align cells and reposition intracellular structures when used to perform image-based particle / cell analysis.
[000196] As an example, several exemplifying PIOAL formulations and methods of using them have been developed. The following are some examples of PIOAL formulations with the desired properties.
[000197] The exemplary compositions described in this document allow staining to occur in a relatively high urine to reagent ratio and staining can occur quickly (for example, within 30 seconds). If desired, the example method can employ the use of a surfactant in combination with heat to achieve membrane permeabilization to maintain the integrity of RBC and still achieve the staining effectiveness of WBC, epithelial cells and bacteria at the desired resolution.
[000198] Figures 4O and 4P show images that demonstrate the comparison between the images obtained with the use of a PIOAL (Figure 4P) versus a conventional wrapping fluid (Figure 4O). The sample containing a concentrated version of the iQ200 positive urine control was analyzed after the instruments were focused using the focusing protocol (in an exemplary autofocus pattern). The sample was injected into the flow cell through a cannula, generating a sample stream in a tape format approximately 2.5 microns thick between two layers of PIOAL or conventional wrap (in controls). The visual analyzer then generates focused images of the particles in the sample stream in a tape format (for example, at about 60 frames per second) to be used for the analysis. As can be seen from Figures 4O and 4P, PIOAL significantly increases the percentage of particles aligned in the concentrated urine sample.
[000199] As an example, Figure 4Q shows the resulting images obtained with the use of the composition and exemplifying methods of the revelation, which demonstrated the effectiveness in the categorization and / or subcategorization of the following particles: red blood cells, white blood cells, epithelial cells scaly stones, stones, crystals and yeasts. The images revealed several cellular components and that nuclear lobes and granular structures are clearly distinguishable for each cell type. The urine sample was collected using the following protocol: The sample was placed in contact with a particle contrast agent composition, as shown below. The following liquids were mixed together to obtain the exemplary particle contrast agent composition: 0.150 ml of 1 mg / ml of violet crystal dissolved in a lytic solution (CDS 5PD-Lytic) and 0.150 ml of PBS, pH 7.2 . The sample specimen was initially prepared by pipetting 300 µl of the exemplary particle contrast agent composition into a test tube and mixing it with 1.7 ml of urine sample. The mixture was heated for 30 seconds in a 60 ° C water bath. The sample was analyzed on an exemplary analyzer (for example, as shown in Figure 1) using the following conditions: sample flow rate of 0.56 ul / s and envelope fluid flow rate of 46 ul / s. The results are shown in Figure 4Q. Therefore, it can be seen that the sample processing techniques disclosed in this document can provide favorable imaging results, in such a way that the particle content and structure is preserved, and the sharp alignment with respect to a geometric imaging axis is Reached.
[000200] It has also been observed that the implementation of PIOAL results in improved alignment based on the use of increasing levels of glycerol (gly) in symmetrical and asymmetric flow cells.
[000201] These results provide evidence for the surprising and unexpected discovery that certain PIOAL compositions have unexpected properties that align cells and reposition intracellular structures when used to perform image-based particle / cell analysis.
[000202] As an example, several exemplifying PIOAL formulations and methods of using them have been developed. The following are some examples of PIOAL formulations with the desired properties. The PIOAL comprises a diluent and at least one viscosity modifying agent.
[000203] Exemplary PIOAL formulation A includes a 30% (by volume) glycerol solution that has 300 ml of glycerol and q.s. (sufficient quantity or to bring the final volume up to) to 1 l with diluent containing 9.84 g sodium sulfate, 4.07 g sodium chloride, 0.11 g procaine HCl, 0.68 g phosphate monobasic potassium, 0.71 g of dibasic sodium phosphate and 1.86 g of disodium EDTA. The initial mixture was followed by q.s. up to 1 l with deionized water, while adjusting the pH to 7.2 with sodium hydroxide.
[000204] The exemplary PIOAL formulation B includes a 6.5% (by volume) glycerol solution that has 65 ml of glycerol and q.s. up to 1 l with suitable exemplifying diluent containing 9.84 g sodium sulfate, 4.07 g sodium chloride, 0.11 g procaine HCl, 0.68 g monobasic potassium phosphate, 0.71 g phosphate of dibasic sodium and 1.86 g of disodium EDTA. The initial mixture was followed by q.s. up to 1 l with deionized water, while adjusting the pH to 7.2 with sodium hydroxide.
[000205] The exemplary PIOAL formulation C includes a 5% (by volume) glycerol solution with 1% PVP (weight by volume) in buffer that has 50 ml of glycerol, 10 g of PVP (PM: 360,000), 1 packet of STF Sigma powder, at pH 7.4 (0.01 M phosphate buffered saline; 0.138 M sodium chloride; 0.0027 M potassium chloride), and qs up to 1 l with deionized water.
[000206] The exemplary PIOAL formulation D includes a 1.6% PVP solution (weight by volume) that has 16 g of PVP (PM: 360,000) and 1 packet of STF Sigma powder, at pH 7.4 ( 0.01 M phosphate buffered saline; 0.138 M sodium chloride; 0.0027 M potassium chloride), and qs up to 1 l with deionized water. Yield rate
[000207] Figure 5 represents a schedule 500 that corresponds to the injection of one or more sample fluids in a flow cell. As shown here, the injection of a first sample fluid can be started in a flow cell, as indicated by step 510. Consequently, particles from the first sample fluid can be imaged in the flow cell, as indicated by step 515. The first sample fluid can have a volume of about 900 μl. In some cases, the flow is 0.232 μl / second (or within a range from 0.2 μl / second to 0.35 μl / second) in the imaging area. The injection of the first sample fluid can be terminated, as indicated by step 520, and the injection of a second sample fluid can be started in the flow cell, as indicated by step 530. The sample fluid transients can be started, as indicated by step 535, as a result of terminating the first injection of sample fluid and initiating the second injection of sample fluid. Subsequently, the sample fluid transients in the flow cell can dissipate, as indicated by step 445. Particles from the second sample fluid can be imaged in the flow cell, as indicated by step 550. The injection of the second fluid of sample can be completed, as indicated by step 560. In some cases, injection and flow procedures are performed at temperatures within a range from about 18 ° C to about 40 ° C.
[000208] Typically, the wrapping fluid stream remains flowing within the flow cell as the sample is injected, and as the injection is completed. Therefore, according to some embodiments, a continuous flow of envelope fluid is maintained while injections of sample fluid are pulsed into the circulating envelope. The continuous flow of the wrapping fluid can contribute to the preservation of a ribbon format in the sample fluid as the sample fluid flows along the flow cell.
[000209] According to some modalities, the image capture associated with step 550 can be performed within four seconds of the image capture associated with step 515. According to some modalities, the time between the first and second injections of fluid sample time (for example, between steps 510 and 530) is about 30 seconds. Correspondingly, according to some modalities, the time between the initiation of imaging of the first and second sample fluids (for example, between the initiation of step 515 and the initiation of step 550) is about 30 seconds. In this way, it is possible to process 120 sample fluids per hour. In some cases, an image capture device operates at a frame rate of 180 frames per second (FPS), thereby producing multiple consecutive single images or frames at a high rate or frequency. As shown here, the duration of an imaging step (for example, 515 or 550) can be 15 seconds, thus producing 2,700 images per sample fluid.
[000210] In some cases, the first sample fluid reaches a stabilized state within about 1 to 3 seconds after injection (for example, step 510) of the first sample fluid from the sample fluid injection tube into circulating wrap fluid. In some cases, the first sample fluid reaches a stabilized state within less than 1 second after injection (e.g., step 510) of the first sample fluid from the sample fluid injection tube into the circulating envelope fluid. Injecting the sample into the flow cell can be a two-step process. According to this modality, a first step is a high speed pulse that cleans the entire diluent from the cannula, and after the initial pulse, the sample flow rate is significantly reduced. The transition time can be defined as the time it takes for the sample (for example, a cell) to move from the cannula outlet to the imaging area under imaging flow conditions (lower sample flow rate) . In some cases, the first sample fluid reaches a stabilized state within about 1.8 seconds after injection (e.g., step 510) of the first sample fluid from the sample fluid injection tube into the circulating envelope fluid . In some cases, the sample fluid has a transit time through the flow cell (for example, from a cannula outlet port to an image capture site) within a range from about 2 to 4 seconds.
[000211] According to some modalities, it takes about 5 seconds for the flow to stabilize or to move from a distal exit port from the cannula to the imaging area. In some cases, an image capture duration period can be about 20 seconds.
[000212] A urinalysis system according to the modalities of the present invention can process a urine sample that has a volume of about 900 μl. According to some modalities, the cannula or injection tube has an internal volume of less than about 30 ul. According to some modalities, the cannula or injection tube has an internal volume greater than about 30 ul. The volume of urine sample is effective for leveling the cannula before starting image collection and, thus, can avoid long periods of time when the sample flow is not stable. For example, the use of a cannula that has an internal volume of about 13 µl can correspond to a period of sample flow instability of about 2 to 3 seconds. According to some modalities, the internal volume of the cannula may not affect the flow stability of the sample. According to some modalities, the internal volume of the cannula can affect the stability of cell concentration in the sample strip itself if the initial high-speed sample pulse is insufficient to replace the entire diluent within the cannula. Correspondingly, the cannula can be cleaned between samples in a short amount of time with the use of a small amount of diluent. In this way, it is possible to achieve a stable sample flow that facilitates the capture of a high quality image and, at the same time, achieve a high rate of yield, with a low persistence of residues. According to some modalities, a cannula with a high internal volume may require a high initial velocity impulse and a high volume of sample to clean all the diluent in the lines and cannula.
[000213] According to some modalities, urinalysis systems can be configured to limit transients and cross-contamination of sequential samples, in order to speed up the capture of images from urine samples. Methods
[000214] Figure 6 represents aspects of an exemplifying method 600 for imaging a plurality of particles with the use of a particle analysis system configured for geometrical and combined viscosity hydro-focusing, according to the modalities of the present invention. The particles can be included in a 610 urine fluid sample that has a sample fluid viscosity. As shown here, urine sample 610 includes particles and can be divided into portions in one or more sample fluids, such as a first sample fluid 612 containing particles and a second sample fluid 614 containing particles.
[000215] The method may include flowing a wrap fluid 620 along a flow path of a flow cell, as indicated by step 630. Wrap fluid 620 may have a wrap fluid viscosity that differs from the fluid viscosity of sample in a viscosity difference in a range of predetermined viscosity difference. The method may also include injecting the urine fluid sample 610 (first sample fluid 612) from a sample fluid injection tube into the circulating envelope fluid within the flow cell, as indicated by step 630, in order to supply a stream of sample fluid enveloped by the wrapping fluid.
[000216] The flow path of the flow cell may have a decrease in the size of the flow path, such that a thickness of the sample fluid stream and the surrounding fluid through a reduction in the size of the flow path in the direction to an imaging site decrease from the initial thickness to a second thickness adjacent to an image capture site. Method 600 may also include imaging a first plurality of particles from the first sample fluid at the flow cell image capture site, as indicated by step 640. As the sample stream and fluids wraps pass through the reduction in size of the flow path or narrowing transition zone, a viscosity hydro-focusing effect induced by an interaction between the wrapping fluid and the sample fluid stream associated with the viscosity difference (as represented in step 650), in combination with a geometric hydro-focusing effect induced by an interaction between the wrapping fluid and the sample fluid stream associated with the reduction in flow path size (as depicted in step 660), is effective in providing a target imaging state in at least some of the plurality of particles at the imaging site, whereas a viscosity agent in the fluid wrap retains the viability of cells in the sample fluid stream outlet structure and the content of the cells intact when the cells extend from the sample fluid stream in the circulating wrap fluid, as represented by step 670. The methods can also include imaging the plurality of particles at the imaging site, as represented by step 680.
[000217] Method 600 may also include the initiation of sample fluid transients. For example, sample fluid transients can be initiated by terminating the injection of the first sample fluid into the circulating envelope fluid, and injecting the second sample fluid into the circulating envelope fluid, as indicated by step 650. Additionally, the Method 600 may include imaging a second plurality of particles from the second sample fluid at the flow cell image capture site, as indicated by step 660. According to some embodiments, imaging the second plurality of particles may be performed substantially after the sample fluid transients and within 4 seconds of imaging the first plurality of particles.
[000218] Figures 6A and 6B represent exemplary current characteristics related to shear force, lateral compression, orientation, differential viscosity, relative movement between the sample and envelope fluids and the like. Shear stress rate
[000219] Figures 7 and 8 represent aspects of shear stress rate values for certain flow conditions in a flow cell according to the modalities of the present invention. In each of these drawings, a 30% glycerol wrap fluid is used. In some cases, the viscosity may have a value of 2.45 x 10-3. A shear stress value can be equal to the product obtained by multiplying a viscosity value with an effort rate value. In relation to Figure 7, the sample can have a flow rate of 0.3 μl / second and the wrapping fluid can have a flow rate of 21 μl / second. In relation to Figure 8, the sample can have a flow rate of 1 μl / second and the wrapping fluid can have a flow rate of 70 μl / second. In each of these figures, it can be seen that the flow has a lower effort value towards the center (C) and a higher effort value towards the periphery (P). Such effort values can correspond to an asymmetric flow cell configuration, in some modalities.
[000220] As shown in Figure 7, according to some modalities, the lower effort rate towards the center portion (C) of the current may have a value of about 500 (1 / s) or less and the rate of greater effort towards the periphery (P) of the current may have a value of about 3,000 (1 / s) or greater. As shown in Figure 8, according to some modalities, the lower effort rate towards the center (C) portion of the current may have a value of about 1,000 (1 / s) or less and the higher effort rate in direction to the periphery (P) of the current may have a value of about 9,000 (1 / s) or greater.
[000221] Therefore, it can be seen that the lower rates of sample fluid and envelope fluid (for example, Figure 7) correspond to lower rates of effort and the higher rates of sample fluid and envelope fluid (for example, Figure 8 ) correspond to higher effort rates. It is understood that the embodiments of the present invention encompass the use of sample fluid and / or envelope fluid that corresponds to different values of viscosity, different values of stress rate and / or different values of shear stress rate.
[000222] The PIOAL has an adequate viscosity and density, and the flow rates at the point of introduction to the sample flow cell are such that the sample fluid will flatten on a thin strip. The sample stream in tape format is loaded together with the PIOAL, to pass in front of a viewing port where an objective lens and a light source are arranged to allow viewing of the sample stream in tape format. The sample fluid is introduced, for example, injected at a point where the flow path of the PIOAL narrows symmetrically. As a result, the sample fluid stream is flattened and extended on a thin strip. A PIOAL of this disclosure can be used as the wrapping fluid with any visual analyzer of this disclosure. In one embodiment, the PIOAL can be introduced at one end of the flow cell to drag the sample fluid towards the discharge.
[000223] The dimension of the tape-shaped sample stream in the viewing area is affected by the geometric thinning of the PIOAL flow path and the differential linear velocity of the sample fluid and PIOAL resulting in the thinning and stretching of the sample stream in the form of tape. The initial differential linear velocity of the sample for PIOAL can vary from 0.5: 1 to 5: 1. The cross section of the PIOAL flow path can be thinned by reducing the depth by a factor of about 10: 1, 15: 1, 20: 1, 25: 1, 30: 1, 35: 1, 40: 1 , 45: 1, 50: 1, 55: 1, 60: 1, 65: 1, 70: 1, 75: 1, 80: 1, 85: 1, 90: 1, 95: 1, 100: 1, 105 : 1, 110: 1, 115: 1, 125: 1, 130: 1, 140: 1, 150: 1, 160: 1, 170: 1, 180: 1, 190: 1 or 200: 1. In one embodiment, the geometric thinning is 40: 1. In one embodiment, the geometric thinning is 30: 1. The factors taken into account are transit time through the flow cell, desired rate of sample yield, obtaining a sample stream thickness in tape format comparable to the particle size, obtaining alignment of particles and organelles, obtaining focusing on particle content, pressure balance, flow and viscosity within operating limits, optimizing tape stream sample thickness, achieving a desired linear speed, ease of fabrication considerations and required sample and PIOAL volumes .
[000224] The length and volume of the cannula and the flattening of the cross section can be selected to reduce the period of sample flow instability, thereby increasing the throughput rate. In some embodiments, the period of flow instability may be less than about 3, 2.75, 2.5, 2.25, 2, 1.75, 1.5, 1.25, or less than about 1 second. A smaller cannula volume can also reduce the time and volume of diluent needed to clean the cannula between sample procedures. In some embodiments, the transit time through the flow cell is 1, 2, 3 or 4 seconds, or any range between any two of these times. In some modalities, the transit time may be less than 4, 3 or 2 seconds.
[000225] The viscosities and flow rates of the sample fluid and the PIOAL and the contour of the flow cell are arranged in such a way that the PIOAL flow flattens and extends the sample flow on a flat tape in a consistent manner across the viewing zone in a trusted location that corresponds to an image capture site. The sample fluid stream can be compressed to approximately 2 to 3 μm in thickness of fluid flow. Several types of blood cells have diameters larger than the current thickness. Shear forces in the direction parallel to the direction of flow cause an increase in an image projection of the particles under imaging conditions in the focal plane of the high-resolution optical imaging device and / or cause intraparticle structures, for example, structures intracellular, organelles or lobes, be positioned, repositioned and / or better positioned to be substantially parallel to the direction of flow. The depth of field of the high-resolution optical imaging device is up to 7 μm, for example, 1 to 4 μm.
[000226] The flow cross section of the PIOAL, with the sample stream in drag form, is constant through a viewing zone in front of a viewing port through which the objective lens is directed. The objective lens can be the objective component of a high resolution optical imaging device or digital image capture device. The strip-shaped sample stream follows a path through the viewing zone in a known and repeatable position within the flow cell, for example, at a known and repeatable distance from two walls of the flow cell, being discharged downstream.
[000227] In some embodiments, the images obtained in any of the compositions and / or methods of this invention can be digitized images. In some embodiments, the images obtained are microscopic images. In certain embodiments, images can be obtained manually. In other modalities, at least part of the procedure for obtaining the images is automated. In some embodiments, images can be obtained using a visual analyzer that comprises a flow cell, a high-resolution optical imaging device or the digital image capture device, optionally with an autofocus feature.
[000228] The optical information from the particles in the sample is detected by a detection section on the analyzer, when the sample stream in tape format is carried through the viewing area in front of the viewing port, thus generating data from of the particles / cells contained in the sample. The use of this analyzer allows the capture, processing, categorization and subcategorization and counting of cells and / or particles contained in samples. The PIOAL liquid can be prepared by adding viscosity modifying agent, buffering agent, pH adjusting agent, antimicrobial agent, ionic strength modifier, surfactant and / or a chelating agent. The exemplary functional components and / or features of the analyzer in the present disclosure may include, for example, the ability to acquire and / or process data from image analysis, sample color processing, image processing and / or image identification particle, counting and / or categorization and subcategorization.
[000229] In one embodiment, this disclosure is based on the surprising and unexpected discovery that the addition of an adequate amount of a viscosity agent in the PIOAL significantly improves the particle / cell alignment in a flow cell, leading to a higher percentage high focus cells, or cellular components, and higher quality images of cells and / or particles in flux. A viscosity differential in combination with a geometric focusing effect of a narrowing transition zone can achieve marked alignment and focus results. The addition of the viscosity agent increases the shear forces on the cells as RBCs, which improves the alignment of the cells in a plane substantially parallel to the flow direction, which results in image optimization. This also results in the positioning, repositioning and / or better positioning of intraparticle structures, such as intracellular structures, organelles or lobes substantially parallel to the flow direction, which results in image optimization. The viscosity agent also reduces cell misalignment, in general, but not limited to cells that are smaller in diameter than the flow stream.
[000230] The alignment of cells that are smaller in diameter than the flow current, for example, red blood cells, can be obtained, for example, by increasing the viscosity of the PIOAL, or by increasing the flow rate ratio . This results in the alignment of the RBCs parallel to the flow direction. In some modalities, a reduction in RBC misalignment and / or an increase in RBC alignment is achieved by increasing the PIOAL viscosity.
[000231] The flow cross-section of the PIOAL, with the sample stream in drag form, is constant through a viewing zone in front of a viewing port through which the high-resolution optical imaging device is directed . The sample stream in ribbon format follows a path through the viewing zone at a known and repeatable distance from each of the rear and front walls of the flow cell being discharged downstream.
[000232] The present disclosure provides a technique to automatically achieve a correct working position of the high-resolution optical imaging device to focus on the ribbon-shaped sample stream. The flow cell structure is configured in such a way that the strip-shaped sample stream has a fixed and repeatable location between the walls of the flow cell that define the flow path of the sample fluid, in a thin strip between layers of PIOAL, passing through a visualization zone in the flow cell. In the flow cell modalities revealed, for example, in Figure 1-4G, the cross section of the flow path for the PIOAL can narrow symmetrically in a transition zone, and a sample can be inserted through a flattened orifice, such as like a tube with a rectangular lumen in the hole. The narrowing flow path (for example, which narrows geometrically in the cross-sectional area for a ratio between 20: 1 and 40: 1) and also due to an optionally higher linear velocity of the PIOAL compared to the sample flow, cooperates to flatten the cross section of the sample for a ratio between about 20: 1 to 70: 1. According to some modalities, the ratio can be within a range from 10: 1 to 100: 1, within a range from 50: 1 to 100: 1, within a range from 70: 1 to 80: 1. According to some modalities, the ratio is 75: 1. Effectively, due to the combination of flow rate, viscosity and geometry, the sample is formed on a thin strip. The narrowing flow path (for example, which narrows geometrically in the area in cross section for a ratio of 40: 1, or for a ratio between 20: 1 to 70: 1) and a difference in linear speed of the PIOAL in comparison with the sample flow, they cooperate to compress the cross section of the sample for a ratio between about 20: 1 to 70: 1. In some embodiments, the thickness ratio in cross section can be 40: 1. In some embodiments, the thickness ratio in cross section can be 30: 1.
[000233] As a result, process variations, such as the specific linear velocities of the sample and the PIOAL, do not tend to displace the ribbon-shaped sample stream from its location in the flow. Regarding the structure of the flow cell, the location of the sample stream in tape format is stable and repeatable.
[000234] In another aspect, this invention relates to a kit comprising the particle contrast agent compositions of that invention. The kit may also contain instructions on how to use the particle contrast agent composition according to any of the methods described in this document. The kit may also include an intracellular organelle and / or particle alignment fluid (PIOAL). The kit may also contain a programmable storage medium and related software for image-based identification of particles, such as neutrophils, lymphocytes, monocytes, eosinophils, basophils, platelets, reticulocytes, nucleated RBCs, blasts, promyelocytes, myelocytes, myelocytes , bacteria, fungi, protists, protozoa or parasites. The kit may also comprise one or more buffers, which may include diluents and / or isotonic buffers. The kit and / or buffer may additionally comprise a surfactant, a pH adjusting agent and / or an antimicrobial agent. In other embodiments, the kit may also comprise a cleaning or rinsing solution. The kit can also comprise standards for positive and negative controls. In some embodiments, the standard may comprise a standard stained cell reagent. The kit may also comprise disposables, such as micropipettes, disposable tips or tubes for transferring the kit components. The kit can contain any or any combination of two or more of these kit components.
[000235] The discrimination of blood cells or other particles in a urine sample is an exemplary application for which the modalities of the present invention are particularly well suited. The sample is prepared by automated techniques and presented to a high-resolution optical imaging device as a thin ribbon-shaped sample stream to be imaged periodically, while the ribbon-shaped sample stream flows through a field of view. . Particle images (such as blood cells) can be distinguished from each other, categorized, subcategorized and counted, using programmed processing techniques of pixel image data, exclusively automatically or with limited human assistance, to identify and count cells or particles. In addition to the cell images, which can be stored and made available in the case of unusual or critical particle traces, the output data includes a count of the occurrences of each particular category and / or subcategory of cell or particle distinguished in the registered sample images .
[000236] The counts of the different particles found in each image can be further processed, for example, used to accumulate exact and statistically significant ratios of cells of each category and / or subcategory distinguished in the sample as a whole. The sample used for visual discrimination can be diluted, but the proportions of cells in each category and / or subcategory are represented in the diluted sample, particularly after a series of images has been processed.
[000237] The apparatus, compositions and methods disclosed in this document are useful in discriminating and quantifying cells in samples based on visual distinctions. The sample can be a biological sample, for example, a sample of body fluid comprising white blood cells, including without limitation, blood, serum, bone marrow, flushing fluid, effusions, exudates, cerebrospinal fluid, pleural fluid, peritoneal fluid and fluid amniotic. In some embodiments, the sample may be a solid tissue sample, for example, a biopsy sample that has been treated to produce a cell suspension. The sample can also be a suspension obtained from the treatment of a fecal sample. A sample can also be a production line or laboratory sample that comprises particles, such as a cell culture sample. The term sample can be used to refer to a sample obtained from a patient or laboratory or any fraction, portion or aliquot of it. The sample can be diluted, divided into portions or stained in some processes.
[000238] In one respect, the systems, compositions and methods of this disclosure provide surprisingly high-quality images of cells in a stream. In one aspect, the visual analyzer can be used in methods of this disclosure to provide differential WBC counting to the automated image base. In certain embodiments, the methods of this disclosure refer to the automated identification of visual distinctions, including morphological traits and / or abnormalities to determine, diagnose, predict, predict and / or support a diagnosis of whether an individual is healthy or has a disease, condition , abnormality and / or infection and / or is responsive or unresponsive to treatment. The system may additionally comprise a particle counter in some embodiments. Applications include categorizing and / or subcategorizing and counting cells in a fluid sample, such as a urine sample. Other similar uses for counting additional types of particles and / or particles in other fluid samples are also contemplated. The system, compositions and methods of this invention can be used for categorization and sub-categorization and real-time visualization of images using any suitable automated particle recognition algorithm. The images captured for each sample can be stored for later viewing.
[000239] In another aspect, the apparatus, compositions and methods of this invention provide surprisingly more accurate cell-based signaling, categorization and sub-categorization, which reduces the rate of manual analysis compared to the rate of manual analysis when uses current automated analyzers. The systems, compositions and methods reduce the rate of manual analysis and allow manual analysis to be performed on the instrument. In addition, the systems, compositions and methods of this development also reduce the percentage of signaled samples during automated analysis, as required by manual analysis.
[000240] Consequently, in some embodiments, the present disclosure features an apparatus and a method for analyzing a sample containing particles, for example, blood cells. According to this disclosure, a visual analyzer is provided to obtain images of a sample that comprises particles suspended in a liquid. In some embodiments, the visual analyzer comprises a flow cell and an autofocus component, in which a liquid sample containing particles of interest is induced to flow through a flow cell that has the viewing port through which a camera is attached to an objective lens captures digital images of particles. Exemplary autofocus techniques that can be deployed using the modalities of the present invention are disclosed in copending US patent application no., The content of which is incorporated herein by reference. The flow cell is coupled to a sample fluid source, such as a diluted and / or treated urine sample or other body fluid sample, as described in this document, and to a source of a clear, or liquid, wrapping fluid alignment of intracellular organelle and / or particle (PIOAL).
[000241] In one embodiment, the apparatus also comprises a particle counter that has at least one detection range, as well as an analyzer, and a processor. The analyzer and processor are configured to provide additional information to correct count, categorization and subcategorization errors associated with the particle counter, and additionally determine the precise concentration or particle count of different particle categories and / or subcategories in the sample.
[000242] In other embodiments, this disclosure refers to a PIOAL that can be used in an analysis based on particle images, as described in this document. The cell category and / or subcategory count in urine samples is used in this disclosure as non-limiting examples of the class of samples that can be analyzed. In some embodiments, cells present in samples may also include bacterial or fungal cells, as well as white blood cells and / or red blood cells.
[000243] According to some modalities, the peculiarities of the sample preparation apparatus and methods for sample dilution, permeabilization and histological staining, are generally performed using precision valves and pumps operated by one or more programmable controls, and are not crucial to this revelation. Examples can be found in patents issued to International Remote Imaging Systems, Inc., such as US 7,319,907, related to programmable controls. Similarly, techniques for distinguishing between certain cell categories and / or subcategories by their attributes, such as relative size and color, can be found in US 5,436,978 in conjunction with white blood cells. The disclosures of these patents are hereby incorporated by reference. According to some modalities, sample preparation techniques may include staining, lysis, permeabilization and other processing modalities, such as those described in copending US patent application no. , the content of which is incorporated herein by reference.
[000244] The term high-resolution optical imaging device may include devices that are capable of obtaining images of particles with sufficient visual distinctions to differentiate features and / or morphological changes. Exemplary high-resolution optical imaging devices may include devices with an optical resolution of 1 μm or less, including, for example, 0.4 to 0.5 μm, such as, for example, 0.46 μm.
[000245] In some embodiments, the images obtained in any of the compositions and / or methods of this invention can be digitized images. In some embodiments, the images obtained are microscopic images. In certain embodiments, images can be obtained manually. In other modalities, at least part of the procedure for obtaining the images is automated. In some embodiments, images can be obtained using a visual analyzer that comprises a flow cell, a high-resolution optical imaging device or the digital image capture device, optionally with an autofocus feature.
[000246] In one embodiment, the images provide information related to the cytosolic, cell nucleus and / or nuclear components of the cell. In one embodiment, the images provide information related to the granular component and / or other morphological features of the cell. In one embodiment, the images provide information related to the cytosolic, nuclear and / or granular components of the cell. Granular and / or nuclear images and / or traces are crucial for cell categorization and subcategorization both independently and in combination with each other. Auto focus target
[000247] Again with reference to Figure 1, particle imaging systems can include a target or autofocus pattern 44 that is fixed in relation to the flow cell 22. Autofocus target 44 can be used to achieve focused images of particles of urine fluid flowing through the flow cell.
[000248] Figure 9A represents an exemplary autofocus target 900, according to the modalities of the present invention. As shown here, target 900 includes an opaque annular band 910 and an aperture or transparent center 920. In operation, the imaging device focuses on band 910 and captures the image through the aperture. As discussed elsewhere in this document, and in copending US patent application no., An image capture process may involve first focusing (or automatically focusing) on the 910 range and then adjusting a distance between the image capture device image and the sample fluid stream before taking the image through aperture 920. Consequently, strip 910 may present a target under which an autofocus system of the image capture device can detect and focus, and certain portions of the target (for example, borders or segments) can be included in the image. In some cases, the target may be provided as a chrome disk that has a central opening. An exemplary target can be provided with a central orifice, which has a diameter of about 0.5 mm, which is glued or attached to the flow cell. The size of the central opening or hole 920 can be selected so that only four edge portions 930 of the opaque annular band 910 are visible in the captured image 940, as shown in Figure 9B. Therefore, the annular strip 910 does not interfere with the capture of cell images (for example, light can pass through aperture 920 in order to illuminate the sample particles, and the field of view is substantially free of the annular strip). Thus, the 910 strip is shown only in the corners of the image.
[000249] Figure 10 represents an exemplary automatic focus target 1000, according to the modalities of the present invention. Target 1000 includes a strip or margin 1010 and a central aperture 1020. Figure 11 shows another exemplary autofocus target 1100, in accordance with the modalities of the present invention. The 1100 target includes a stripe or margin 1110 and a central aperture 1120. According to some modalities, the 1100 autofocus target provides an image with 50 pixels of black at the top and bottom. In some cases, the 1100 autofocus target provides a flow cell focus (FCFO) compensation of about 65.3 μm.
[000250] Figure 12A represents an exemplary autofocus target 1200, according to the modalities of the present invention. Target 1200 is presented as a mailbox design and includes a first margin or upper margin 1210 and a second margin or lower margin 1220. Target 1200 also includes a transparent opening or passageway 1230 between the first and second margins. According to some modalities, the target has a diameter of about 4 mm, and the mailbox height is 265 μm. In some cases, the upper and lower margins can be present as half circles and can be produced with a deposited metal, such as chromium oxide or some other opaque material.
[000251] In another aspect of the methods of this invention, cells brought into contact with the particle and / or imaged contrast agent composition are abnormal cells, such as cells infected with malaria, atypical lymphocytes. In some aspects of this invention, cells are abnormal cells that can be used to identify, predict, diagnose, predict or support a diagnosis of a condition, disease, infection and / or syndrome.
[000252] Figure 12B shows a close-up view of the central portion of the autofocus target 1200. As shown here, the first margin 1210 includes a negative / positive numerical scale, with a centralized zero value. The second margin 1220 includes a similar scale. In some cases, the scale increments are 100 μm. According to some modalities, scales can be used to facilitate the positioning of the flow cell so that the field of view of the imaging device or camera can be centered on the sample stream. As shown here, sample stream 1240 flows in a direction perpendicular to the scales of the first and second margins. As part of a focusing protocol, the image capture device can operate to focus the numbers or other characters or objects that can be seen present in margins 1210, 1220.
[000253] The modalities of the present invention include techniques to deal with the thermal deviation associated with the use of the particle analysis system, through which such thermal effects can otherwise compromise the quality of images obtained with the imaging device. Figure 13A represents a partial side view of a flow cell 1320 that has a thermal sensor 1370, a reflector 1380, and an autofocus target 1344. During the operation of a particle analysis system, thermal effects can cause the sample stream to slowly deviate from the focus of the imaging device. For example, thermal effects can be caused by the thermal expansion of the flow cell through the radiated heat that comes from the lamp. Additionally, thermal effects can be caused by the thermal expansion of the flow cell assembly and optical bench assembly (OBA) through conductive and radioactive heating. In some modalities, certain components of the OBA may expand, which may contribute to targeting errors. For example, such components may include metal plates that hold the camera 24 together, a metal plate that holds or is connected to the flow cell, or a metal plate that holds both the flow cell and the camera 24 together . Figure 13B represents a partial perspective view of flow cell 1320 that has a thermal sensor 1370 and autofocus target 1344. Additionally, Figure 13C represents another perspective view of flow cell 1320 that has a thermal sensor 1370, reflector. 1380 and auto focus target 1344.
[000254] Figure 13C represents another perspective view of flow cell 1320 that has a thermal sensor 1370, reflector 1380 and targeting imaging or autofocus 1344. Reflector 1380 can operate to reduce or limit the amount of heat absorbed by the cell flow rate 1320. For example, reflector 1380 can block heat radiated by a 1342 flash lamp, as shown in Figure 13A. Therefore, reflector 1380 can minimize the thermal impact of the lamp. The 1342 reflector can also reduce the glare and scatter of light generated by the lamp, thus resulting in improved image quality. The 1370 thermal sensor is positioned close to the fluid flow channel and adjacent to the image capture site, so that accurate temperature readings can be obtained. Information from the temperature sensor can be used to focus the image capture device on the sample fluid ribbon stream. The exemplary autofocusing techniques disclosed in this document can be based on temperature fluctuations that occur within certain elements of the analyzer.
[000255] As shown in Figure 13D, a flow cell 1300d can include a flow path 1322d that has a port or vent 1301d through which bubbles 1302d can be released or removed. As described here, a tube 1303d, through which the vacuum can be applied, can be placed in contact with port 1301d in order to remove bubbles 1302d from the chain. Such a bubble removal mechanism is suitable for removing bubbles from the circulating fluid within the flow cell, and can operate to prevent bubbles or microbubbles from being lodged or trapped within the flow cell. The flow current is represented in an upward direction in Figure 13D. It should be understood that, in some embodiments, the current can move through the flow cell in a downward direction. The bubbles shown here float towards the top of the fluid within the flow cell.
[000256] According to some modalities, a method for imaging particles in a urine sample may include flowing an envelope fluid along a flow path of a flow cell, and injecting the urine sample into the circulating envelope fluid inside the flow cell, so that the urine sample flows in a sample stream with a stream width greater than a stream thickness, such that the flow cell has an associated temperature. In addition, the method may include focusing an image capture device, along a geometrical axis of imaging, on the current for a first focal state, while the temperature associated with the flow cell is at a first temperature, and acquiring a first focused image of a first subset of particles within the stream with the image capture device in the first focal state. In addition, the method may include determining that the temperature associated with the flow cell has undergone a change from the first temperature to a second temperature, and automatically adjusting the focus of the image capture device from the first focal state to a second focal state in response to the change in temperature and a known relationship between the flow cell temperature and the desired focus. In addition, the method may include acquiring a second focused image of a second subset of particles within the stream with the image capture device in the second focal state.
[000257] In some cases, the process of adjusting the focus of the image capture device includes adjusting a distance between the image capture device and the flow cell using the change in temperature and the known relationship between the temperature of flow cell and the desired focus. In some cases, the process of adjusting the focus of the image capture device includes adjusting a focal length of the image capture device using the change in temperature and the known relationship between the flow cell temperature and the desired focus. Focused images
[000258] Figures 14A and 14B provide lateral cross-sectional views illustrating imaging systems and methods, in accordance with the modalities of the present invention. With reference to Figure 14A, a particle analysis system 1400a, such as a urine sample analyzer, can be configured for geometric and / or viscosity hydro-focusing, for example, using flow cell techniques and viscous wrap fluid, such as those described in this document. An exemplary method for imaging particles in a urine sample using the particle analysis system may include flowing an envelope fluid 1410a along a flow path 1420a of a flow cell 1430a of the particle analysis system . Flow path 1420a can be defined at least in part by opposing flow cell walls 1422a, 1424a of the flow cell. The wrapping fluid 1410a may have a viscosity that is different from a viscosity of the urine sample. The imaging method may further include injecting the urine sample into the circulating envelope fluid 1410a within flow cell 1430a so that the urine sample fluid flows into a sample stream 1440a. The sample stream 1440a can have a stream width greater than a stream thickness. The sample stream 1440a can also flow through a decrease in the size of the flow path and traverse an imaging axis 1450a. In the illustration in Figure 14A, the flow direction is from left to right.
[000259] Additionally, the imaging method may include focusing on an image capture device 1460a by imaging an imaging target 1470a that has a fixed position relative to flow cell 1430a. For example, as shown here, the imaging target 1470a can have a fixed position in relation to a lighting cell 1480a of the flow cell. In some cases, the imaging target 1470a can be embedded within or fixed under the window 1480a. The methods may also include acquiring a focused image of the sample fluid particles (e.g., particle 1490a, at least partially arranged within the stream 1440a) with the image capture device 1460a. The focused image is suitable for the characterization and counting of particles.
[000260] The image capture device 1460a can be focused on the sample stream 1440a using an offset distance. For example, the travel distance may correspond to a distance D between the sample stream 1440a and the imaging target 1470a. The difference in viscosity between the wrapping fluid 1410a and the urine sample, in combination with the decrease in flow path size, is effective for the hydrofocusing of the sample fluid in the sample stream 1440a on the geometry axis 1450a, while retaining cell viability in the urine sample. For example, a viscosity hydro-focusing effect induced by an interaction between the wrapping fluid 1410a and the sample fluid stream 1440a associated with the difference in viscosity, in combination with a geometric hydro-focusing effect induced by an interaction between the envelope fluid 1410a and the sample fluid stream 1440a associated with the reduction in size of the flow path, is effective in providing a target imaging state in at least part of the plurality of fluid sample particles on the imaging geometry axis 1450a, while that a viscosity agent in the wrapping fluid 1410a retains the viability of cells in the sample fluid stream outlet structure 1440a and the content of the cells intact when the cells extend from the sample fluid stream 1440a in the circulating wrap fluid 1410a .
[000261] As the image capture device 1460a is focused on the sample stream 1440a using the offset distance, the image capture device 1460a can take images of particles or cells within the sample stream 1440a on the axis imaging geometry 1450a, or at an image capture site associated with the imaging geometry axis 1450a. In some cases, the particles can be illuminated with a 1426a lamp or light source. Images of sample stream 1440a can be obtained as the particles approach the geometry axis 1450a, as the particles traverse the geometry axis 1450a and / or as the particles flow away from the geometry axis of imaging 1450a.
[000262] Figure 14B represents aspects of an alternative flow cell configuration, where imaging target 1470b has a fixed position relative to a viewing window 1482b of flow cell 1430b. For example, imaging target 1470b can be embedded within or fixed under window 1482b. As shown here, the imaging method may include focusing on an image capture device 1460b by imaging an imaging target 1470b that has a fixed position relative to flow cell 1430b. Additionally, the image capture device 1460b can be focused on the sample stream 1440b using an offset distance. For example, the travel distance may correspond to a distance D between the sample stream 1440b and the imaging target 1470b.
[000263] Figure 14C represents an end view in cross section of a flow cell 1430c, which illustrates several alternative placement locations for an imaging target or autofocus. For example, an imaging target 1472c may be located in a viewing window 1482c of flow cell 1430c. Optionally, an imaging target 1474c can be located in a lighting window 1480c of flow cell 1430c. Still optionally, an imaging target 1476c can be located on a side flow cell wall (e.g., 1432c and / or 1434c). The image capture device 1460c can be focused on a sample stream 1440c, which is enveloped within a wrapping fluid 1410c, using the travel distance. In some embodiments, the travel distance may correspond to or be defined by a distance D1 along the imaging axis 1450c between the sample stream 1440c (or a center plane 1441c defined by the stream 1440c) and the window imaging target 1472c display. In some embodiments, the displacement distance may correspond to or be defined by a distance D2 along the geometry axis between the sample stream 1440a (or a central plane 1441c) and the imaging target of the lighting window 1476c. In some embodiments, the displacement distance may correspond to or be defined by a distance D3 along the geometry axis between the sample stream 1440a (or the central plane 1441c) and the imaging target of the sidewall of the flow cell 1474c. In some cases, distance D3 has a value greater than zero. In some cases, distance D3 has a value of zero; that is, where the sample stream 1440a (or the central plane 1441c) is coplanar with the imaging target 1474c. In some cases, it is possible to define a travel distance that is not calculated based on distance D1, distance D2 or distance D3. For example, a travel distance can be a predetermined value or number that is provided by a hematology analyzer or flow cell manufacturer.
[000264] According to some modalities, the sample stream 1440c can have a thickness T1 on the imaging axis within a range from about 2 μm to about 10 μm. In some cases, the flow path or the wrapping fluid 1410c may have a T2 thickness of about 150 μm on the geometry axis. As shown here, an imaging target 1472c can be located in a viewing window 1482c disposed between sample stream 1440c and image capture device 1460c. In some cases, an imaging target (for example, 1474c) may be located between a lighting window 1480c and a viewing window 1482c. As discussed elsewhere in this document, the process of acquiring a focused image may include adjusting a distance between the image capture device 1460c and flow cell 1430c using the travel distance. In some cases, as discussed elsewhere in this document, the process of acquiring a focused image may include adjusting a focal length between the 1460c image capture device using the offset distance. In some cases, the process of acquiring a focused image may include adjusting the distance between the image capture device 1460c and the flow cell 1430c, and the process of adjusting the distance includes moving the flow cell 1430c, for example, to a position closer to the image capture device 1460c, or to a position further away from the image capture device 1460c.
[000265] As shown in Figure 14D, a first focal length of the 1460d image capture device can correspond to a D1 distance (for example, along the 1450d imaging axis) between the 1460d image capture device and the target 1470d, and a second focal length of the 1460d image capture device may correspond to a D2 distance (for example, along the 1450d imaging axis) between the 1460d image capture device and the 1440d sample stream ( or a central plane defined by the sample stream). In some cases, the imaging target may be located elsewhere in the flow cell, for example, as shown in Figure 14C. According to some modalities, the displacement distance may correspond to a difference in distance between the first focal length (or D1 distance) and the second focal length (or D2 distance). The image capture device 1460d can be focused on the sample stream 1440d using this travel distance (for example, difference between D1 and D2).
[000266] Figure 15 represents an elevation view that shows modalities of an autofocus pattern (or imaging target), which, for example, can be located in the window or lighting holes, in a view window or entrance or at another flow cell location. The target may weaken as the distance or position of the high resolution optical imaging device is moved relative to the ribbon-shaped sample stream. As shown in Figures 9 to 12B, a focus or imaging target (autofocus pattern) can be found on the periphery of the viewing area in which the sample is to appear. Referring again to Figure 15, it can be seen that it is also possible that the focus target can be defined by opposite formats that are in the field of view.
[000267] When the imaging device is in focus on the autofocus (target) pattern (panel B in Figure 15), the formats as imaged by the device are well defined and can be used for autofocusing, as described in this document , that is, to search for the distance between the target and the imaging device in which the formats produce the greatest contrast in amplitude between adjacent pixels located along lines that cross the formats, such as the lines shown as arrowheads. The focus setting shown in panel B corresponds to an analog focus setting shown in Figure 16A. As shown in Figure 16A, the focal plane of the image capture device is aligned with the autofocus target, and therefore the image capture device is in a position to obtain sharp images of the autofocus target.
[000268] Referring again to Figure 15, when the workplace (for example, the focal plane of the imaging device) is moved away from the autofocus pattern (shown in panels A and C, shown on the left and right of the autofocus pattern in Figure 15), for example, by adjusting the lens working distance or the distance between the lens and its focal plane, the shapes of the focus target now go out of focus and in the position where the high-resolution optical imaging is focused on the sample stream in a tape format, the focus target formats are no longer discernible (see panel D in Figure 15). The focus setting shown in panel D can correspond to a similar focus setting shown in Figure 16B. As shown in Figure 16B, the focal plane of the image capture device is aligned with the sample fluid stream and, therefore, the image capture device is in a position to obtain sharp images of particles in the sample stream. The focal plane of Figure 16A is separated from the focal plane of Figure 16B by a distance D. As shown in Figure 16B, by moving the image capture device at a distance D, it is also possible to move the focal plane at a distance D and, therefore, moving the focal plane from the autofocus target to the sample stream. In some cases, the focal plane can be moved from the autofocus target to the sample stream by internally adjusting the focal length of the image capture device, while keeping the image capture device in a fixed position. in relation to the flow cell. In some cases, the focal plane can be moved from the autofocus target to the sample stream by internally adjusting the focal length of the image capture device, in combination with adjusting the position of the image capture device in relation to to the flow cell. The autofocus formats can be provided anywhere that is within the view and is fixed in relation to the flow cell, such as in the window or lighting opening, or in front or behind the view window or door, through which the high-resolution optical imaging device is directed, in an accessory fixed to the photocell, to retain a target in the position to be imaged.
[000269] According to some modalities, when the high resolution optical imaging device is moved over the displacement distance and the autofocus pattern goes out of focus, the lines that appear in focus are the blood cells as opposed to the auto focus. In the mode of Figure 15, the autofocus pattern is defined by formats in the field of view. The shapes are relatively thin discrete shapes of a limited size, and therefore, after movement by the displacement distance, the shapes become substantially invisible in the scanned image when focused on the ribbon-shaped sample stream. A typical travel distance can be, for example, 50 to 100 μm in a flow cell sized for urinalysis imaging applications. In some embodiments, the autofocus feature keeps the high resolution optical imaging device within 1 μm. the ideal focus distance.
[000270] Consequently, the features described in Figure 15 provide an exemplary technique for determining a travel distance. For example, a method for determining a travel distance may include an autofocusing process that involves injecting a sample of test fluid into a wrapping fluid to form a stream of test sample within a flow cell, and obtain a first focused image of the imaging target using an image capture device. The first focused image can correspond to panel B in Figure 15, where the focused imaging target and the image capture device define a first focal length. As shown here, the focal plane or distance / workplace of the image capture device is positioned on the imaging target. The autofocusing process may also include obtaining a second focused image of the test sample stream using the image capture device. The second focused image can correspond to panel D in Figure 15, where the focused test sample stream and the image capture device define a second focal length. As shown here, the focal plane or distance / workplace of the image capture device is positioned on the imaging target. The autofocusing process can also include obtaining the travel distance by calculating a difference between the first focal length and the second focal length. In some cases, the test fluid sample is the same as the urine sample and the test sample stream is equal to the sample stream. In some cases, the autofocusing process establishes a focal plane associated with the image capture device, and the focal plane remains stationary in relation to the image capture device. In some cases, the process of auto-focusing the image capture device includes determining an ideal focus position from among a plurality of focus positions.
[000271] According to some modalities, the image capture device can be focused on the sample stream without using temperature data. For example, a process of focusing the image capture device on the sample stream can be performed regardless of the temperature of the image capture device. In some cases, an imaging target may include a scale (for example, as shown in Figure 12B) for use in positioning the imaging axis of the image capture device in relation to the sample stream. In some cases, the imaging target may include an iris aligned with respect to the geometry axis of the imaging, such that the imaged particles are arranged within an aperture defined by the iris, and one or more portions of the iris edge are imaged during auto focus.
[000272] In exemplary modalities, autofocusing techniques can position the flow cell within ± 1 μm from an ideal focal position of the sample stream. In some cases, the modalities include autofocus techniques that can automatically focus the imaging system without the need for a separate focusing solution or liquid or any user intervention. Exemplary autofocusing techniques may also be responsible for the mechanical causes of suboptimal focusing performance, such as deviation or thermal expansion that can cause fluctuations in the distance between the lens of the imaging device and the flow cell. In some cases, it has been observed that the sample flow location within the flow cell can be very stable and temperature independent. Therefore, exemplary imaging techniques may involve focusing on an imaging target in the flow cell, and using a fixed offset to achieve the ideal focus on the sample stream.
[000273] According to some modalities, the microscope objective that is used in an imaging system has a numerical aperture of 0.75, resulting in a theoretical depth of field (DOF) of ± 0.5 μm. In certain experimental tests, it was observed that good image quality could be obtained at ± 1.25 μm from an ideal focal point. It was also observed that a practical or experimental depth of field could be different from the theoretical depth of field. For example, in certain experimental tests, it was observed that a depth of field was around 2.5 to 3 μm. Based on certain experimental studies, it was found that the autofocus performance for positioning the flow cell within ± 1.25 μm could ensure good image quality. In some embodiments, an autofocus system can operate to position the flow cell within ± 1 μm from an ideal focus position of the sample stream. In certain experimental tests, it has been observed that autofocus techniques, as disclosed in this document, can repeatedly locate a target in a flow cell with a standard deviation of less than 0.3 μm. In some cases, the test autofocus system procedures demonstrated excellent repeatability (standard deviation <0.23 μm) and were able to determine the focus position of the sample stream within <0.6 μm from a optimized metric position that is within a positional tolerance of ± 1 μm. Additional autofocus test procedures in a variety of temperature conditions also exhibited excellent positioning performance (for example, flow cell positioning within a tolerance of ± 1 μm required for an ideal focus position). This degree of accuracy and an automated analyzer system is well suited to consistently and reliably obtain high-quality images of particles from a urine sample flowing in a thin ribbon stream, as revealed elsewhere in this document. , in relation to an operating temperature range that corresponds to normal laboratory conditions.
[000274] Except where expressly stated otherwise, references to "particle" or "particles" made in this disclosure will be understood to encompass any formed or discrete object dispersed in a fluid. For use in the present invention, "particle" can include all measurable and detectable components (for example, by image and / or other measurable parameters) in biological fluids. The particles are of any material, any shape and any size. In certain embodiments, the particles can comprise cells. Examples of particles include, but are not limited to, cells, including blood cells, fetal, epithelial cells, stem cells, tumor cells, or bacteria, parasites, or fragments of any of the above or other fragments in a fluid biological. Blood cells can be any blood cell, including any normal or abnormal, mature or immature cells that potentially exist in a biological fluid, for example, red blood cells (RBCs), white blood cells (WBCs), platelets (PLTs) and other cells. The limbs also include immature or abnormal cells. Immature WBCs can include metamielocytes, myelocytes, promyelocytes and blasts. In addition to mature RBCs, members of RBCs may include nucleated RBCs (NRBCs), normal or abnormal RBCs, and reticulocytes. PLTs can include "giant" PLTs and PLT nodes. Blood cells and elements formed are further described elsewhere in this disclosure.
[000275] Exemplary particles can include elements formed in biological fluid samples, including, for example, spherical and non-spherical particles. In certain embodiments, the particles may comprise non-spherical components. The image projection of non-spherical components can be maximized in the focal plane of the high-resolution optical imaging device. In certain embodiments, the non-spherical particles are aligned in the focal plane of the optical high-resolution imaging device (aligned in a plane substantially parallel to the direction of flow). In some embodiments, platelets, reticulocytes, nucleated RBCs and WBCs are counted and analyzed as particles. For use in the present invention, exemplifying white blood cells (WBC) can include, for example, neutrophils, lymphocytes, monocytes, eosinophils, basophils, immature granulocytes including meta-myelocytes, myelocytes, promyelocytes and blasts, and abnormal white blood cells.
[000276] For use in the present invention, measurable and detectable particle parameters may include, for example, visual and / or non-image based indices of size, shape, symmetry, contour and / or other characteristics.
[000277] In another embodiment, this disclosure refers to a method for particle imaging using, for example, the kits of this invention, in methods that comprise, for example: 1) illuminating the particles with light in a visual analyzer ; 2) obtain a scanned image of sample particles enveloped in a PIOAL; and 3) analyze the samples containing particles based on the image information. In other embodiments, the method may further comprise placing the sample containing particles in contact with a particle contrast agent composition before lighting the treated sample.
[000278] In one embodiment, the analyzed particles comprise at least one of a spherical particle, a non-spherical particle, or both. In another embodiment, the particles comprise at least one spherical particle. In yet another embodiment, the particles comprise at least one non-spherical particle. In another embodiment, an image projection of non-spherical particles or particles that have non-spherical components is maximized in a plane substantially parallel to the direction of flow. The particles can be, for example, WBCs, RBCs and / or platelets. In one embodiment, at least 50% of the non-spherical particles are aligned in a plane substantially parallel to the direction of flow. In another aspect, the use of the PIOALs of this invention in a flow cell allows at least 90% of the non-spherical particles to be aligned in a plane substantially parallel to the direction of flow.
[000279] In one embodiment, the non-spherical particles comprise red blood cells. In another aspect of this invention, the spherical particles comprise white blood cells or nucleated red blood cells.
[000280] The flow of cells smaller than the thickness of the sample stream in the form of PIOAL enveloped tape, results in the alignment of those cells parallel to the flow direction. In one embodiment of this disclosure, at least 92% of the non-spherical particles are aligned in a plane substantially parallel to the direction of flow. In yet another embodiment, at least 90% of the non-spherical particles are aligned in a plane substantially parallel to the direction of flow. In another modality, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94% or at least 95% of the particles are substantially aligned, that is, within 20 degrees from a plane substantially parallel to the direction of flow. In another embodiment, the percentage of non-spherical and / or spherical particles that are aligned in a plane substantially parallel to the direction of flow can be in any range between any two of the percentages referred to, for example, at least 75 to 85%, 75 to 80%, and other ranges, such as 75 to 92%.
[000281] Shear forces in the direction parallel to the flow direction as a result of the flow of larger cells in the sample enveloped in the PIOAL, such as WBCs, result in the positioning, repositioning and / or better positioning of nuclear structures, cytosolic structures or granules or other intracellular components or structures closer to a plane parallel to the flow direction.
[000282] In one embodiment of this disclosure, the cross section of the image comprises at least one among differentially stained nuclear structure, differentially stained cytosolic structure or differentially stained granules in a WBC, including a neutrophil, lymphocyte, monocyte, eosinophil, basophil, or WBC immature including a blast, promyelocyte, myelocyte or metamielocyte. In another mode, at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92 %, 93%, 94% or at least 95% of spherical and / or non-spherical particles have nuclear structures, cytosolic structures or granules in the focal plane or depth of field of the high-resolution optical imaging device.
[000283] In some embodiments of the methods of this invention, the image information is the image cross section of a particle. In some respects, the cross section of the image comprises at least one of a differentially stained nuclear structure, a differentially stained cytosolic structure or differentially stained granules in a WBC, including a neutrophil, lymphocyte, monocyte, eosinophil, basophil, or immature WBC including one blast, promyelocyte, myelocyte or metamyelocyte.
[000284] In one embodiment, the methods of this invention provide surprisingly high quality images of cells with a high percentage of particles and particle content in focus in the flow, which are useful in the automated acquisition of WBC differentials based on image, as well as automated identification of morphological abnormalities useful in the determination, diagnosis, prognosis, prediction or support of a diagnosis of whether an individual is healthy or has a disease, condition, abnormality or infection and / or is responsive or unresponsive to treatment.
[000285] In another aspect, the compositions and methods of this invention provide more accurate image-based cell signaling, categorization and subcategorization, which greatly reduces the rate of manual analysis compared to current analyzers.
[000286] For use in the present invention, the viscosity agent can include viscosity agents or viscosity modifiers. An exemplifying viscosity modifier / agent has a characteristic viscosity that is different from the viscosity of the sample, such that when the PIOAL and the viscosity agent are mixed, the viscosity of the PIOAL is changed and / or increased in order to maximize the particle alignment. In certain embodiments, the difference in viscosity and / or a difference in speed between the stranded sample stream and the PIOAL can introduce shear forces to act on the particles, while in flux, thus reducing misalignment and / or causing the particles to align.
[000287] For use in the present invention, particle contrast agent compositions can be adapted for use in combination with an intracellular organelle and / or particle alignment liquid (PIOAL) in a visual analyzer to analyze particles in a sample of an individual. The exemplary PIOAL is useful, for example, in methods for the automated recognition of different types of particles in a sample of an individual.
[000288] In another aspect, cells can be enveloped in PIOAL when images are obtained. Exemplary and suitable intracellular organelle alignment liquids are described herein.
[000289] In one embodiment, this disclosure refers to a PIOAL for use in a visual analyzer. In certain modalities, the PIOAL can comprise at least one of the buffer; a pH adjusting agent; a buffer; a viscosity modifier / agent; ionic strength modifier, a surfactant, a chelating agent and / or an antimicrobial agent.
[000290] In one aspect, the PIOAL can comprise two or more viscosity modifying agents / agents. In one aspect, the PIOAL of that invention can have a viscosity between about 1 to about 10 centipoise. In one embodiment, the PIOAL of that invention may comprise a viscosity modifier / agent. In one embodiment, PIOAL comprises up to 100% of a viscosity agent.
[000291] For use in the present invention, the viscosity agent and / or viscosity modifier can include any substance suitable for achieving a viscosity of about 1 to about 10 centipoise, with optical characteristics, including optical clarity, suitable for use in an imaging system. In general, the viscosity modifier or agent is non-toxic, biocompatible and leaves the cell structure and contents substantially intact. The viscosity agent and / or viscosity modifier can comprise at least one of glycerol; glycerol derivative; ethylene glycol; propylene glycol (dihydroxypropane); polyethylene glycol; water-soluble polymer and / or dextran. In one aspect, the viscosity modifier / agent in the PIOAL can be glycerol. As an example, in one aspect, the viscosity modifying agent in the PIOAL can be a glycerol derivative. As an example, in one aspect, the viscosity modifying agent in the PIOAL may be a polyvinyl pyrrolidone (PVP). As another example, the viscosity modifying agent in the PIOAL can be ethylene glycol. As another example, the viscosity modifier / agent in the PIOAL may be propylene glycol (dihydroxypropane). As another example, the viscosity modifying agent in the PIOAL can be polyethylene glycol. As another example, the viscosity modifier / agent in the PIOAL can be water soluble polymer or dextran. In other respects, the viscosity modifier / agent in the PIOAL may comprise two or more of glycerol, derived from glycerol; ethylene glycol; propylene glycol (dihydroxypropane); polyvinyl pyrrolidone (PVP); polyethylene glycol; water-soluble polymer or dextran. The viscosity modifying agent / agents can include any agent suitable for providing a viscosity of about 1 to about 10 centipoise, with optical characteristics, including optical clarity, suitable for use in an imaging system.
[000292] For use in the present invention, other viscosity modifiers / agents may include, for example, natural hydrocolloids (and derivatives), such as acacia, tragacanth, alginic acid, carrageenan, locust bean gum, guar gum, xanthan gum, gum arabic, guar gum, gelatin, cellulose, alginates, starches, sugars, dextrans; gelatine; sugars (and derivatives), such as dextrose, fructose; polydextrose; dextrans; polydextrans; saccharides; and polysaccharides; semi-synthetic hydrocolloids (and derivatives), such as glycerol, methylcellulose, hydroxy ethyl starch (hetastarch), sodium carbonoxy methyl cellulose, hydroxy ethyl cellulose, hydroxy-propyl-methyl cellulose, polyvinyl pyrrolidone (PVP); synthetic hydrocolloids (and derivatives), such as polyvinyl alcohol (PVA) and / or Carbopol®. Other cell-compatible viscosity agents / modifiers are also considered useful for this purpose.
[000293] In another aspect, the viscosity modifying agent in the PIOAL can be glycerol present at a concentration of about 1 to about 50% (by volume) of the PIOAL. As an example, In one embodiment, the viscosity modifier / agent can be present in the PIOAL at a concentration of about 5.0% to about 8.0% (by volume). In another aspect, the viscosity modifier / agent can be present at a concentration of about 6.5% (by volume). In one embodiment, the viscosity modifier / agent is glycerol present at a concentration of about 6.5% (by volume).
[000294] In yet another embodiment, the PIOAL may comprise a glycerol viscosity modifying agent present at a concentration of about 30% (by volume).
[000295] In another aspect, the viscosity modifier / agent in the PIOAL can be PVP present at a concentration of about 0.5 to about 2.5% (by weight by volume). As an example, in one embodiment, the PVP viscosity modifier / agent can be present in the PIOAL at a concentration of about 1.0 to about 1.6% (by weight by volume). In one embodiment, PVP is present at a concentration of about 1.0% (weight by volume). In another aspect, the agent / viscosity modifier in PIOAL can be PVP and glycerol. As an example, in one embodiment, glycerol can be present in the PIOAL at a concentration of about 5% (by volume) in combination with about 1% (weight by volume) of PVP.
[000296] In one embodiment, the PIOAL of this invention can be used in a visual analyzer to image particles. In one aspect, the visual analyzer comprises a flow cell with a symmetrical flow path and an autofocus component.
[000297] A viscosity agent and / or viscosity adjusting / modifying agents, such as glycerol, can be included in the PIOAL. The viscosity agent, or viscosity modifying agent, when introduced, can adequately adjust the viscosity of the PIOAL to the desired range. Any suitable viscosity agent can be used, which sufficiently increases the viscosity of the PIOAL, which has adequate optical characteristics to allow high quality imaging of cells in flux. The PIOAL will have an adequate viscosity to align cells and / or cellular structures in a single plane that is substantially parallel to the direction of flow, thus increasing, in part, the focused contents of the particles.
[000298] PIOAL can be used with any analyzer of this development.
[000299] For use in the present invention, the term "glycerols" encompasses glycerol and a glycerol derivative (hereinafter referred to as a glycerol derivative). Examples of a glycerol derivative include thioglycerol, polyglycerol and the like. Usable examples of polyglycerol can include diglycerol, POLYGlycerin no. 310 (Sakamoto Yakuhin Kogyo Co., Ltd.), POLYGLYCERINE no. 750 (Sakamoto Yakuhin Kogyo Co., Ltd.), POLYGLYCERINE no. 500 (Sakamoto Yakuhin Kogyo Co., Ltd.) and the like.
[000300] In another embodiment, the PIOAL of this disclosure additionally comprises a pH adjusting agent. In one aspect, the final pH of the PIOAL and / or the sample is between about 6.0 to about 8.0. In another aspect, the final pH of the PIOAL and / or the sample is between about 6.6 to about 7.4. In one aspect, the final pH of the PIOAL can be equal to the pH of the prepared sample 12A (with reference to Figure 1C).
Exemplary pH adjusting agents may include, for example, acids (examples include organic acids and mineral acids), bases (examples include organic bases and alkali metal and alkaline earth metals). Exemplifying organic acids can include acetic, lactic, formic, citric, oxalic and uric acid. Exemplary mineral acids can include, for example, hydrochloric, nitric, phosphoric, sulfuric, boric, hydrofluoric, hydrobromic and perchloric acid. Exemplary organic bases can include, for example, pyridine, methylamine, imidazole, benzimidazole, histidine, phosphazene and cation hydroxides. Exemplifying alkali metal and alkaline earth metal hydroxides may include, for example, potassium hydroxide (KOH), barium hydroxide (Ba (OH) 2), cesium hydroxide (CsOH), sodium hydroxide (NaOH), strontium hydroxide (Sr (OH) 2), calcium hydroxide (Ca (OH) 2), lithium hydroxide (LiOH) and rubidium hydroxide (RbOH). In some embodiments, using a buffer, the pH of PIOAL is, preferably maintained from about 6.0 to about 8.5, more preferably from about 7.0 to about 8.0. In some embodiments, it is preferable to add a buffering agent to the PIOAL in order to adjust the pH of the PIOAL. Any suitable buffering agent or agent can be used, as long as the agent or agents adjust the pH of the PIOAL to the appropriate range. Examples of such a buffering agent include STF, Good buffers (specifically, tris buffer, MES, Bis-Tris, ADA, PIPES, ACES, MOPSO, BES, MOPS, TES, HEPES, DIPSO, TAPSO, POPSO, HEPPSO, EPPS , tricine, bicin, TAPS and the like), disodium hydrogen phosphate, sodium dihydrogen phosphate, monobasic potassium phosphate, veronal sodium HCl, collidine HCl, tris (hydroxy methyl) aminomethane-maleic acid, tris (methyl hydroxide) aminomethane-HCl , which can be used alone or in combinations.
[000302] In another embodiment, the PIOAL of this invention comprises an ionic strength modifier to adjust the ionic strength of the resulting formulation. Exemplary ionic strength modifiers can include Li +, Na +, K +, Mg ++, Ca ++, Cl-, Br-, HCO-3, sulfates, pyrosulfates, phosphates, pyrophosphates (e.g., potassium pyrophosphate), citrates, cacodylates, or others suitable salts. In one embodiment, the PIOAL can be isotonic.
[000303] Surfactants can be added to PIOAL. The types of surfactants are not particularly limited, as long as they are compatible with other components of the PIOAL, and compatible with the ribbon-shaped sample stream and the particles in the sample. Surfactants can include, for example, cationic, anionic, non-ionic and ampholytic surfactants. Exemplary surfactants may include polyoxyethylene alkyl ester surfactants, polyoxyethylene alkyl phenyl ether surfactants (eg NISSAN NONION NS-240 (NOF CORPORATION, trademark)), sorbitan polyoxyethylene alkyl ester surfactants (eg , RHEODOL TW-0120 (Kao Corporation, registered trademark)), polyol copolymers (e.g. PLURONIC F-127, F-123, F-109, F-87, F-86, F- 68, T-1107, T-1102 (BASF Corporation, registered trademark)), MEGA-8, sucrose monocaprate, deoxy-BIGCHAP, n-octyl-β-D-thioglycoside, n-nonyl-β-D-thiomaltoside, n-hepty-β- D-thioglycoside, n-octyl-β-D-thioglycoside, CHAPS, CHAPSO and the like, can be used. Other surfactants may include Triton-X-100 and Tween 20 in concentrations compatible with the sample and stranded sample stream.
[000304] The concentration of the surfactant in the PIOAL is preferably the level of concentration at which the particles, such as cells, in the sample are unaffected and / or remain substantially intact. Specifically, the concentration is preferably from 5 to 5,000 mg / l, more preferably from 100 to 3,000 mg / l.
[000305] When the particles contained in the sample are analyzed with the analyzer, amorphous salts, such as ammonium phosphate, magnesium phosphate, calcium carbonate, can precipitate in the sample. Chelating agents can be added to the PIOAL in order to dissolve these amorphous salts. The addition of chelating agents allows not only the dissolution of amorphous salts, but also the inhibition of PIOAL oxidation. Usable examples of a chelating agent include salts of EDTA, CyDTA, DHEG, DPTA-OH, EDDA, EDDP, GEDTA, HDTA, HIDA, methyl-EDTA, NTA, NTP, NTPO, EDDPO and the like. The concentration of the chelating agent in the PIOAL is preferably in the range of 0.05 to 5 g / l.
[000306] In another embodiment, the PIOAL may additionally comprise one or more antimicrobial agents. In some aspects, the antimicrobial agent can be, for example, substances that have fungicidal activity (fungicidal agents) and / or substances that have bactericidal activity (bactericidal agents). In certain embodiments, suitable antimicrobial agents may include, for example, parabens, isothiazolinone, phenolics, acidic preservatives, halogenated compounds, quaternium and alcohol. Exemplifying parabens can include parabens and paraben salts. Exemplary isothiazolinones may include methyl chloro isothiazolinone, methyl isothiazolinone, benzisothiazolinone ProClin 150, ProClin 200, ProClin 300 and ProClin 950. Exemplary phenolic types may include phenoxy ethanol, benzyl alcohol and phenethyl alcohol. Exemplary acid preservatives can include hydroxy acetic acid, benzoic acid, ascorbic acid, salicylic acid, formic acid, propionic acid. Exemplary halogenated compounds can include 2-bromo-2-nitropropane-1,3-diol, chloroacetamide, chlorobutanol, chloroxylenol, chlorphenenesin, dichlorobenzyl alcohol, iodopropynyl butylcarbamate, methyl glutaronitrile. Exemplary quaternions can include benzalkonium chloride, benzethonium chloride, chlorhexidine, hexamidine diisethionate and polyaminopropyl biguanide. Exemplary alcohols can include ethyl alcohol and isopropyl alcohol. Examples of these include triazine antimicrobial agents, thiazole bactericidal agents (for example, benzisothiazolone, etc.), pyrithione, pyridine bactericidal agents (for example, 1-hydroxy pyridine-2-thiosodium etc.), 2-phenoxy ethanol and the like. Specifically, Proxel GXL (Avecia), TOMICIDE S (API Corporation) and the like, can be used. Bactericidal and / or fungicidal agents help to improve the stability of the PIOAL.
[000307] In one embodiment, the concentration of the antimicrobial agent can be from 0.01% to 0.5% (weight by volume). The concentration can be from 0.03 to 0.05% (weight by volume).
[000308] The sample that is submitted to analysis with the use of the analyzer with PIOAL in the modality is not particularly limited. Samples obtained from the living organism (biological samples) are normally used. Alternatively, those samples can be diluted, purified, placed in contact with a contrast agent, or the like, for use. Specifically, examples of such a sample may include blood, semen, cerebrospinal fluid and the like. The samples can also include particle suspensions derived from tissue samples. The PIOAL in the modality is properly used when the particles (red blood cell, white blood cell, bacteria, etc.) are analyzed.
[000309] The PIOAL of this invention can be used in a visual analyzer that subjects the particles to imaging. In one aspect, the visual analyzer comprises a flow cell capable of maintaining the flow of a ribbon-shaped sample stream with predetermined dimensional characteristics, such as an advantageous ribbon-shaped sample stream thickness. In some embodiments, the flow cell can have a symmetrical flow path and can be used in combination with an autofocus component.
[000310] This disclosure refers to a method for imaging a particle comprising: 1) bringing the sample into contact with a particle contrast agent composition; 2) illuminate the prepared particle; 3) obtain a scanned image of the particle in a sample stream in the form of an envelope wrapped in a PIOAL; and; 4) analyze the image information to categorize or subcategorize the particles. In some embodiments, the particle can be at least one of any particle disclosed in this document and can be counted and analyzed based on the particle image information.
[000311] In some embodiments, the visual analyzer comprises a flow cell with a symmetrical or asymmetric flow path, and an autofocus component.
[000312] In general, the exemplary PIOAL and methods of using it are useful when used in combination with an automated analyzer found in research laboratories and / or doctors. Exemplary automated analyzers are instruments designed to measure different formed elements and / or other characteristics in a series of biological samples, quickly, including, for example, samples of human body fluid, with minimal human assistance. Exemplary automated analyzers may include, for example, urinalysis analyzers. Exemplary analyzers can process samples individually, in batches or continuously.
[000313] In one aspect, the analyzer / example system comprises an automated particle counter configured to detect a plurality of particles that meet one or more selection criteria, and to provide a particle count of them, in which the selection criteria include members of at least two categories within said particles. An analyzer, which may comprise a processor, which may include components of the meter, is programmed to distinguish particles from at least two categories. A distribution of each of the particles is determined using the analyzer. The processor uses the distribution to correct the particle count for members of at least one of at least two categories and / or subcategories. In some embodiments, the particle counter comprises at least one channel configured to provide the particle count for at least one category and / or subcategory of particles based on a predetermined range based on volume, size, shape and / or other criteria . For example, members of at least one category and / or subcategory comprise at least one type of particle selected from a group consisting of subcategories of white blood cells (WBCs), red blood cells (RBCs), giant platelets (PLTs) and nucleated red blood cells (NRBCs). In a particle counter, due to the similar size or other measured characteristic, cells, such as giant PLTs and NRBCs, can be counted as WBCs. Through the operation of the device, as described in this document, the particle concentration or count of giant PLTs and NRBCs can be accurately measured.
[000314] In one aspect, the systems, compositions and methods of this disclosure provide surprisingly high-quality images of cells in a stream. In one aspect, the visual analyzer can be used in methods of this disclosure to provide automated image-based urine sediment particle counting. In certain embodiments, the methods of this disclosure refer to the automated identification of visual distinctions, including morphological abnormalities to determine, diagnose, predict, predict and / or support a diagnosis of whether an individual is healthy or has a disease, condition, abnormality or infection and / or to monitor whether an individual is responsive or unresponsive to treatment. Applications include categorizing, subcategorizing and counting cells in a fluid sample, such as a urine sample, specifically according to the category or subcategory. Other similar uses for counting additional types of particles and / or particles in other fluid samples are also contemplated. The system, compositions and methods of this invention can be used for categorization and sub-categorization and real-time visualization of images using any suitable automated particle recognition algorithm. The images captured for each sample can be stored for later viewing.
[000315] In another aspect, the analyzer, compositions and methods of this invention provide surprisingly more accurate cell-based signaling, categorization and sub-categorization, which reduces the rate of manual analysis compared to the rate of manual analysis when uses automated image-based analyzers. The systems, compositions and methods reduce the initial manual analysis rate and allow the initial manual analysis to be carried out on the instrument. In addition, the systems, compositions and methods of this development also reduce the percentage of signaled samples during automated analysis, as required by manual analysis.
[000316] Consequently, in some embodiments, the present disclosure features an analyzer and a method for analyzing a sample containing particles, for example, particles in urine. According to this disclosure, a visual analyzer is provided to obtain images of a sample that comprises particles suspended in a liquid. In some embodiments, the visual analyzer comprises a flow cell and an autofocus component, in which a liquid sample containing particles of interest is induced to flow through a flow cell that has the viewing port through which a camera is attached to an objective lens captures digital images of particles. The flow cell is coupled to a sample fluid source, such as a diluted and / or undiluted urine sample, or the like, and to a source of a clear envelope fluid, or intracellular organelle alignment liquid and / or particle (PIOAL).
[000317] In one embodiment, the analyzer also comprises a particle counter that has at least one detection range, as well as an analyzer, and a processor. The analyzer and processor are configured to provide information to categorize, subcategorize and determine the precise concentration and / or particle count in the sample.
[000318] In other embodiments, this disclosure refers to a PIOAL that can be used in an analysis based on particle images, as described in this document. The category and / or subcategory counting of particles in urine samples is used in this disclosure as non-limiting examples of the class of samples that can be analyzed. In some embodiments, cells present in samples may also include bacterial or fungal cells, as well as white blood cells or red blood cells. In some embodiments, particle suspensions obtained from tissues or aspirates can be analyzed.
[000319] The discrimination of urine sediment particles in a urine sample is an exemplary application for which the subject is particularly well suited. The sample is prepared by automated techniques and presented to a high resolution optical imaging device as a sample stream in a ribbon format to be imaged periodically, while the sample flows through a field of view. Particle images (such as in urine sediment particles) can be distinguished from each other, categorized, subcategorized and counted, using the techniques of programmed processing of pixel image data, exclusively automatically or with limited human assistance , to identify and count cells or particles. In addition to particle images, which can be stored and made available in the case of unusual or critical traits, the output data includes a count of the occurrences of each particular cell and / or subcategory distinguished in the registered sample images. The counts of the different particles found in each image can be further processed, for example, used to accumulate exact and statistically significant proportion ratios, or functions of the same particles of each category and / or subcategory distinguished in the sample as a whole. The sample used for visual discrimination can also be highly diluted, but the proportions of cells in each category and / or subcategory are represented in the distribution for the diluted sample, particularly after a series of images has been processed. For use in the present invention, the use of image-based (for example, visual) information for the identification of particles / cells covers the spectral range for ultraviolet, visible or infrared light from 200 nm to 10 mm.
[000320] In some respects, samples are presented, imaged and analyzed in an automated manner. In the case of urine samples, the sample can be substantially diluted in water or saline, which reduces the extent to which the vision of some cells and / or particles could be obscured by other cells and / or particles in an undiluted sample or less diluted. Cells can be treated with agents that enhance the contrast of some cell aspects, for example, with the use of permeabilizing agents to make cell membranes permeable, and histological stains to adhere and reveal traces, such as cytoplasm in the cell. In some embodiments, it may be desirable to stain an aliquot of the sample for particle counting and characterization and subpopulation counting, characterization and analysis of particles including white blood cells, epithelial cells and / or bacteria.
[000321] The particularities of the sample preparation analyzer and methods for sample dilution, histological staining, are generally performed with the use of precision valves and pumps operated by one or more programmable controls, and are not crucial for this disclosure. Examples can be found in patents issued to International Remote Imaging Systems, Inc., such as US 7,319,907, related to programmable controls. Similarly, techniques for distinguishing between certain cells by their attributes, such as color when colored with B021, can be found in US 5,436,978. The disclosures of these patents are hereby incorporated by reference.
[000322] To facilitate the capacity, speed and efficiency by which particles, such as cells, are categorized and subcategorized, it is advantageous to provide clear, high-quality images of urine particles for automated analysis by the data processing system. According to the present disclosure, a stream of prepared sample is arranged on a thin strip which has a stable position between the opposite walls of a flow cell. The positioning of the sample stream and its flattening into a strip-shaped sample stream can be achieved by the flow between layers of a PIOAL introduced into the flow cell that differs in viscosity from the sample fluid and flows through a flow channel symmetrical.
[000323] The PIOAL and the sample have flow rates and viscosities coordinated at the point of introduction to the sample flow cell in such a way that the sample fluid will flatten into a thin ribbon format. The sample stream in tape format is loaded together with the PIOAL, to pass in front of a viewing port where an objective lens and a light source are arranged to allow viewing of the sample stream in tape format. The sample fluid is introduced, for example, injected at a point where the flow path of the PIOAL narrows symmetrically. As a result, the sample fluid stream is flattened and extended on a thin strip. A PIOAL of this disclosure can be used as the wrapping fluid with any visual analyzer of this disclosure. In one embodiment, the PIOAL can be introduced at one end of the flow cell to drag the sample fluid towards the discharge.
[000324] The size of the tape-shaped sample stream in the viewing area is affected by the geometric thinning of the PIOAL flow path and the differential linear velocity of the sample fluid and PIOAL resulting in the thinning and stretching of the sample stream in the form of tape. The initial linear speed ratios between the sample and the PIOAL can vary from 0.5 to 5.0. The cross section of the flow path of PIOAL can be thinned by reducing the depth to achieve a reduction in the cross section area of the flow path by a factor of about 5: 1, 10: 1, 15: 1, 20: 1, 25: 1, 30: 1, 35: 1, 40: 1, 45: 1, 50: 1, 55: 1, 60: 1, 65: 1, 70: 1, 75: 1, 80: 1, 85: 1, 90: 1, 95: 1, 100: 1, 105: 1, 110: 1, 115: 1, 125: 1, 130: 1, 140: 1, 150: 1, 160: 1, 170: 1, 180: 1, 190: 1 or 200: 1. In one embodiment, this geometric thinning is 40: 1. The factors taken into account are transit time through the flow cell, desired rate of sample yield, obtaining a sample stream thickness in tape format comparable to the particle size, obtaining alignment of particles and organelles, obtaining focusing on particle content, pressure balance, flow and viscosity within operating limits, optimizing tape stream sample thickness, achieving a desired linear speed, ease of fabrication considerations and required sample and PIOAL volumes .
[000325] The length and volume of the cannula and the flattening of the cross section can be selected to reduce the period of sample flow instability, thereby increasing the throughput rate. In some embodiments, the period of flow instability may be less than about 3, 2.75, 2.5, 2.25, 2, 1.75, 1.5, 1.25, or less than about 1 second. A smaller cannula volume can also reduce the time and volume of diluent needed to clean the cannula between sample procedures. In some embodiments, the transit time through the flow cell is 1, 2, 3 or 4 seconds, or any range between any two of these times. In some modalities, the transit time may be less than 4, 3 or 2 seconds.
[000326] The viscosities and flow rates of the sample fluid and the PIOAL and the contour of the flow cell are arranged in such a way that the PIOAL flow flattens and extends the sample flow on a flat ribbon consistently across the viewing zone in a trusted location. The sample fluid stream can be compressed to approximately 2 to 3 μm in thickness of fluid flow. Several types of cells in the urine have diameters larger than the current thickness. Shear forces in the direction parallel to the flow direction cause an increase in an image projection of the particles under imaging conditions in the focal plane of the high-resolution optical imaging device and / or cause intracellular structures, for example, organelles or lobes, are positioned, repositioned and / or better positioned to be substantially parallel to the direction of flow. The depth of field of the high-resolution optical imaging device is up to 7 μm, for example, 1 to 4 μm.
[000327] The flow thickness of the PIOAL, with the sample stream in drag form, is constant through a viewing zone in front of a viewing port through which the objective lens is directed. The objective lens can be the objective component of a high resolution optical imaging device or digital image capture device. The strip-shaped sample stream follows a path through the viewing zone in a known and repeatable position within the flow cell, for example, at a known and repeatable distance from two walls of the flow cell, being discharged downstream.
[000328] The optical information from the particles in the sample is detected by a detection section in the analyzer, when the sample stream in tape format is carried through the display zone in front of the display port, thus generating data from of the particles / cells contained in the sample. The use of this analyzer allows the capture, processing, categorization and subcategorization and counting of cells and / or particles contained in samples. The PIOAL liquid can be prepared by adding viscosity modifying agent, buffering agent, pH adjusting agent, antimicrobial agent, ionic strength modifier, surfactant and / or a chelating agent. The functional components and / or exemplifying features of the analyzer in the present disclosure may include, for example, the ability to acquire and / or process data from image analysis, sample color processing, image processing and / or identification, counting and / or particle image categorization and subcategorization.
[000329] In one embodiment, this disclosure was based on the surprising and unexpected discovery that the addition of an adequate amount of a viscosity agent in the PIOAL significantly improves the particle / cell alignment in a flow cell, leading to a higher percentage high focus cells, or cellular components, and higher quality images of cells and / or particles in flux. The addition of the viscosity agent increases the shear forces on the cells as RBCs, which improves the alignment of the cells in a plane substantially parallel to the flow direction, which results in image optimization. This also results in the positioning, repositioning and / or better positioning of intraparticle structures, such as intracellular structures, organelles or lobes substantially parallel to the flow direction, which results in image optimization. The viscosity agent also reduces cell misalignment, in general, but not limited to cells that are smaller in diameter than the flow stream.
[000330] The alignment of cells that are smaller in diameter than the flow current, for example, red blood cells and / or bacteria stems, can be obtained, for example, by increasing the viscosity of the PIOAL and / or by increasing the linear flow rate ratio. This results in the alignment of the RBCs or rods of bacteria parallel to the direction of flow. In some embodiments, a reduction in misalignment of RBC or rods of bacteria and / or an increase in alignment of RBC or rods of bacteria is achieved by increasing the viscosity of the PIOAL.
[000331] In one aspect, this disclosure refers to a method for differentially classifying particles and / or counting particles with the use of image-based particle categorization, sub-categorization and counting. Exemplary methods may include putting a sample containing the particles or cells in contact with a particle contrast agent composition in an amount effective to generate visual distinctions to categorize and / or subcategorize the particles, apply the sample to at least one cell of flow, introduce with the first portion brought into contact with the sample, in at least one flow cell, an intracellular organelle alignment particle and liquid (PIOAL) that has a viscosity different from the viscosity of the treated sample, and effective to sustain the flow sample, align particles and increase the content of particles and cell organelles that flow in the flow path, analyze the cells with the use of a device that includes a visual analyzer, and a processor, perform the categorization and subcategorization of particle by determining one or more visual distinctions, and counting the particles in the categories and subcategories with based on visual distinctions.
[000332] In this and any of the other methods of this disclosure, the particles can be any category and / or subcategory of cells present in the sample, and can include particles selected from erythrocytes (RBCs), dysmorphic erythrocytes, leukocytes (WBCs) ), neutrophils, lymphocytes, phagocytic cells, eosinophils, basophils, squamous epithelial cells, transitional epithelial cells, decoy cells, renal tubular epithelial cells, stones, crystals, bacteria, yeast, parasites, oval fat bodies, fat droplets, sperm, mucus, trichomonas, cell nodules and cell fragments.
[000333] The present disclosure provides a technique to automatically achieve a correct working position of the high resolution optical imaging device to focus on the ribbon-shaped sample stream. The flow cell structure is configured in such a way that the strip-shaped sample stream has a fixed and repeatable location between the walls of the flow cell that define the flow path of the sample fluid, in a thin strip between layers of PIOAL, passing through a visualization zone in the flow cell. In the revealed flow cell modalities, schematically in Figure 1 and in the practical modality in Figures 6 and 7, the cross section of the flow path to the PIOAL narrows symmetrically at the point where the sample is inserted through a flattened orifice, such as like a tube with a rectangular lumen in the hole. The narrowing flow path (for example, which narrows geometrically in the cross-sectional area for a ratio of 20: 1 to 40: 1) and also due to a higher linear velocity of the PIOAL compared to the sample flow, cooperate to flatten and spread the cross section of the sample for a ratio of about 20: 1 to 70: 1. Effectively, due to the combination of flow rate, viscosity and current thickness, the sample is formed on a thin strip. The narrowing flow path (for example, which narrows geometrically in the area in cross section for a ratio of 40: 1, or for a ratio between 20: 1 to 70: 1) and a difference in linear speed of the PIOAL in comparison with the sample flow, they cooperate to thin the sample cross section for a ratio between about 20: 1 to 70: 1. In some embodiments, the thickness ratio in cross section can be 40: 1. In some embodiments, the thickness ratio in cross section can be 30: 1.
[000334] As a result, process variations, such as the specific linear velocities of the sample and the PIOAL, do not tend to displace the ribbon-shaped sample stream from its central location in the flow. Regarding the structure of the flow cell, the location of the sample stream in tape format is stable and repeatable.
[000335] The high optical resolution and the optics of the imaging device have a certain focal length, and the optics are first precisely positioned in relation to the flow cell, that is, by focusing the high resolution optical imaging device on an autofocus pattern. The travel distance between the autofocus pattern and the sample stream is known precisely, preferably, as a result of initial calibration steps. After autofocusing in the autofocus pattern, the flow cell and the high-resolution optical image capture device or digital image capture device are shifted relative to each other in relation to the displacement distance. As a result, the high resolution optical image capture device is precisely focused on the sample stream.
[000336] Thus, it may not be necessary to focus automatically or depend on an aspect of image content that is variable between different images, or is less highly defined as contrast, or could be located somewhere in a range of positions, such as the basis for determining a distance location for reference. Having found the ideal focus location for the autofocus pattern, the relative positions of the high resolution optical imaging device and the flow cell are shifted to move the ideal focus position from the location of the autofocus pattern to the sample stream location in ribbon format.
[000337] In one embodiment, this disclosure refers to a particle contrast agent composition that can be used to stain cells. The particle contrast agent compositions and methods of this invention can be used in one embodiment, for example, to categorize, count and characterize any of the particles disclosed in this document, as well as to sub-categorize, count, characterize and analyze. In one embodiment, particle contrast agent compositions are suitable for use with partially automated or automated image-based analyzers.
[000338] In some embodiments, the particle contrast agent composition is used to accentuate cellular and / or subcellular traits under conditions where one or more cell types remain vital or viable and / or cells and / or cell traits and / or subcellular remain substantially intact. Particle contrast agent compositions can be used to generate visual distinctions for particle categorization and subcategorization. In some embodiments, particle contrast agent compositions can be used to stain white blood cells. In some embodiments, the particle contrast agent composition can also optimize viewable traces of, for example, epithelial cells, bacteria and / or inclusions in pathological calculations in addition to white blood cells. In other embodiments, particle contrast agent compositions can stain white blood cells, as well as epithelial cells, bacteria and / or inclusions in pathological calculi.
[000339] The aspects and modalities of the present disclosure stem from the discovery that certain dye formulations comprising these components have surprising and unexpected efficacy and properties when used as contrast agents for intensifying image-based analysis, such as categorization, subcategory and counting. In one embodiment, this disclosure relates to a particle contrast agent composition that can be used to treat and / or stain cells. The particle contrast agent compositions and methods of this invention can be used in a modality, for example, for counting and characterizing white blood cells and characterizing and analyzing white blood cell differential, and for particle counting, characterization and analysis of particles in biological fluids. In one embodiment, particle contrast agent compositions are suitable for use with analyzers that are partially automated or automated. In some aspects of this invention, methods and compositions for conducting image-based urinary sediment analysis are provided. In one embodiment, the related compositions and methods allow users to view cells and their cell content that could facilitate the identification of abnormal cells based on contrast and / or morphology.
[000340] In other embodiments, particle contrast agent compositions can accentuate and / or stain subcellular structures of WBCs, as well as epithelial cells, bacteria, inclusions in pathological stones, or cell fragments.
[000341] The aspects and modalities of the present disclosure are based on the surprising and unexpected discovery that certain dye compositions and / or combinations thereof, have unexpected efficacy and properties when used to perform urine sediment sample analysis. Exemplary dye compositions and / or combinations thereof are discussed in copending US patent application no., The content of which is incorporated herein by way of reference.
[000342] In another aspect, this invention relates to a kit comprising the particle contrast agent compositions of that invention. The kit may also contain instructions on how to use the particle contrast agent composition according to any of the methods described in this document. The kit may also include an intracellular organelle and / or particle alignment fluid (PIOAL). The kit may also contain a programmable storage medium and related software for image-based identification of particles, such as erythrocytes (RBCs), dysmorphic erythrocytes, leukocytes (WBCs), neutrophils, lymphocytes, phagocytic cells, eosinophils, basophils, squamous epithelial cells, transitional epithelial cells, decoy cells, renal tubular epithelial cells, stones, crystals, bacteria, yeast, parasites, oval fat bodies, fat droplets, sperm, mucus, trichomonas, cell nodules, and cell fragments. The kit may also comprise one or more buffers, which may include diluents and / or isotonic buffers. The kit and / or buffer may additionally comprise a surfactant, a pH adjusting agent and / or an antimicrobial agent. In other embodiments, the kit may also comprise a cleaning or rinsing solution. The kit can also comprise standards for positive and negative controls. In some embodiments, the standard may comprise a standard stained cell reagent. The kit may also comprise disposables, such as micropipettes, disposable tips or tubes for transferring the kit components. The kit can contain any or any combination of two or more of these kit components.
[000343] In another embodiment, this disclosure refers to methods for performing the categorization and sub-categorization of an image-based cell comprising: a) bringing the samples containing particles into contact with a particle contrast agent composition according to any of the methods described in this document; b) obtain images of the particles including intraparticle structures; c) determine one or more cell traits; and d) perform categorization and subcategorization based on image and / or particle analysis.
[000344] For use in the present invention, the functional components and / or exemplifying features of an analyzer in the present disclosure may include, for example, a visual analyzer capable of acquiring and / or processing images and / or identification, counting, categorizing and sub-categorizing particle image. The analyzer can be used in the methods of this invention to analyze urine samples or other samples to categorize and / or subcategorize and / or count cells present in the sample, or to identify cells present in the sample based on particle trace analysis.
[000345] In certain modalities, the image is obtained by an example analyzer. An analyzer can include a flow cell coupled to a source of the sample and a source of an alignment liquid and organelle, for example, a PIOAL, in which the flow cell defines an internal flow path, the cell of which flow is configured to direct a flow of the enveloped sample with the PIOAL through a viewing zone in the flow cell. An analyzer may also include a high-resolution digital optical imaging device with a lens on an optical geometric axis that crosses the sample stream in ribbon form, with a relative distance between the lens and the flow cell being variable by operation of a motor drive, to separate and collect a scanned image in a photosensor matrix. In addition, an analyzer may include an autofocus pattern and / or autofocus patterns that have a fixed position in relation to the flow cell, the autofocus pattern being located at a predetermined distance from the plane of the sample stream at ribbon format. In addition, an analyzer can include a light source configured to illuminate the ribbon-shaped sample stream and the autofocus pattern, and at least one digital processor coupled to operate the motor drive and to analyze the scanned image. The processor can be configured to determine a focus position of the autofocus pattern and to shift relative to the lens and flow cell relative to the predetermined distance from the focused position, to focus the high resolution optical imaging device on the current sample in tape format.
[000346] The term high-resolution optical imaging device may include devices that are capable of obtaining images of particles with sufficient visual distinctions to differentiate features and / or morphological changes. Exemplary high-resolution optical imaging devices may include devices with a resolution of 1 µm or less, including, for example, 0.6 to 0.8 µm, such as, for example, 0.7 µm. In another example, the high-resolution optical imaging device may have a resolution of 0.3 to 0.4 µm, such as, for example, 0.35 µm. In another example, the high-resolution optical imaging device may have a resolution of 0.4 to 0.5 µm, such as, for example, 0.43 µm.
[000347] In some embodiments, the images obtained in any of the compositions and / or methods of this invention can be digitized images. In some embodiments, the images obtained are microscopic images. In certain embodiments, images can be obtained manually. In other modalities, at least part of the procedure for obtaining the images is automated. In some embodiments, images can be obtained using an analyzer that comprises a flow cell, a high-resolution optical imaging device or the digital image capture device, optionally with an autofocus feature.
[000348] In one embodiment, the images provide information related to the cytosolic, cell nucleus and / or nuclear components of the cell. In one embodiment, the images provide information related to the granular component and / or other morphological features of the cell. In one embodiment, the images provide information related to the cytosolic, nuclear and / or granular components of the cell. Granular and / or nuclear images and / or traits are crucial for cell categorization and sub-categorization, both independently and in combination with each other.
[000349] In one aspect of the methods of this invention, cells that are brought into contact with the particle contrast agent composition can comprise white blood cells, epithelial cells and / or bacteria. In another aspect, the methods of this invention may further comprise white blood cell categorization and sub-categorization.
[000350] In one aspect of the methods of this invention, the cells placed in contact with the particle and / or imaged contrast agent composition are red blood cells. In yet another aspect, the methods of this invention refer to a method for carrying out the categorization and sub-categorization of an image-based urine particle comprising: a) imaging a portion of the cell particles; and b) determine the morphology of the imaged particles. In one embodiment, the particles in the urine may be red blood cells. For use in the present invention, red blood cells (RBC) can include, for example, normal red blood cells and / or dysmorphic red blood cells. In some modalities, the imaging is performed using the analyzer of this disclosure, such as an analyzer that comprises a visual analyzer and a processor
[000351] For use in the present invention, an exemplary complete urine sediment analysis may include a test panel typically requested by a physician or other medical professional that provides information about the elements formed (e.g., cells and / or other particles) present in a patient's urine sample. Exemplary formed elements found in urine can generally include, but are not limited to, any particle disclosed in this document.
[000352] For use in the present invention, high abnormality counts can indicate the presence of disease, disorder and / or condition. Thus, a complete urine sediment analysis is one of the urine tests commonly performed on medication, as it can provide an overview of a patient's general health status. Consequently, an analysis of urinary sediment is usually performed during annual physical examinations.
[000353] For use in the present invention, the individual typically collects a urine sample, usually in a cup. The sample is then transported to a laboratory. In a traditional method, the urine sample is first subjected to centrifugal separation and enriched, the sediments thus obtained are, in some cases, stained and then loaded onto a microscope slide (for example, a specialized counting slide or examination fresh) and are subjected to manual determination and counting under the microscope. In another modality, the sample is processed with an automated analyzer in which the particles are categorized, subcategorized and counted, while the particles are enveloped in a wrapping fluid.
[000354] For use in the present invention, in general, urine analyzers can aspirate a very small amount of the specimen through narrow tubing. The sensors can detect the count and / or the number of cells that pass through the tubing, and can identify the cell type. Exemplary sensors can include light detectors (for example, visible, UV or IR) and / or electrical impedance. Exemplary detection parameters can include cell size, volume and / or characteristics. In certain embodiments, the sensors can detect visible and non-visible light over a wavelength spectrum in the range of about 200 nm to about 1.0 mm. In certain embodiments, the sensors can detect a wavelength between about 380 nm and about 760 nm.
[000355] In another aspect of the methods of this invention, particles brought into contact with the particle contrast agent composition and / or imaged particles, such as blood cells, squamous and non-squamous epithelial cells, stones, trichomes, or bacteria . In some aspects of this invention, the abnormal presence of these particles can be used to identify, predict, diagnose, predict or support a diagnosis of a condition, disease, infection and / or syndrome and / or monitor whether an individual is responsive or unresponsive to treatment.
[000356] For use in the present invention, the measurable and detectable particle parameters can include, for example, visual images and / or indices based on non-image of size, shape, symmetry, contour and / or other characteristics.
[000357] For use in the present invention, the urine sample can be diluted, divided into portions or treated with a particle contrast agent in some processes.
[000358] The methods disclosed in this document are applicable to samples from a wide range of organisms, including mammals, eg humans, non-human primates (eg monkeys), horses, cows or other livestock, dogs, cats or other mammals raised as pets, rats, mice, or other laboratory animals; birds, for example, chickens; reptiles, for example, alligators; fish, for example, salmon and other farmed species; and amphibians.
[000359] Samples can be obtained using any conventional method, for example, excretion, extraction, collection, aspiration or a biopsy. The sample may be from an individual considered healthy, for example, a sample collected as part of a routine physical examination. The sample may also be from an individual who has, is at risk, or is suspected of having a disorder. The disorder can be the result of an illness, a genetic abnormality, an infection, an injury, or unknown causes. Alternatively or in addition, the methods may be useful for monitoring an individual during the course of treatment for a disorder. Where there are signs of no ability to respond to treatment and / or therapy, a clinician may choose an alternative or adjunctive agent. Depending on the condition of the individual and the particular disorder, if any, samples can be collected when (or twice, three times, etc.) daily, weekly, monthly or annually.
[000360] Particles may vary depending on the urine sample. The particles can be cells found in urine, for example, blood cells, fetal cells, stem cells, tumor cells or fragments thereof. In some embodiments, the particles can be an infectious agent, for example, viruses, bacteria, protists, protozoa, fungi or parasites.
[000361] The reference to a "formed element" will be understood as covering non-fluid elements present in biological fluid samples. Formed elements include, for example, blood cell classes based on scientific classification or physiological function including erythrocytes (RBCs), leukocytes (WBCs), WBC nodules, leukocyte subclasses, which include mature leukocytes, such as monocytes, neutrophils, eosinophils, basophils. The "formed elements" for use in the present invention will also include particles, such as stones, epithelial cells, yeasts, crystals, bacteria, mucus, microorganisms, bacteria, fungi, protists, protozoa, parasites, cysts, including cysts parasites, or fragments thereof or other cell fragments.
[000362] Except where expressly stated otherwise, the reference to a "category" of particles made in this disclosure will be understood to encompass a group of particles detected using at least one measured, detected or derived detection criterion, such as size , shape, texture or color. In some embodiments, the members of at least one category and / or subcategory of particles counted by the analyzer in this disclosure will be the same type of element formed. The reference to a "category" of particles made in this disclosure will be understood to encompass a grouping of particles that corresponds to the measured, detected or derived criteria, such as size, shape, texture or color. In some embodiments, the members of at least one category and / or subcategory of particles counted by the analyzer in this disclosure will be the same type of element formed.
[000363] The reference to a "member" or "members" of a category and / or subcategory of particles made in this disclosure will be understood to encompass individual particles within a category or subcategory of particles.
[000364] For use in the present invention, the term high resolution optical imaging device can include devices that are capable of obtaining images of particles with sufficient visual distinctions to differentiate features and / or morphological changes. Exemplary high-resolution optical imaging devices may include devices with a resolution of 1 µm or less, including, for example, 0.7 to 0.9 µm, such as, for example, 0.8 µm. Another exemplary high-resolution optical imaging device has a resolution of 0.4 to 0.5 µm, such as, for example, 0.43 µm. Exemplary high-resolution optical imaging devices may include devices with an optical resolution of 1 μm or less, including, for example, 0.46 μm.
[000365] For use in the present invention, particle contrast agent compositions can be adapted for use in combination with an intracellular organelle and / or particle alignment liquid (PIOAL) in a visual analyzer to analyze particles in a sample of an individual. The exemplary PIOAL is useful, for example, in methods for the automated recognition of different types of particles in a sample of an individual.
[000366] In another aspect, cells can be enveloped in PIOAL when images are obtained. The suitable exemplary PIOAL is described in this document.
[000367] For use in the present invention, "alignment" can be characterized in part by the alignment of spherical and / or non-spherical particles. For example, particles, such as non-spherical particles, can be aligned in a plane substantially parallel to the direction of flow. In certain embodiments, the alignment of the non-spherical particles is characterized by the orientation of the particles that increase an image projection of the non-spherical particles under imaging conditions in the focal plane of the high-resolution optical imaging device. Particles, such as spherical particles, may have an increase in the amount of the intraparticle contents in focus of the particles and cells. Intraparticle particle structures, such as spherical particles, can be positioned, repositioned and / or better positioned to be substantially parallel to the flow direction. For example, intracellular structures, organelles or lobes can also be positioned, repositioned and / or better positioned to be substantially parallel to the direction of flow.
[000368] The reference to a "class" of particles made in this disclosure will be understood as covering a group of particles based on scientific classification. For example, the largest classes of elements formed in a urine sample include, but are not limited to, erythrocytes (RBCs), dysmorphic erythrocytes, leukocytes (WBCs), neutrophils, lymphocytes, phagocytic cells, eosinophils, basophils, squamous epithelial cells, transitional epithelial cells, decoy cells, renal tubular epithelial cells, stones, crystals, bacteria, yeast, parasites, oval fat bodies, fat droplets, sperm, mucus, trichomonas, cell nodules, and cell fragments.
[000369] The reference to a "member" or "members" of particles made in this disclosure will be understood to encompass a subcategory of particles in a category of particles. For example, each class of urine sediment can be further divided into subcategories or subcategories. The largest subcategories of WBCs include, but are not limited to, neutrophils, lymphocytes, monocytes, eosinophils and basophils. In addition to mature RBCs, RBC members may include abnormally shaped RBCs.
[000370] The reference to "abnormal" cells or particles will be understood as covering those associated with a certain disease or condition, or irregularities that may, in some cases, be associated with certain diseases or conditions. Variations in size, shape, color, number of particles and / or intracellular structures can be associated with certain diseases or conditions or lack thereof.
[000371] The reference to "counting" of particles or "counting of particles" made in this disclosure will be understood as covering the numbers of particles obtained by accumulating the number of all particles detected and categorized or subcategorized by the visual analyzer. The reference to "concentration" of a class, category or a subclass or subcategory of particles made in this disclosure will be understood as referring to the numbers of the particles per unit volume (for example, per liter) or per sample of a known volume. For example, a visual analyzer can provide counts, concentrations, ratios or other parameters based on concentration for each category or subcategory of particles.
[000372] The present disclosure provides a technique to automatically achieve a correct working position of the high-resolution optical imaging device to focus on the tape-shaped sample stream. The flow cell structure is configured in such a way that the ribbon-shaped sample stream has a fixed and reliable location within the flow cell that defines the sample fluid flow path, on a thin ribbon between layers of PIOAL , passing through a viewing zone in the flow cell. In the revealed flow cell modalities, schematically in Figure 1 and in the practical modality in Figures 6 and 7, the cross section of the flow path to the PIOAL narrows symmetrically at the point where the sample is inserted through a flattened orifice, such as like a tube with a rectangular lumen in the orifice, or cannula. The narrowing flow path (for example, which narrows geometrically in the cross-sectional area by a ratio of 20: 1, or by a ratio between 20: 1 to 70: 1) and a difference in linear speed of the PIOAL in comparison with the sample flow, they cooperate to compress the cross section of the sample by a ratio of about 20: 1 to 70: 1. In some embodiments, the thickness ratio in cross section can be 40: 1.
[000373] In one aspect, the symmetrical nature of the flow cell and the way of injecting the sample fluid and PIOAL provide a repeatable position within the flow cell for the ribbon-shaped sample stream between the two layers of the PIOAL. As a result, process variations, such as the specific linear velocities of the sample and the PIOAL, do not tend to displace the ribbon-shaped sample stream from its central location in the flow. Regarding the structure of the flow cell, the location of the sample stream in tape format is stable and repeatable.
[000374] However, the relative positions of the flow cell and the optical high-resolution imaging device of the optical system may be subject to change and require occasional position adjustments to maintain the ideal distance between the high-resolution optical imaging device and the ribbon-shaped sample stream, thereby providing a quality focus image of the enveloped particles in the ribbon-shaped sample stream. There is an ideal distance between the high resolution optical imaging device and the ribbon-shaped sample stream to obtain focused images of the enveloped particles. The optics are first precisely positioned in relation to the flow cell, schematically in Figure 1, that is, by autofocus techniques to locate the high resolution optical imaging device at the ideal distance from an autofocus pattern with a fixed position in relation to the flow cell. The displacement distance between the autofocus pattern and the ribbon-shaped sample stream is known precisely, preferably, as a result of initial calibration steps. After autofocusing in the autofocus pattern, the flow cell and / or high resolution optical imaging device is then shifted to provide the known travel distance between the flow cell and the high resolution optical imaging device. or the digital image capture device and the sample stream in tape format. As a result, the objective lens of the high-resolution optical imaging device is precisely focused on the ribbon-shaped sample stream that contains the enveloped particles.
[000375] In photographic systems with aspects of autofocus, it is usually the case that the processes of autofocus try to increase the contrast of the object that appears in the image. However, according to the present technique, autofocusing is simplified by autofocusing in the autofocus pattern, which, in some cases, is a high-contrast figure that defines a known location along a line parallel to the geometric axis. optical high resolution imaging device or digital image capture device. The autofocus pattern has a known offset or distance from the location of the ribbon-shaped sample stream. A contrast measurement algorithm can be employed specifically in the traces of the autofocus pattern. In one example, the position of the optical high resolution imaging device is varied along a line parallel to the optical geometric axis of the optical high resolution imaging device to find the depth or distance at which one or more maximum differential amplitudes are found. between the pixel luminance values that occur along a line of pixels in the image that are known to cross an edge of the contrast figure. The autofocus pattern advantageously has no variation along the line parallel to the optical geometric axis of the high resolution optical imaging device, which is also the line along which a motorized control operates to adjust the position of the imaging device. high optical resolution to provide the recorded travel distance.
[000376] The method additionally comprises forming the sample stream in a tape format into a tape format. The ribbon format is presented in such a way that the optical geometric axis of the high resolution optical imaging device is substantially perpendicular to the ribbon-shaped sample stream, that is, orthogonal to the plane of the ribbon-shaped stream.
[000377] The visual analyzer 17 may also comprise at least one contact member 26 configured to supply at least one chemical comprising at least one of a diluent, a permeabilizing agent, an effective contrast agent to generate visual distinctions for categorization and particle subcategory. For example, as shown in Figure 1 and elsewhere, the sample brought into contact is introduced into the flow cell through the sample injector 29, and an intracellular organelle alignment reagent or wrap is introduced from the injector 27.
[000378] A diluent can be used to dilute the sample to an appropriate concentration. A contrast agent and / or permeabilizing agent is used to generate visual distinctions to categorize and / or subcategorize particles. PIOAL is used to align a particular type of cell or cell structure in one direction for better imaging. In some modalities, at least one chemical can be applied to contact a sample first, and then the treated sample is supplied to the visual analyzer 17.
[000379] The treatment of the sample with at least the addition of at least one chemical product can be carried out at room temperature. In some embodiments, such treatment can be carried out at a temperature, such as 10, 15, 20, 25, 30, 35, 36, 37, 38, 38, 39, 40, 45, 46, 47, 48, 49, 50 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79 or 80 ° C. The treatment at a selected temperature can be carried out in an incubator that is separate from the visual analyzer 17, or in a visual analyzer 17 that has a controlled temperature.
[000380] In some modalities, the visual analyzer may have a contact chamber to place the sample in contact with a contrast agent and / or permeabilizing or surfactant agent. In other modalities, the sample can be placed in contact with the contrast agent and / or permeabilizing agent before injection into the visual analyzer. In other embodiments, the visual analyzer that contains a heating element to heat the sample while in contact with the contrast agent and / or permeabilizing agent, at a controlled temperature for a controlled time. The visual analyzer may also have a cooling element to cool the sample mixture after the heating step.
[000381] In addition to providing accurate results, the visual analyzer 17 offers significant advantages in improving the speed of analysis. In Figure 1C, the exact results of counting different urine sediments can be provided via screen 63. During an analysis process, an operator can interact with processor 18 via terminal 65. The operator may need to make slides to identify or check classes or members of classes of cells or other particles in a sample, and insert the information into processor 18. Previously, up to about 25% to 30% of results were analyzed manually by producing microscope slides (for example, slides counting or fresh examination) with which they have been examined under a microscope by an operator. Through the operation of the analyzer as described in this disclosure, the images can be analyzed on the visual analyzer and the samples will require less frequent manual analysis.
[000382] The following categories of applications are described for the purpose of illustrating the analyzer in this disclosure. Applications are not limited to those described below.
[000383] The present disclosure features innovative compositions and methods of using them to conduct particle analysis. In particular, the present disclosure relates to an intracellular organelle and / or particle alignment liquid (PIOAL) used in an analyzer to analyze particles in a sample. The terms wrap fluid and PIOAL can be used interchangeably throughout this disclosure. The present disclosure further provides methods for producing PIOAL and methods for using PIOAL to analyze particles. The PIOAL of this invention is useful, for example, in methods for automated categorization and subcategorization of particles in a sample.
[000384] The PIOAL may comprise one or more viscosity agents or viscosity modifiers. For use in the present invention, PIOAL is a compound or composition that has a characteristic viscosity that is different from the sample viscosity. In some embodiments, the viscosity of the PIOAL is increased or decreased in order to maximize the alignment of particles, while in flux, and surprisingly also to increase the contents in focus of particles and / or intracellular particle organelles when presented for imaging. For example, particles and / or cells can be oriented to increase an image projection of the particles under imaging conditions in the focal plane of the optical high resolution imaging device. Intraparticle structures, such as intracellular structures, organelles or lobes, can also be positioned, repositioned and / or better positioned to be substantially parallel to the direction of flow. In some embodiments, one or more viscosity agents comprise the entire liquid portion of the PIOAL, which may contain additional salts or other components. In other embodiments, the sample viscosity is increased or decreased to maximize the relative difference in sample viscosity and PIOAL viscosity, in order to maximize the alignment of particles, while in flow, and to increase the focused contents of the particles and / or intracellular particle organelles when presented for imaging.
[000385] In certain embodiments, the difference in viscosity and / or speed difference between the ribbon-shaped sample stream and the PIOAL and / or the thickness of the ribbon-shaped sample stream can introduce shear forces to act on the particles, while in flux, thus causing the particles to align and remain in alignment throughout the imaging process in the visual analyzer. In some modalities, the sample will have marked contrast. In some embodiments, PIOAL can comprise up to 100% of a viscosity agent.
[000386] In other embodiments, this disclosure refers to a PIOAL that can be used in image-based analysis of particles in urine samples or other samples of biological fluid, such as cerebrospinal fluid and / or effusions associated with particular conditions. Particle category and / or subcategory counts, as described, for use in urine samples in this disclosure, are non-limiting examples of the class of samples that can be analyzed. In some embodiments, cells present in samples may also include bacterial or fungal cells, as well as white blood cells or red blood cells. In some embodiments, particle suspensions obtained from tissues or aspirates can be analyzed.
[000387] In some embodiments, a stream of sample fluid can be injected through a cannula with a flattened opening to establish a flow path with considerable width. The PIOAL can be introduced into the flow cell and carries the sample fluid along the imaging area, then towards a discharge. PIOAL has a different viscosity, for example, relatively higher than the sample fluid and, optionally, a different flow rate at the injection point to the sample stream in tape format results in flattening the sample fluid into a tape format thin. The thin strip of sample fluid is loaded together with the PIOAL, to pass in front of a viewing port where a high resolution optical imaging device and a light source are arranged to view the sample stream in tape format .
[000388] In one embodiment, the viscosity of the PIOAL may be greater than the viscosity of the sample. The viscosity of the PIOAL, the viscosity of the sample material, the flow rate of the PIOAL and the flow rate of the sample material are coordinated to maintain the flow in a ribbon-shaped sample stream with predetermined dimensional characteristics, such as a sample stream thickness in advantageous tape format. Maintaining an advantageous thickness of sample stream in ribbon format provides, for example, a high percentage of particles in focus, such as cells and / or cellular components in focus.
[000389] The disclosure is based on the discovery that the addition of an adequate amount of a viscosity agent in the PIOAL significantly improves the particle / cell alignment in a flow cell, and increases the intracellular contents of cells in focus, resulting in superior quality images of cells in flux compared to using a conventional viscous unmodified wrap fluid. The addition of the viscosity agent increases the shear forces in cells such as RBCs, which then align the cells in a plane substantially parallel to the flow direction, which results in image optimization. For cells such as WBCs, this also results in the positioning, repositioning and / or better positioning of intracellular structures, organelles or lobes substantially parallel to the direction of flow.
[000390] The alignment of particles that are smaller in diameter than the flow current, can be obtained by increasing the viscosity of the PIOAL. This results in the improved alignment of those particles on a plane substantially parallel to the direction of flow.
[000391] An exemplary PIOAL modality is used in a flow cell for particle analysis. A sample is enveloped in the PIOAL stream and passed through the flow cell of the analyzer device. Then, the sample information when it passes through the detection area is collected, making it possible to analyze particles / cells contained in the sample. The use of PIOAL in such an analyzer allows the categorization and subcategorization and exact counting of particles, such as cells and other particles contained in samples.
[000392] For use in the present invention, PIOAL is useful in obtaining information related to the following cells and / or particles disclosed in this document.
[000393] For use in the present invention, the viscosity agent and / or viscosity modifier can include any substance suitable to achieve an absolute value of a difference between the viscosity of the PIOAL and the viscosity of the sample between 0.1 to 10 centipoise, with optical characteristics, including optical clarity, suitable for use in an imaging system. The viscosity agent / viscosity modifying agents can include any substance suitable to achieve an absolute value of a difference between the viscosity of the PIOAL and the viscosity of the sample between 0.1 to 10 centipoise (cP), with optical characteristics, including optical clarity , suitable for use in an imaging system.
[000394] Additional suitable buffers may include, for example, pH buffers that act in a physiological range of pH 6 to 8, including 2-Amino-2-methyl-1,3-propanediol BioXtra, pH 10.0 to 12 0.0 (20 ° C, 0.5 M in H2O); ACES; ADA; BES; bicin; BIS-TRIS; DIPSO; EPPS; Gly-Gly; HEPBS; HEPES; MONTH; MOBS; MOPS; MOPSO; phosphates; PIPES; POPSO; sodium carbonate; sodium bicarbonate; TAPS; TAPSO; TES; tricine; triethanol amine hydrochloride; and Tris; Trizma.
[000395] In one aspect, the analyzer / example system comprises an automated visual analyzer component in which a liquid sample containing particles of interest is induced to flow through a flow cell that has a viewing port through which an imaging device high-resolution optical captures a digital image. The flow cell is coupled to a source of sample fluid, and to a source of PIOAL. The sample can be treated with one or more of the exemplary particle contrast agent compositions described in this document prior to imaging analysis. The urine sample can be diluted, divided into portions, stained in some processes, and induced to flow through a flow cell that has a transparent window or door through which the pixel data image is captured using a high resolution optical imaging device comprising a digital camera. The pixel data image can be displayed on a monitor and analyzed automatically and / or interactively to discern visible traces of particles of interest. Traces allow particles to be distinguished, categorized, subcategorized and counted, such as elements formed in urine samples.
[000396] Samples can be obtained using any conventional method, for example, a urine sample collection. The sample may be from an individual considered healthy, for example, a sample collected as part of a routine physical examination. The sample may also be from an individual who has, is at risk, or is suspected of having a disorder. The disorder can be the result of an illness, a genetic abnormality, an infection, an injury, or unknown causes. Alternatively or in addition, the methods may be useful for monitoring an individual during the course of treatment. Where there are signs of responsiveness, the clinician can adjust the dose or treatment accordingly. Where there are signs of no ability to respond to treatment, a clinician may adjust the dose or choose an alternative or adjunctive agent. Depending on the condition of the individual and the particular disorder, if any, samples can be collected when (or twice, three times, etc.) daily, weekly, monthly or annually.
[000397] The high-resolution optical imaging device and the light source can be placed on opposite sides of the flow cell, to obtain illuminated images behind the particles. The high-resolution optical imaging device captures an image of sample pixel data through a viewport in the flow cell. For example, the high-resolution optical imaging device captures images at a repetition frequency consistent with the flow rate such that sections of the ribbon-shaped sample stream are imaged without gaps or substantial overlap.
[000398] There are a number of structural and functional challenges in the design and operation of a system for collecting high-resolution images of a sample stream in ribbon form in advance through a flow cell. One need is to obtain a sharply focused image of the particles, sufficiently clear to reveal the different features of the different types of particles that allow the types of particles to be distinguished from each other.
[000399] In order to maintain focus, the distance between the high resolution optical imaging device and the ribbon-shaped sample stream needs to be adjusted in such a way that the ribbon-shaped sample stream is at the correct distance of the high-resolution optical imaging device along the optical geometric axis. The objective lens of the high-resolution optical imaging device separates an image focused on a photosensor matrix, such as a two-dimensional charge coupling device matrix, from which the pixel data is digitized. The dimensions of the sample area that is imaged and the depth of field that is in focus in the sample are determined by the optical configuration. Aperture adjustments and zoom adjustments may be possible, but for the sake of simplicity, the examples in this disclosure are such that focusing the high resolution optical imaging device on the particles in the ribbon-shaped sample stream simply requires the positioning of the high-resolution optical imaging device at a correct predetermined distance from the ribbon-shaped sample stream in the flow cell, that is, the distance that results in a particle image focused on the photosensor matrix.
[000400] In one aspect, visual analyzers, or image analyzers, for use with the compositions of this invention, can capture reliably focused images of the sample by accurately adjusting the distance between the tape-shaped sample stream and the high resolution optical imaging device of the optical system. In some embodiments, visual analyzers can be used in combination with the compositions of that invention and algorithms to establish that distance.
[000401] It is desirable to imagine a thin layer of prepared sample. The sample is arranged in the flow cell and illuminated to allow visualization through a viewing port. The individual particles appear clearly in the captured pixel data image, with sufficient trace contrast, for example, to reveal attributes that are then compared and correlated with known parameters to distinguish categories and subcategories of particles from each other.
[000402] It is an objective to employ a flow cell in combination with suitable particle contrast agent compositions, and an exemplary PIOAL to allow the analyzer to collect images optimized for particle recognition. In addition, the PIOAL and the flow cell provide a stable, highly repeatable position for a ribbon-shaped sample stream injected into a PIOAL stream, in combination with an autofocus mechanism that maintains the ideal distance from the imaging device. high optical resolution for the ribbon-shaped sample stream, thus providing a focused, quality image.
[000403] It is known to use automated focus processes in digital photography in general, and in digital image microscopy in particular, to focus on an individual in a position of uncertain depth. However, a programmed processor does not have a perception of the image content. Typically, focus quality is assessed by finding the distance at which the individual's image has the highest total contrast, as determined by a numerical algorithm applied to the pixel data in the image. For example, a sum of the differences in luminance amplitude for each pixel in the image versus its adjacent pixels can be calculated as a measured total contrast. In equal circumstances, the larger sum found in the images at slightly different distances corresponds to the greater contrast. However, the image content affects the result of such numerical measurements, and the image content may differ over different distances. Thus, it is desirable, as a manual procedure, to imagine a thin layer of diluted colored sample, for example, of a thickness comparable to the thickness of the cells or particles, when using a flow cell instead of samples mounted on slides. glass. The sample needs to be arranged in the flow cell to allow visualization through an illuminated viewing port.
[000404] Therefore, it is advantageous to have automated focusing processes so that the individual particles appear clearly in the captured pixel data image, with sufficient trace contrast to reveal visible attributes that are then compared and correlated with the parameters known for distinguish categories and subcategories of particles from each other.
[000405] It is an objective to employ a flow cell in combination with the exemplary PIOAL disclosed in this document that provides a stable and highly repeatable position for a sample stream injected into a PIOAL flow, in combination with an autofocus imaging device high-resolution optical image that maintains the focal plane of the high-resolution optical imaging device over the ribbon-shaped sample stream, substantially parallel to the flow direction, thus providing a focused image quality of the particles in the sample, but the which does not require constant or even frequent repetition of the autofocus process. The image is focused on a plane substantially parallel to the flow direction of the visual analyzer.
[000406] As an example, a first step is to determine a precise relative position of the high-resolution optical imaging device in relation to the flow cell that carries the exemplary PIOAL and the tape-shaped sample stream. Advantageously, the flow cell and / or high-resolution optical imaging device are moved relative to one another in an autofocusing process using an autofocus pattern with edges sharply contrasting with the reference point as an object. The strip-shaped sample stream is fixed in position relative to that reference point.
[000407] The PIOAL flow path can be arranged symmetrically in such a way that the equal PIOAL flows spread and locate the sample stream like a thin strip at a fixed distance from the autofocus pattern along the line parallel to the axis optical geometry of the high resolution optical imaging device. In one embodiment, the autofocus pattern comprises an opaque border around an opening that admits light from a backlight source and the distance from the autofocus pattern is readily and unambiguously concentrated by the autofocus controls. Then, the ribbon-shaped sample stream is brought into focus by moving the high-resolution optical imaging device from the position of the autofocus pattern to the position of the ribbon-shaped sample stream, which is a fixed displacement distance, without the need to auto focus on the sample image content, although additional auto focus is conceivable.
[000408] A motor drive is provided and controlled by a processor that evaluates a focus quality measurement, for example, a contrast measurement, and operates the motor drive for automatic focusing. In normal operation, the processor operates the motor drive to automatically focus on the autofocus pattern and then adjusts the distance between the high resolution optical imaging device and the flow cell by the travel distance recorded from the autofocus to the ribbon-shaped sample stream. As long as the device continues to move the ribbon-shaped sample stream in the same way, and thermal expansion or similar confounding factors do not appear, the image of the ribbon-shaped sample stream will remain in focus.
[000409] A calibration or preliminary setup process can be used to determine and record the displacement distance between the autofocus pattern and the location of a ribbon-shaped sample stream in the flow cell. The exact displacement distance, which can differ for different flow cells, is established by preliminary testing, such as by alternatively autofocusing on the autofocus pattern and on a test strip-shaped sample stream several times, and registering the average result as a constant associated with the flow cell.
[000410] The particles in the urine sample are imaged by the high resolution optical imaging device that collects digital images that are analyzed by image analysis processes at least partially automated. An autofocus process is performed on an autofocus pattern or similar focusing target, preferably a flat target with little or no variation in distance in the direction of the optical geometric axis, rather than the current sample of tape format . The autofocus pattern has a known distance offset from the distance of the ribbon-shaped sample stream. An automated focusing configuration includes a motor drive that adjusts the relative position of the flow cell and a high-resolution optical imaging device along the optical geometric axis, responsive to control signals from a processor that collects one or more focus quality measurements over a range of distances and seeks an ideal distance. Autofocus is applied to fix the focal point of the optical high-resolution imaging device at the depth of the target pattern located at a displacement distance of the flat ribbon-shaped sample stream parallel to the flow stream.
[000411] Having focused on the autofocus pattern, the processor operates the motor drive over the fixed displacement distance, thus placing the sample stream in ribbon format in focus on the digital image. The autofocus pattern can have a high degree of visual contrast and, in some modalities, can help with a flat alignment, that is, placing the flow cell in a plane orthogonal to the optical geometric axis of the high resolution optical imaging device .
[000412] In one aspect, the methods of this invention provide surprisingly high quality images of particles in flux that allow the counting of urine sediment based on automated image, as well as the automated identification of morphological abnormalities useful in the determination, diagnosis, prognosis, predicting and / or supporting a diagnosis of whether an individual has a disease, condition, abnormality or infection and / or monitoring whether an individual is responsive or unresponsive to treatment. In another aspect, the compositions and methods of this invention provide more accurate cell signaling, categorization and subcategorization, which reduces the rate of manual analysis compared to today's automated analyzers.
[000413] In some embodiments, this invention additionally refers to a kit that comprises the PIOAL of that invention. In another embodiment, this invention relates to a kit comprising the PIOAL of that invention and at least one particle contrast agent. In some respects, the kit may contain two particle contrast agents in addition to the PIOAL. In some embodiments, the particle contrast agent is a composition comprising new methylene blue, crystal violet, safranin O, eosin Y and / or methyl green.
[000414] In one embodiment, the non-spherical particles comprise red blood cells, epithelial cells, stones, white blood cell nodules and / or hyphae or germination yeasts. In another aspect of this invention, the spherical particles comprise white blood cells, fat bodies, trichomonas.
[000415] The particles in urine samples to be analyzed include characteristic sediments or elements formed. The elements formed may include the exemplary particles disclosed in this document.
[000416] Exemplary calculations can include acellular pigment calculations, unclassified calculations (for example, granular calculations). Exemplary acellular calculations may include, for example, waxy calculations, broad calculations, fatty calculations and crystal calculations. Exemplary cell calculations may include, for example, RBC calculations, WBC calculations and cell calculations.
[000417] Exemplary crystals may include, for example, calcium oxalate, triple phosphate, calcium phosphate, uric acid, calcium carbonate, leucine, cystine, tyrosine and amorphous crystals.
[000418] Exemplifying non-squamous epithelial cells may include, for example, renal epithelial cells and transitional epithelial cells.
[000419] Exemplary yeast may include, for example, germinating yeast and yeast with pseudo-hyphae.
[000420] Exemplary bacterial pathogens may include, for example, Bacillus anthracis, Yersinia pestis, Yersinia enterocolitica, Clostridium botulinum, Clostridium perfringens Francisella tularensis, Brucella species, Salmonella spp., Including Salmonella enteriditis, Escherichia coli including E. coli O7: E. coli O7 , Streptococcus pneumoniae, Staphylococcus aureus, Burkholderia mallei, Burkholderia pseudomallei, Chlamydia spp., Coxiella burnetii, Rickettsia prowazekii, Vibrio spp., Shigella spp. Listeria monocytogenes, Mycobacteria tuberculosis, M. leprae, Borrelia burgdorferi, Actinobacillus pleuropneumoniae, Helicobacter pylori, Neisseria meningitidis, Bordetella pertussis, Porphyromonas gingivalis and Campylobacter jejuni. Fungal pathogens can include, without limitation, members of the genera Aspergillus, Penecillium, Stachybotrys, Trichoderma, mycoplasma, Histoplasma capsulatum, Cryptococcus neoformans, Chlamydia trachomatis and Candida albicans. Pathogenic protozoa may include, for example, members of the genus cryptosporidium, for example, Cryptosporidium parvum, Giardia lamblia, Microsporidia and Toxoplasma, for example, Toxoplasma brucei, Toxoplasma gondii, Entamoeba histolytica, Plasmodium falcipariaa and Leishmanta major.
[000421] The exemplary urine sediment particle can also include RBC nodules, fat, oval fat bodies and trichomonas.
[000422] Conditions associated with hemoglobin in urine include, for example, bilirubin crystals or amorphous deposits seen in severe hyperbilirubinemia; cystine crystals, seen in hemosiderin cystinosis, seen in iron overload; and erythrocytes, seen in cold paroxysmal hemoglobinuria.
[000423] In some modalities, the results obtained can be compared with a reference.
[000424] Standard reference levels typically represent cell numbers derived from a large reference population. The reference population may include individuals of age, body size; ethnic background or general health similar to the individual in question.
[000425] In one aspect, the exemplary coloring compositions disclosed in this document are useful for categorizing, subcategorizing and counting particles disclosed in this document.
[000426] For use in the present invention, the particle contrast agent composition can be used in combination with a PIOAL in a visual analyzer to generate images that contain a greater number of cell contents in focus (e.g., lobes, nucleus , nuclear contents, cytoplasm and granules).
[000427] The use of PIOAL reduces the sample stream, helping to direct the flow to a flat, thin strip. In some embodiments, the use of the exemplary PIOAL results in more cell content in focus, which may include lobes, cytoplasm and granular components of the cell. In addition, in some embodiments, the flow cell design has a symmetrical flow path that yields less cell misalignment than a flow cell with an asymmetric flow path.
[000428] For use in the present invention, contrast agents are used to stain a variety of cell types, including, for example, white blood cells, epithelial cells and / or bacteria.
[000429] In some embodiments, traces of imaged cells stained by the particle contrast agent compositions of this disclosure are shown in Table 1.


[000430] In certain embodiments, the particle contrast agent composition is formulated for limited stability, ease of storage, elimination and / or toxicity.
[000431] In some embodiments, the methods and analyzer disclosed in this document can be used to monitor cell morphology. Changes in cell morphology are associated with many types of disorders. Such changes may vary depending on the specific cell type and disorder, but generally include irregularities in size, shape, color and intracellular structures or any combination of irregularities in size, shape, color and intracellular structures. For example, changes in RBC format may be an indicator of kidney / kidney disease.
[000432] In some modalities, the values obtained can be compared with a reference level. Standard reference levels typically represent particle numbers derived from a large population of individuals. The reference population may include individuals of age, body size; ethnic background or general health similar to the individual in question.
[000433] The cells can be decoy cells or tumor cells.
[000434] In other embodiments, this disclosure includes kits that contain one or more reagents for use in the methods disclosed in this document. In one embodiment, the kit may comprise one or more PIOAL units. In other embodiments, the kit may additionally comprise one or more particle contrast agent compositions. The kit can also comprise one or more buffers, which can be isotonic and / or a diluent. The kit and / or buffer may additionally comprise a surfactant, a pH adjusting agent, an ionic strength modifier, chelating agent, sugar, sugar alcohol, protein stabilizer, antimicrobial agent and / or hemoglobin reagent. In other embodiments, the kit may also comprise a cleaning or rinsing solution. The kit can also comprise standards for positive and negative controls. In some embodiments, the standard may comprise a standard colored particle reagent (calibrators or controls). The kit can also include concentrates from any of those mentioned above. The kit may also comprise disposables, such as micropipettes, disposable tips or tubes for transferring kit components, connectors, cleaners (solution), or instruction manual, operation manual, certificate of analysis, MSDS, etc., and packaging that associates such elements as a unit.
[000435] Particle contrast agents used to enhance traits in particles, cells or cellular structures, including structures in white blood cells, epithelial cells, pathological stones and / or bacteria, are further described in copending US patent application No. 14 / 2,116,562, deposited on March 17, 2014, the content of which is incorporated herein, as a reference.
[000436] The analyzer and methods disclosed in this document can be used to evaluate any sample that comprises particles in urine. The methods are applicable to samples from a wide range of individuals, including mammals, for example, humans, non-human primates (for example, monkeys), horses, cows or other cattle, dogs, cats or other mammals raised as animals pets, rats, mice, or other laboratory animals; birds, for example, chickens; reptiles, for example, alligators; fish, for example, salmon and other farmed species; and amphibians.
[000437] In some embodiments, the methods and compositions disclosed in this document can be used to monitor cell counts, cell traits / morphology and / or changes in cell traits / morphology. Such changes may be associated with disorders and may vary depending on the specific disorder and cell type, but generally include irregularities in size, shape, color and intracellular strokes / structures or any combination of irregularities in size, shape, color and intracellular strokes / structures . For example, changes in RBC format may be indicative of kidney / kidney disease.
[000438] The present disclosure also provides exemplary particle contrast agent compositions and methods for use in particle analysis. The particle contrast agent compositions can be used in any suitable analyzer to detect and / or analyze a sample containing particles, including the analyzer described herein. In general, exemplary particle contrast compositions and methods of using them are useful when used in combination with an automated analyzer found in research and / or medical laboratories. Exemplary automated analyzers are instruments designed to quickly detect traces and / or other characteristics in a series of biological samples, including, for example, samples of human body fluid, with minimal human assistance. Exemplary automated analyzers include, for example, automatic urine sediment analyzers. Exemplary analyzers can process samples individually, in batches or continuously. In one embodiment, the exemplary particle contrast compositions described in this document can also be used in conventional microscopy applications without requiring the use of an automatic particle counter and / or visual analyzer.
[000439] The sample can be diluted, divided into portions or concentrated. In some respects, prior to image analysis, the sample may be placed in contact, on or off the analyzer, with an exemplary particle contrast agent composition described in this document. The treatment with the exemplary particle contrast agent composition can also be carried out online in the analyzer. In certain embodiments, the sample containing the particle is brought into contact with the particle contrast agent composition and the prepared sample is transported through the flow cell, while enveloped in an exemplary PIOAL. In some respects, the prepared sample can be directed to flow through a flow cell that has a transparent window or door through which an image of pixel data is captured periodically or continuously with the use of an image imaging device. high optical resolution. The pixel data image can be displayed on a monitor and / or analyzed automatically and / or in a way that is at least partially interactive to discern visible traces of interest. The visually distinguishable features of a typical object are used to categorize, subcategorize and / or classify or subclassify and count particles, such as elements formed in urine samples.
[000440] In one aspect, this disclosure refers to a visual analyzer for imaging a sample comprising particles suspended in a liquid, in which the visual analyzer includes a flow cell coupled to a sample source and a source of a PIOAL, in which the flow cell defines an internal flow path, the flow cell being configured to direct a flow of the sample stream in the form of an enveloped ribbon with the PIOAL through a viewing zone in the flow cell . An objective lens associated with a high resolution optical imaging device is located in such a way that the optical geometric axis of the objective crosses the ribbon-shaped sample stream in the flow cell. The relative distance between the objective lens and the flow cell is variable by operating a motor drive coupled to a controller, to separate and collect a scanned image focused on a photosensor matrix. An autofocus pattern (for example, visible on scanned images) is located at a fixed position in relation to the flow cell, the autofocus pattern being located at a predetermined distance from the plane of the sample stream in ribbon format . A light source illuminates the ribbon-shaped sample stream and the autofocus pattern. At least one digital processor is associated with the coupled controller to operate the motor drive. The processor is also willing to analyze the scanned image. The processor determines a focus position of the autofocus pattern and shifts the lens and the flow cell relative to the predetermined distance (for example, the "displacement distance") from the focused position, to focus the imaging device high optical resolution in the ribbon-shaped sample stream.
[000441] In another aspect, a visual analyzer can comprise a processor to facilitate automated analysis of images. In one aspect, the visual analyzer can be used in methods of this disclosure to provide counts of elements formed from image-based urine. In certain respects, the methods of this disclosure refer to the automated identification of morphological abnormalities to determine, diagnose, predict, predict and / or support a diagnosis of whether an individual is healthy or has a disease, condition, abnormality and / or infection and / or monitoring of an individual is responsive or unresponsive to treatment.
[000442] In one embodiment, the PIOAL is introduced into the flow cell and carries the sample fluid through the imaging area, then, towards the discharge. The sample fluid stream can be injected through a cannula with a flattened opening to establish a flow path with considerable width. In some embodiments, the injected sample fluid has been prepared by treating it with a particle contrast agent composition prior to injection. In another aspect of this invention, the sample can be injected into the flow cell by operating a sequence of valves and pumps. In one aspect, sample and PIOAL fluid flows are introduced into the flow cell at flow rates selected by precision fluid pumps.
[000443] The viscosities and flow rates of the sample fluid and the PIOAL and the contour and dimensions of the flow cell can be selected in such a way that the PIOAL flow flattens and extends the sample flow on a flat ribbon in a way consistent across the viewing zone in a trusted location. For example, PIOAL can flow along a flow path with a symmetrically flattened cross section, which tends to hold an injected sample in position at a constant level in the flow. In some embodiments, the PIOAL has a relatively higher viscosity than the sample fluid, and the relative linear flow rates of the sample and relative PIOAL at the sample injection point are such that the sample fluid will flatten in a sample stream at thin ribbon format.
[000444] The sample stream in thin ribbon format is loaded together with the PIOAL, to pass in front of a viewport in which a high resolution imaging device and a light source (for example, UV, visible, IV) are arranged to visualize the particles in the sample stream in a tape format. The high-resolution optical imaging device and the light source can be placed on opposite sides of the flow cell to obtain backlit images of the particles. The high-resolution optical imaging device captures pixel data images of the sample particles through a viewport in the flow cell. For example, the high-resolution optical imaging device captures images at a repetition frequency consistent with the sample flow rate such that sections of the tape-shaped sample stream are imaged without gaps or substantial overlap.
[000445] The modalities of the present invention provide a series of unique functional and structural features implanted in the design and operation of a system to collect images of a sample stream in a ribbon format flowing through a flow cell. The exemplifying modalities are configured to obtain sufficiently focused images of the particles, with sufficient clarity and resolution to reveal the different features of the various particles, such as blood cells, which allow the types of particle and / or cell to be distinguished from each other.
[000446] In one aspect, the symmetrical nature of the flow cell and the way of injecting the sample fluid and PIOAL provide a repeatable position within the flow cell for the ribbon-shaped sample stream in the PIOAL. However, the relative positions of the flow cell and the high-resolution optical imaging device are subject to change and require occasional position adjustments to maintain the ideal distance between the high-resolution optical imaging device and the sample-shaped sample stream. tape, thus providing a quality focus image of the particles.
[000447] The modalities of the present invention encompass automated visual analyzer systems and methods for urine and / or other biological fluids that incorporate an autofocus device / apparatus to provide reliably focused images of the sample by accurately adjusting the distance between the current sample in tape format and the high-resolution optical imaging device. In one aspect, the modalities of the autofocus system disclosed in this document can accurately adjust the distance between the ribbon-shaped sample stream and the high-resolution optical imaging device and capture reliably focused images of the sample. In some modalities, algorithms are used to establish the distance that achieves good focus results.
[000448] It is an objective to employ a flow cell that provides a stable and highly repeatable position for a sample stream in tape format enveloped in a PIOAL stream, in combination with a high resolution optical imaging device and analyzer / device autofocus that maintains the ideal focal distance between the high-resolution optical imaging device and the ribbon-shaped sample stream, thus providing a focused quality image.
[000449] Such apparatus and methods are disclosed and claimed in this document. A symmetric flow cell is provided, which has been shown to produce a repeatable ribbon-shaped sample stream distance within the flow cell. Focusing involves adjusting a precisely correct relative position of the high-resolution optical imaging device relative to the ribbon-shaped sample stream in order to maintain focus on the ribbon-shaped sample stream.
[000450] Advantageously, the flow cell and / or the high-resolution optical imaging device can be moved relative to each other in an autofocusing process using an autofocus pattern, such as a high contrast pattern or similar focusing target, preferably a flat pattern with sharply contrasting strokes, such as edges, the autofocus pattern being fixed in position in relation to the flow cell and used as a focusing object in place of the sample itself . The strip-shaped sample stream is a thin strip at a fixed distance from the autofocus pattern along a line parallel to the optical geometric axis of the high-resolution optical imaging device. The travel distance between the autofocus pattern and the sample stream current position is a constant distance, which is initially determined and programmed into the autofocus device / analyzer. The exemplary technique, therefore, is to automatically focus on the autofocus pattern, then shift the high resolution optical image device and / or flow cell relative to each other by the predetermined distance, where the distance between the image device high-resolution optical and the tape-shaped sample stream location is the ideal distance to provide a focused quality image of the tape-shaped sample stream. For example, first, an autofocus algorithm focuses the position of the high-resolution optical imaging device on the autofocus pattern located at a fixed distance from the tape-shaped sample stream. Having focused on the autofocus pattern, the processor operates the motor drive over the predetermined displacement, thus placing the ribbon-shaped sample stream into focus of the high-resolution optical imaging device.
[000451] An exemplary high-resolution optical image device comprises an objective lens and associated pixel image sensor, capable of capturing an image that reveals particles in magnification and sufficient resolution to provide sufficient detail to separate image traces (for example , visual) of the particles.
[000452] The flow path of the PIOAL can be arranged symmetrically in such a way that equal amounts of PIOAL flow above and below the sample stream, which extends and locates the sample stream like a thin strip at a fixed distance from the pattern of automatic focus along the line parallel to the optical geometric axis of the high resolution optical imaging device. In one embodiment, the autofocus pattern comprises an opaque border around an opening that admits light from a backlight source and the distance from the autofocus pattern is readily and unambiguously concentrated by the autofocus controls. There is no need for autofocusing directly on the sample image content, although additional autofocusing is conceivable.
[000453] An automated focusing configuration includes a motor drive that adjusts the relative position of the flow cell and a high-resolution optical imaging device along the optical geometric axis, responsive to control signals from a processor that evaluates one or more focus quality measurements over a range of distances and look for an ideal distance. For example, the processor can evaluate a contrast measurement and operate the motor drive for autofocus. In normal operation, the processor operates the motor drive to automatically focus on the autofocus pattern and then adjusts the distance between the high resolution optical imaging device and the flow cell by the travel distance recorded from the autofocus to bring the sample stream in ribbon form into focus. As long as the device continues to move the ribbon-shaped sample stream in the same way, and thermal expansion or similar confounding factors do not appear, the image of the ribbon-shaped sample stream will remain in focus.
[000454] A calibration or preliminary setup process can be used to determine and record the displacement distance between the autofocus pattern and the position of the ribbon-shaped sample stream in the flow cell. The exact displacement distance, which may differ slightly for different flow cells, is established by preliminary testing, such as by alternatively autofocusing the autofocus pattern and a test sample stream several times, and recording it the average result as a constant associated with the flow cell.
[000455] Consequently, a sample to be imaged, such as a prepared urine sample, is directed along a defined flow path through a viewing zone in a flow cell. The PIOAL flow path is preferably symmetrical and the sample is injected into the center of the PIOAL flow, with which the sample is enveloped. The flow rates and viscosity and density characteristics of the sample and the PIOAL, together with the contour of the flow cell, cooperate to form the sample on a flat ribbon that flows consistently through the viewing zone in a repeatable position.
[000456] The sample can be imaged by a camera component of the high resolution optical imaging device and digital images collected to be analyzed by at least partially automated image analysis processes, including an autofocus process as described in this document. .
[000457] One objective is to distinguish, categorize, subcategorize and / or count particles in a urine sample, such as blood cells, described in this document, which can be associated with particular conditions. In one aspect, the particle contrast agent compositions of this disclosure can be combined with an analyzer, such as the analyzer described herein in a method to provide surprisingly high quality images of flowing particles. High quality particle images can be automatically captured and processed.
[000458] The images allow the counting of elements formed from urine based on automated image, as well as the automated identification of morphological abnormalities useful in the determination, diagnosis, prognosis, prediction and / or support of a diagnosis of whether an individual is healthy or has a disease, condition, abnormality and / or infection and / or monitoring whether an individual is responsive or unresponsive to treatment. The cell category and / or subcategory count in urine samples is used in this disclosure as non-limiting examples of the class of fluids that can be analyzed.
[000459] It is an objective to employ a flow cell in combination with the exemplary contrast agent compositions described in this document, and an exemplary PIOAL, which provides ideal quality images and details for particle recognition. In addition, the PIOAL and the device provide a stable and highly repeatable position for a sample stream in the form of an enveloped ribbon in a PIOAL stream. This, in combination with a high-resolution optical imaging device and the autofocus device / apparatus that maintains the ideal distance from the high-resolution optical imaging device to the ribbon-shaped sample stream, provides a quality focused image .
[000460] In comparison, other analyzers, for example, image-based discriminators, such as visual analyzers, are able to discriminate between exemplifying cells and / or particles of different categories and subcategories, based on the appearance of the aggregated cells or cells and / or particles or aggregated particles. In one embodiment, the images provide information related to the cell's nuclear component or cell nucleus. In one embodiment, the images of the particles treated with the particle contrast agent compositions of this disclosure provide information related to the cell lines and / or granular composition. In one embodiment, the images provide information related to the nuclear cytoplasmic components and granular components of the cell. Granular, cytoplasmic and / or nuclear traits are imaged based on distinctions (for example, visual) that can be, at least in part, determinants of cell categorization and sub-categorization both independently and in combination with one another.
[000461] By selecting the particle contrast agent compositions of this disclosure to provide optimal contrast for particle recognition by software in an automated device, the compositions of this disclosure are useful in particle categorization and subcategorization methods, such as categorization and subcategory of urinary sediment particles.
[000462] In one aspect of the methods of this invention, the cells that are brought into contact with the particle contrast agent composition and imaged can be white blood cells. In another aspect, the methods of this invention may further comprise white blood cell categorization and sub-categorization.
[000463] In another aspect of the methods of this invention, cells brought into contact with a particle contrast agent composition and imaged are abnormal particles, such as malaria-infected cells, cancer cells, bacteria or parasites.
[000464] Conventional wrap fluids used in particle imaging systems substantially do not align the particles or increase the particle content in focus. There is a need for methods and compositions useful for the intracellular organelle and / or particle alignment liquid (PIOAL) to perform automated particle categorization and subcategorization. Also provided in some aspects of this disclosure, PIOALs are used in the flow cells of the systems in this disclosure.
[000465] The present disclosure features innovative compositions and methods of using them to conduct particle analysis. In particular, the present disclosure relates to a PIOAL used in an analyzer to analyze particles in a sample. The present disclosure further provides methods for producing PIOAL and methods for using PIOAL to analyze particles. The PIOAL of this invention is useful, for example, in methods for automated categorization and subcategorization of particles in a sample.
[000466] One aspect of the invention of this disclosure is based on the unexpected observation that the inclusion of at least one viscosity agent and / or viscosity modifying agent in the PIOAL significantly improves the alignment of particles, cells and the focused contents of structures intraparticle, such as intracellular cell structures that flow through a flow cell. PIOAL optimizes the alignment of cells in a plane substantially parallel to the direction of flow, maximizing an image projection of non-spherical particles in the focal plane of the optical high-resolution imaging device, which results in image optimization and an increase in the number of particles in focus. This also results in the positioning, repositioning and / or better positioning of intraparticle structures, such as structures, organelles or intracellular lobes, substantially parallel to the direction of flow. Consequently, in some respects, the compositions and methods of that invention result in increased cell content in focus, such as lobes, cytoplasm and / or granules in focus. The compositions and methods of this invention additionally provide the most accurate categorization and / or subcategorization and counting of particles and allow differential particle counts.
[000467] This invention refers to a PIOAL suitable for use in an analyzer. In one aspect, the present disclosure provides a PIOAL for use in an analyzer configured to direct the flow of a urine sample of a particular viscosity into a flow path, in which the PIOAL comprises: a fluid that has a viscosity different from that of sample viscosity, where PIOAL is effective to sustain sample flow and to align particles and / or to improve alignment and a plane substantially parallel to the flow direction and to increase the focused content of particles and cells flowing in the flow path, so that the intracellular particles and organelles of aligned cells can be imaged. In one embodiment, the PIOAL additionally comprises at least one of: a plug; a pH adjusting agent; an antimicrobial agent; an ionic strength modifier; a surfactant, and a chelating agent. In some embodiments, PIOAL may contain additional compatible components.
[000468] In one aspect, the viscosity modifier / agent is present in the PIOAL in a concentration sufficient to effectively achieve an absolute value of a difference between the viscosity of the PIOAL and the viscosity of the sample between about 0.1 to about 10 centipoise (cP), about 1.0 to about 9.0 centipoise, 3.0 to 7.0 centipoise, or about 5.0 centipoise under operating conditions. In one aspect, PIOAL can be used with a sample with a lower viscosity. In another aspect, PIOAL can be used with a sample that has a higher viscosity. In one aspect, PIOAL comprises up to 100% viscosity agent.
[000469] In another aspect, the PIOAL of this invention additionally comprises a pH adjusting agent. In one embodiment, the pH of the PIOAL is between about 6.0 to about 8.0 under operating conditions prior to its introduction into the sample. In one embodiment, the pH of the PIOAL is between about 6.5 to about 7.5 under operating conditions. In one embodiment, the pH is between about 6.8 to about 7.2 under operating conditions.
[000470] In one aspect, the PIOAL of that invention may additionally comprise one or more antimicrobial agents. In some aspects, the antimicrobial agent can be, for example, a substance that has fungicidal activity (fungicidal agents) and / or substances that have bactericidal activity (bactericidal agents).
[000471] In certain embodiments, PIOAL may contain additional compatible components, such as procaine HCl.
[000472] In certain embodiments, the PIOAL may additionally comprise detectable inert markers suitable for batch or batch identification. In one aspect, the development provides a PIOAL for use in a visual analyzer / analyzer configured to direct the flow of a sample of a particular viscosity in a flow path, in which the liquid comprises a fluid that has a viscosity different from that of the viscosity of the sample, for example, a PIOAL has a higher viscosity than the sample, where the PIOAL is effective for aligning and increasing the content of intracellular particles and organelles in cells that flow in the flow path and to allow high quality imaging of particles and cells in flux.
[000473] In another embodiment, the PIOAL of this disclosure comprises an ionic strength modifier to adjust the ionic strength. Exemplary ionic strength modifiers can include Li +, Na +, K +, Mg ++, Ca ++, Cl-, Br-, HCO3-, sulfates, pyrosulfates, phosphates, pyrophosphates, citrates, cacodylates or other suitable salts. In one embodiment, the PIOAL can be isotonic. In one embodiment, the PIOAL is isotonic and / or comprises an aqueous solution that is isotonic. In one embodiment, PIOAL comprises sodium chloride. In one embodiment, said sodium chloride is present at a concentration of about 0.9%. In one respect, PIOAL has the same osmolality as urine. In one embodiment, the sodium chloride in the PIOAL of that invention can be present in a concentration between about 0.1 and about 10% (weight by volume). The concentration of sodium chloride in the PIOAL can be, for example, about 0.9 grams of sodium chloride in 100 milliliters.
[000474] In one aspect, PIOAL has a target viscosity between about 1 to 10 centipoise under operating conditions and temperatures. In one embodiment, a concentrated PIOAL stock solution is provided, wherein said concentrated stock solution can be diluted to achieve the PIOAL viscosity. In one embodiment, the concentration of the stock solution is present at least about 1.1x to at least about 100x the concentration of the PIOAL under operating conditions. For use in the present invention, the operating temperature can be in the range from about 10 to 40 ° C, including about 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 and 30 ° C. Typically, viscosity measurements are reported at room temperature, or about 25 ° C.
[000475] In one aspect, the development provides a stock solution of intracellular organelle and concentrated particle alignment liquid, in which the stock solution can be diluted to achieve a viscosity between about 1 to 10 centipoise under operating conditions.
[000476] The viscosity agent is any compound capable of aligning cells in a plane substantially parallel to the direction of flow and / or for the positioning, repositioning and / or better positioning of intraparticle structures, such as intracellular structures, organelles or lobes substantially parallel to the direction of flow. In one embodiment, PIOAL comprises at least one viscosity agent selected from at least one of glycerol, derived from glycerol, ethylene glycol, propylene glycol (dihydroxypropane), polyethylene glycol, polyvinyl pyrrolidone (PVP), carboxymethylcellulose (CMC), dextran and water-soluble polymer. In one embodiment, the viscosity agent is glycerol. In one embodiment, the viscosity agent comprises glycerol and polyvinyl pyrrolidone (PVP). In one embodiment, the viscosity agent comprises PVP. In one embodiment, the viscosity agent comprises propylene glycol (dihydroxypropane). In one embodiment, the viscosity agent comprises polyethylene glycol. In one embodiment, the viscosity agent comprises water-soluble dextran. In one embodiment, the viscosity agent comprises glycerol and carboxymethylcellulose (CMC). In one embodiment, the viscosity agent comprises glycerol and dextran, for example, dextran sulfate. In one embodiment, the viscosity agent comprises a glycerol derivative. In one embodiment, the viscosity agent comprises ethylene glycol. In one embodiment, the viscosity agent comprises propylene glycol (dihydroxypropane). The viscosity agent may also comprise lactose, sucrose, sucralose, maltodextrin, dextrose, mannitol, sorbitol, cellulose, maize starch, wheat starch, rice starch, potato starch, gelatin, tragacanth gum, methyl cellulose, propyl hydroxy methyl cellulose, a carboxy methyl cellulose (CMC), carboxy methyl sodium cellulose (NaCMC), ethyl cellulose (EC), hydroxy propyl methyl cellulose (HPMC), sodium carboxy methyl cellulose (CMC), polyvinyl pyrrolidone (PVP: povidone), hydroxy propyl methyl cellulose (HPMC) and combinations thereof. In addition, additional agents for modifying viscosity have been described in Remington’s Pharmaceutical Sciences; June 1990, Mack Publishing Co. These agents can be selected according to the desired final tonicity and viscosity. Viscosity modifying agents can include any agent suitable for providing a viscosity of about 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5 to about 10 centipoise in PIOAL, with optical characteristics, including optical clarity, suitable for use in a visual analyzer.
[000477] In another aspect, the viscosity modifying agent in the PIOAL can be present at a concentration of about 1 to about 50% (by volume) under operating conditions. For example, the viscosity modifier / agent can also be present in the PIOAL at a concentration of about 3 to about 30% (by volume) under operating conditions. As an example, In one embodiment, the glycerol viscosity modifier / agent can be present in the PIOAL at a final concentration of about 5.0% to about 8.0% (by volume) under operating conditions. In another aspect, the glycerol viscosity modifier / agent can be present at a final concentration of about 6.5% (by volume) under operating conditions. In yet another embodiment, the glycerol viscosity modifier / agent is glycerol present at a concentration of about 5% (by volume) under operating conditions. In yet another embodiment, the glycerol viscosity modifier / agent is glycerol present at a concentration of about 30% (by volume) under operating conditions.
[000478] In another aspect, the viscosity modifying agent in the PIOAL can be PVP present at a concentration of about 1 to about 50% (by volume) of the PIOAL under operating conditions. As an example, the PVP viscosity modifier / agent can be present in the PIOAL at a concentration of about 1.0 to about 1.6% (by weight by volume). In one embodiment, the PVP is present at a concentration in the PIOAL of about 1.0% (weight by volume).
[000479] In another aspect, the viscosity modifier / agent in the PIOAL can be a combination of glycerol and PVP with glycerol present at a concentration of about 1 to about 10% (by volume) of the PIOAL with PVP present at a concentration of about 0.5 to about 2.5% (weight by volume). As an example, in one embodiment, glycerol can be present in the PIOAL at a concentration of about 5% (by volume) in combination with about 1% (weight by volume) of PVP.
[000480] In one embodiment, the PIOAL of this disclosure can be used with any analyzer in this disclosure, for example, an analyzer comprising a visual analyzer, and a processor. In one embodiment, the visual analyzer comprises a flow cell with a symmetrical flow path and an autofocus component. In one embodiment, the analyzer may comprise a particle counter.
[000481] In one aspect, the development provides a method of particle imaging using the exemplary PIOAL by providing a visual analyzer / analyzer for a sample comprising particles in a liquid. The visual analyzer has a flow cell coupled to a sample source and a source of a PIOAL, in which the flow cell defines an internal flow path, in which the flow cell directs a flow of the sample stream in shape of tape enveloped with the PIOAL through a viewing area in the flow cell. The analyzer may comprise a high resolution optical imaging device for this disclosure.
[000482] A laminar flow is established, including the sample stream in tape format enveloped by or between at least two layers of PIOAL. The sample stream in tape format and the PIOAL can have different viscosities. In one embodiment, the viscosity of the sample is less than that of the PIOAL. In another modality, the viscosity of the PIOAL is less than that of the sample.
[000483] In one embodiment, the analyzed particles comprise at least one of a spherical particle that can include a spherical particle, a non-spherical particle, or both. In their respective modalities, the particles may comprise erythrocytes (RBCs), dysmorphic erythrocytes, leukocytes (WBCs), neutrophils, lymphocytes, phagocytic cells, eosinophils, basophils, squamous epithelial cells, transitional epithelial cells, decoy cells, renal tubular epithelial cells, stones, crystals, bacteria, yeast, parasites, oval fat bodies, fat droplets, sperm, mucus, trichomonas, cell nodules and cell fragments. In one embodiment, the particles comprise at least one spherical particle. In one embodiment, the spherical particles are white blood cells or microorganisms. In one embodiment, the particles comprise at least one non-spherical particle. In one embodiment, an image projection of non-spherical particles under imaging conditions is increased in the focal plane of the analyzer. In one embodiment, the non-spherical particles are red blood cells, epithelial cells, stones, white blood cell nodules and / or hyphae or germination yeasts.
[000484] In one aspect, the disclosure provides a method for differentially categorizing and / or subcategorizing a particle comprising: a) placing the particle in a sample in contact with the particle contrast agent composition; b) illuminate the particle in the prepared sample with light in a visual analyzer; c) to obtain a digitized image of the enveloped particle in the PIOAL; d) analyze the particle in the sample based on the image traces (for example, visual); and e) categorize and / or subcategorize the particle according to the visual features characteristic of each category and / or subcategory of particles.
[000485] In one embodiment, the image information includes the content in focus of a particle / cell, including spherical particles. In one embodiment, said particle, cell or portion thereof can be selected from at least one of erythrocytes (RBCs), dysmorphic erythrocytes, leukocytes (WBCs), neutrophils, lymphocytes, phagocytic cells, eosinophils, basophils, squamous epithelial cells , transitional epithelial cells, decoy cells, renal tubular epithelial cells, stones, crystals, bacteria, yeast, parasites, oval fat bodies, fat droplets, sperm, mucus. Particulate matter, cell nodules or cellular components or fragments. In one embodiment, said content in focus of a particle comprises at least one among differentially colored nuclear structure, differentially colored cytosolic structure or differentially colored elements.
[000486] In one embodiment, at least 50% of the non-spherical particles are aligned in a substantially parallel plane, for example, parallel to the direction of flow, or have image projections maximized under imaging conditions in the focal plane of the imaging device. high optical resolution. In another aspect, the use of the PIOAL of this invention in a flow cell allows at least 90% of the non-spherical particles to be aligned in a plane substantially parallel to the flow direction, or to have image projections maximized under imaging conditions in the plane focal length of the high-resolution optical imaging device. In one aspect of this invention, at least 92% of the non-spherical particles are aligned in a plane substantially parallel to the direction of flow, or have image projections maximized under imaging conditions in the focal plane of the high-resolution optical imaging device. In another modality, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94% or 95% of the non-spherical particles are aligned on a plane substantially parallel to the direction of flow and / or have image projections maximized under imaging conditions on the focal plane of the optical high resolution imaging device. In another embodiment, the percentage of non-spherical particles aligned in a plane substantially parallel to the direction of flow or that have image projections maximized under imaging conditions in the focal plane of the optical high resolution imaging device can be in any range between any two of the percentages referred to, for example, at least 75 to 85%, 75 to 80%, 75% to 92%, 92% to 95% or other ranges.
[000487] In one embodiment, spherical particles have organelles, nuclear structures, cytosolic structures or granules better positioned, repositioned and / or better positioned substantially parallel to the direction of flow, and at least 50% of nuclear structures, cytosolic structures or granules are substantially parallel to the direction of flow in the focal plane of the optical high-resolution imaging device. In one embodiment, spherical particles are at least about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90% , 91% or at least 92% of nuclear structures, cytosolic structures or granules that are substantially parallel to the direction of flow in the focal plane of the optical high resolution imaging device, or aligned in a plane substantially parallel, for example, parallel to the flow direction. In another embodiment, the percentage of spherical particle structures substantially parallel to the direction of flow in the focal plane of the high resolution optical imaging device may be in the range between any two of the percentages referred to. In one embodiment, at least 75% of the content of non-spherical particles is substantially parallel to the direction of flow in the focal plane of the high-resolution optical imaging device. In another aspect, the use of the PIOAL of this invention in a flow cell allows at least 90% or 92% of the content of non-spherical particles to be substantially parallel to the direction of flow in the focal plane of the high-resolution optical imaging device.
[000488] In some embodiments of the methods of this invention, the image information is the image of the particle contents. In some respects, the particle content comprises at least one among differentially colored nuclear structure, differentially colored cytosolic structure or differentially colored elements in a particle. Examples of staining sensitive particles are WBCs and epithelial cells.
[000489] In one aspect, the methods of this invention provide surprisingly high quality images of cells in flux useful in obtaining analysis of elements formed from image-based urine, as well as the automated identification of morphological abnormalities useful in the determination, diagnosis, prognosis, prediction and / or support of a diagnosis of whether an individual has a disease, condition, abnormality or infection and / or monitoring whether an individual is responsive or unresponsive to treatment.
[000490] In one aspect, the present disclosure relates to a particle contrast agent composition that can be used to stain particles in biological fluids, such as urine. The compositions and methods of this invention can be used, in one aspect, for example, to accentuate particle traits for counting and characterizing particles, such as erythrocytes (RBCs), dysmorphic erythrocytes, leukocytes (WBCs), neutrophils, lymphocytes, phagocytic cells, eosinophils, basophils, squamous epithelial cells, transitional epithelial cells, decoy cells, renal tubular epithelial cells, calculi, crystals, bacteria, yeast, parasites, oval fat bodies, fat droplets, sperm, mucus, trichomonas, nodules of cell, and cell fragments, as well as for differential white blood cell count and white blood cell categorization, subcategorization, characterization and analysis. In some aspects of the methods of this disclosure, a sample can be treated with an in-line particle contrast agent composition on the analyzer. In other respects, a sample can be treated with a particle contrast agent composition prior to introduction to the visual analyzer.
[000491] In one aspect, the particle contrast agent composition is used to accentuate particle and / or cell traces under conditions where one or more cell types remain substantially intact. In other respects, the particle contrast agent composition is used to treat cell fragments or other particles. In some respects, particle contrast agent compositions can be used to stain and / or enhance cellular traces of white blood cells and / or epithelial cells and / or bacteria.
[000492] The aspects and modalities of the present invention are based on the surprising and unexpected discovery that certain particle contrast agent compositions, including, for example, coloring / dye compositions, and / or combinations thereof, have properties and effectiveness unexpected when used to perform automated image-based urine sample analysis. In one aspect, this invention relates to a particle contrast agent composition that comprises at least one of crystal violet, safranin O, eosin Y, new methylene blue and / or methyl green. The staining / dyes can be present in an amount effective to stain viable and / or substantially intact cells and generate visual distinctions for image-based categorization and sub-categorization. In certain embodiments, the particles of interest may comprise cell particles that additionally comprise cell membranes. In certain embodiments, the permeability of the cell membrane can be altered or modulated by the use of permeabilizing and / or fixing agents to increase the accessibility of the contrast agents to the intracellular contents in these cell particles, thus accentuating the traces of the cell contents when viewed or imaged. In one embodiment, the permeabilizing agent comprises a quaternary ammonium salt.
[000493] In certain respects, several components of the particle contrast agent composition are present in an amount to effectively allow a one-step, fast particle staining procedure.
[000494] In some ways, methods for purifying particle contrast agents are provided. The purification of one or more dyes / dyes used in the compositions and methods of this invention reduces the content of precipitates formed under contact with a sample, thus reducing the background, and perfecting the results from the analysis of the urine-based sample imaging with a reduced need for additional image analysis or manually prepared microscopy.
[000495] In one aspect, a particle contrast agent composition is used to contact particles that may be cells or other particles, to generate visual distinctions to categorize and subcategorize particles, for example, by accentuating the cell lines under conditions in which the cells remain substantially intact. The exemplary particle contrast agent composition can be used in the methods of this disclosure to obtain stained images of vital and / or substantially intact cells with the use of contrast agents in a solvent system with a base other than alcohol. In another aspect, the particle contrast agent composition can also include a particle permeabilizing agent to permeate cell membranes and / or cell walls. In some respects, it was surprisingly found that the particle contrast agent compositions of that invention, which comprise a permeabilizing agent, have the ability to permeabilize the cell membrane by allowing the contrast agent to penetrate into the cells, while the cells remain substantially intact.
[000496] In some respects, particle contrast agent compositions can be used to treat white blood cells, epithelial cells and / or bacteria. As an example, in some respects, particle contrast agent compositions can be used to treat at least one of white blood cells, epithelial cells, bacteria and / or to analyze cell morphologies. In another aspect, the methods of this invention may further comprise white blood cell categorization and sub-categorization.
[000497] In one aspect of the methods of this invention, the cells brought into contact with the particle and / or imaged contrast agent composition are, for example, bacteria, parasites or trichomonas. In some aspects of this invention, cells are abnormal cells that can be used to identify, predict, diagnose, predict and / or support a diagnosis of a condition, disease, infection and / or syndrome and / or monitor whether an individual is responsive or unresponsive to treatment. Exemplary contrast agent compositions and methods for their use and manufacture are disclosed in copending US patent application number, the content of which is incorporated herein by reference.
[000498] In another aspect, the revelation provides a kit. In one aspect, the kit comprises one or more units of a PIOAL, as described in this document. In another aspect, this invention relates to a kit comprising the particle contrast agent compositions of that invention or components and / or concentrates thereof that can be combined to form the particle contrast agent compositions of that invention, and any of the compositions described in this document can be included in the kit. The kit may also contain instructions on the use of the particle contrast agent composition according to any of the methods described in this document and / or instructions for the use of any other component of the kit. The kit may also comprise one or more buffers and / or thinners. The kit and / or buffer may additionally comprise at least one of a pH adjusting agent; ionic strength modifier, a surfactant, a chelating agent, sugar, sugar alcohol, protein stabilizers and / or an antimicrobial agent. In other embodiments, the kit may also comprise a cleaning or rinsing solution. The kit can also comprise standards for positive and negative controls, calibrators or controls. In some embodiments, the pattern may comprise a pattern that contains calibrators and / or controls. The kit may also comprise disposables, such as micropipettes, disposable tips or tubes for transferring the kit components.
[000499] In another aspect, this invention refers to a kit that comprises the PIOAL of that invention and at least one particle contrast agent. In some respects, the kit may contain two particle contrast agents in addition to the PIOAL. In one embodiment, the kit comprises at least one permeabilizing agent and at least one among violet crystal, new methylene blue, eosin Y, safranin O and methyl green in an amount effective to stain viable and / or substantially intact cells for categorization and subcategory.
[000500] The kit can be used in the methods disclosed in this document and can be useful for the identification of elements formed in urine, such as erythrocytes (RBCs), dysmorphic erythrocytes, leukocytes (WBCs), neutrophils, lymphocytes, phagocytic cells, eosinophils , basophils, squamous epithelial cells, transitional epithelial cells, decoy cells, renal tubular epithelial cells, stones, crystals, bacteria, yeast, parasites, oval fat bodies, fat droplets, sperm, mucus, trichomonas, cell nodules and / or cell fragments. The kit may also contain software for identifying elements formed from urine, such as erythrocytes (RBCs), dysmorphic erythrocytes, leukocytes (WBCs), neutrophils, lymphocytes, phagocytic cells, eosinophils, basophils, squamous epithelial cells, transitional epithelial cells, transitional epithelial cells, decoy, renal tubular epithelial cells, stones, crystals, bacteria, yeast, parasites, oval fat bodies, fat droplets, sperm, mucus, trichomonas, cell nodules and / or cell fragments.
[000501] In another aspect, the disclosure provides a method to perform the categorization and subcategorization of particle / differential cell with the use of exemplary reagent kits.
[000502] In one aspect, this method refers to a method for categorizing, subcategorizing and / or counting particles using, for example, the reagent kits of this invention, in which the method comprises: 1) placing the sample containing particles in contact with a particle contrast agent composition, 2) introducing the resulting treated sample into a visual analyzer; 3) illuminate the sample particles treated with light in the visual analyzer; 4) obtain digitized images of the treated sample particles enveloped in a PIOAL; and 5) categorize, sub-categorize and count particles based on image information. In one embodiment, the method comprises automatic in-line coloring. In another embodiment, the sample can be introduced into the visual analyzer prior to contact with the particle contrast agent composition.
[000503] In another aspect, the disclosure provides a method for producing the liquid PIOAL composition described in this document.
[000504] In another aspect, the disclosure provides a method to categorize and / or subcategorize in a differential way particles / cell with the use of image-based particle categorization and subcategorization comprising: a) putting a sample of particles in contact with a particle contrast agent composition, as described in this document, in an amount effective to generate visual distinctions to categorize and subcategorize particles, for example, by accentuating traces of intracellular particle content in a sample when presented for imaging ; b) obtain images of the particles and their internal details; and c) perform categorization and subcategorization based on the image of the particles based on visual distinctions. In some respects, the particle contrast agent comprises at least one permeabilizing agent, at least one fixative, and at least one among crystal violet, new methylene blue, safranin O, eosin Y, and methyl green in an amount effective for generate visual distinctions for particle categorization and subcategorization. In one embodiment, the contact of the sample containing particles with the particle contrast agent composition is carried out at an elevated temperature.
[000505] In some respects, categorization, sub-categorization and counting may comprise a) bringing the sample containing the particles into contact with a particle contrast agent composition, b) enveloping the sample stream in tape format containing the treated particles in a PIOAL; c) illuminate the sample particles treated with light in a visual analyzer; d) obtain digitized images of the treated sample particles enveloped in a PIOAL or imagine the particles with the use of a visual analyzer; and e) categorize and / or subcategorize and count the particles based on the image characteristics, where the particles can be any of the particles disclosed in this document. In some respects, PIOAL can comprise any of the viscosity agents disclosed in this document. The analyzer can be any analyzer disclosed in this document.
[000506] In another aspect, the development provides a fluid composition for PIOAL in an analyzer configured to support a sample flow that carries at least one of the particles and / or cells. The fluid composition can include a sample fluid containing particles, and the sample fluid can have a certain viscosity. In addition, the fluid composition can include a PIOAL that is in contiguity with the sample fluid along an interface surface, with a PIOAL being substantially transparent, having a viscosity greater or less than the viscosity of the sample fluid, so so that the particles and cells are aligned. The particles can be aligned or positioned as disclosed in this document.
[000507] In one embodiment, the PIOAL and the sample fluid have different average linear velocities at an initial point of contact between the sample fluid and the PIOAL. In one embodiment, the sample fluid is disposed between two layers of the PIOAL, thus defining two so-called interface surfaces on which the PIOAL is in contiguity with the sample fluid, with the interface surfaces being spaced apart by a distance. In one embodiment, the spacing distance of the interface layers is less than or equal to the widest dimension of said at least one of the particles and cells. In one embodiment, the spacing distance of the interface layers narrows along a flow direction of at least one of the PIOAL and the sample fluid. In one embodiment, the spacing distance of the interface layers narrows in a transition zone in the direction of flow to a distance that is less than or equal to the widest dimension of at least one of the particles. In one embodiment, the alignment of the widest dimension of at least one of the particles and the relative positions of intracellular organelles or portions of cell organelles in a direction parallel to the flow direction is increased in the transition zone. In one embodiment, a difference in the viscosity of the PIOAL to the viscosity of the sample fluid is about 0.1 centipoise to about 10 centipoise. The differences in viscosities allow the generation of favorable / adequate shear forces to act on the sample stream in tape format.
[000508] The present disclosure presents exemplary particle contrast agent compositions and methods of using them in an analyzer suitable for analyzing a sample containing particles. In general, the exemplary compositions and methods of using them are useful when used in combination with an automated analyzer found in research laboratories and / or doctors. Exemplary automated analyzers are instruments designed to measure different parameters of particles and biochemical components in a series of biological samples, including, for example, urine, with minimal human assistance, and a high throughput rate. Exemplary automated analyzers can include, for example, automated urine microscopy analyzers and / or cell counters, which can perform, for example, counting elements formed from complete urine. In some respects, analyzers can process samples individually, in batches or continuously.
[000509] In some respects, the sample can be treated with the exemplary particle contrast agent compositions described in this document prior to imaging analysis. In some respects, treatment with exemplary particle contrast agent compositions can also be carried out online in the analyzer or before supplying the sample to the analyzer. In some embodiments, the sample can be heated during part or all of the particle staining process. The sample can also be cooled after heating.
[000510] In one aspect, the present disclosure provides a method for analyzing a urine sample, the method comprising: a) introducing the sample into at least one flow cell configured to direct the flow of the sample along a trajectory flow; b) introducing into the flow cell together with the sample, a PIOAL that has a viscosity different from a viscosity of the sample, in which the PIOAL is effective to support the flow of the sample on a flat ribbon; c) imagine the particle in an analyzer that comprises a visual analyzer; d) detecting and counting particles that have one or more visual distinctions, in which the particles include at least one among erythrocytes (RBCs), dysmorphic erythrocytes, leukocytes (WBCs), neutrophils, lymphocytes, phagocytic cells, eosinophils, basophils, squamous epithelial cells , transitional epithelial cells, decoy cells, renal tubular epithelial cells, stones, crystals, bacteria, yeast, parasites, oval fat bodies, fat droplets, sperm, mucus, trichomonas, cell nodules and cell fragments.
[000511] In another aspect, the present disclosure also provides a method for focusing a visual urine analysis analyzer comprising: a) a high-resolution optical imaging device in a fixed autofocus pattern relative to a cell of flow, b) the autofocus pattern that is located at a displacement distance of a sample stream in the form of a urine strip that is predetermined, c) the high-resolution optical imaging device with a lens on an optical geometric axis which crosses the sample stream in tape format, d) a relative distance between the optical high-resolution imaging device and the flow cell that is variable by operating a motor drive, e) the high-resolution imaging device optics configured to separate and collect a scanned image in a photosensor matrix; and operating the motor drive over the travel distance to focus the high-resolution optical imaging device on the ribbon-shaped sample stream. In one embodiment, the method additionally comprises forming the sample stream in a tape format into a tape format. In another embodiment, the optical geometric axis is substantially perpendicular to the ribbon-shaped sample stream. In another embodiment, the autofocus pattern includes shapes with limited size and the displacement distance is sufficient for the shapes to be substantially invisible in the scanned image when focused on the ribbon-shaped sample stream. In yet another modality, the method comprises: a) detecting an auto focus reset signal; b) refocus on the autofocus pattern; c) operate the motor drive over the travel distance (the predetermined distance between the autofocus pattern and the sample stream in ribbon format); so that the high-resolution imaging device is focused on the ribbon-shaped sample stream. In one embodiment, the auto-focus reset signal includes at least one of a change in temperature, a decrease in focus quality, time, or user input.
[000512] In one embodiment, the internal flow path forms a sample stream in a tape format. In one embodiment, the sample source is configured to deliver the sample at a controllable sample flow rate. In one embodiment, the PIOAL source is configured to provide PIOAL at a controllable PIOAL flow rate. In one embodiment, PIOAL has a predetermined viscosity. In one embodiment, PIOAL has a different viscosity than the sample. In one embodiment, the viscosity of the PIOAL, the viscosity of the sample material, the linear speed of the PIOAL and the linear speed of the sample material are coordinated to maintain the tape-shaped sample stream at the travel distance from the pattern of auto focus. In one embodiment, the PIOAL has a linear velocity greater than the sample stream in tape format under initial contact with the sample stream in tape format. In one embodiment, the autofocus pattern is located at the edge of a field of view of the high-resolution optical imaging device.
[000513] In one embodiment, at least one said digital processor is additionally configured to perform the categorization and sub-categorization based on the image of erythrocytes (RBCs), dysmorphic erythrocytes, leukocytes (WBCs), neutrophils, lymphocytes, phagocytic cells, eosinophils, basophils, squamous epithelial cells, transitional epithelial cells, decoy cells, renal tubular epithelial cells, stones, crystals, bacteria, yeast, parasites, oval fat bodies, fat droplets, sperm, mucus, trichomonas, cell nodules and cell fragments . In one embodiment, at least one said digital processor is additionally configured to: detect an auto focus reset signal; the auto focus reset signal is triggered by at least one of a change in temperature, a decrease in focus quality, time or user input. In one embodiment, the analyzer has an internal flow path of the analyzer that narrows to produce the sample stream thickness in tape form from 2 to 4 μm. In one embodiment, the internal flow path results in the sample stream in a ribbon format of 500 to 3,000 μm in width. In one embodiment, the internal flow path results in the sample stream in a ribbon format from 1,500 to 2,500 μm in width. In one embodiment, the analyzer is configured so that a linear velocity of the particles in the sample is such that the particles are not substantially blurred in the image. In one embodiment, the analyzer is configured so that a light source is additionally configured to illuminate the ribbon-shaped sample stream and the autofocus pattern.
[000514] In one aspect, the present disclosure provides a method for imaging particles in urine using a PIOAL, as described in this document, which comprises: providing a visual analyzer for a sample comprising particles suspended in a liquid; establish a flow that has laminar sections that are of higher and lower viscosity in the analyzer, in which the analyzer additionally comprises: a flow cell coupled to a sample source and to a source of a PIOAL, in which the flow cell defines an internal flow path, in which the flow cell directs a flow of the sample enveloped with the PIOAL through a visualization zone in the flow cell; a high-resolution optical imaging device with a lens on an optical geometric axis that crosses the ribbon-shaped sample stream, the relative distance between the high-resolution optical imaging device and the flow cell being variable by operation a motor drive, to separate and collect a scanned image in a photosensor matrix; an autofocus pattern that has a fixed position in relation to the flow cell, the autofocus pattern being located at a distance from the plane of the sample stream in ribbon form; a light source configured to illuminate the ribbon-shaped sample stream and the autofocus pattern; and at least one digital processor coupled to operate the motor drive and to analyze the scanned image, where the processor is configured to determine a focus position of the autofocus pattern and to relatively shift the high resolution optical imaging device and the flow cell over the displacement distance from the focused position, so that the high-resolution optical imaging device is focused on the ribbon-shaped sample stream. In one embodiment, the particles comprise at least one spherical particle. In one embodiment, the particles comprise at least one non-spherical particle. In one embodiment, the method comprises a feature in which an image projection of non-spherical particles under imaging conditions is increased in the focal plane of the high-resolution optical imaging device. In one embodiment, the particles comprise at least one among erythrocytes (RBCs), dysmorphic erythrocytes, leukocytes (WBCs), neutrophils, lymphocytes, phagocytic cells, eosinophils, basophils, squamous epithelial cells, transitional epithelial cells, decoy cells, renal tubular epithelial cells , calculi, crystals, bacteria, yeast, parasites, oval fat bodies, fat droplets, sperm, mucus, trichomonas, cell nodules and cell fragments.
[000515] In one embodiment, at least 50% of the non-spherical particles are aligned in a plane substantially parallel to the direction of flow, so that the image projection of non-spherical particles under imaging conditions in the focal plane of the imaging device high optical resolution (HORID) is increased or maximized. In one embodiment, at least 90% of the non-spherical particles are aligned in a plane substantially parallel to the direction of flow, so that the image projection of non-spherical particles under imaging conditions in the HORID focal plane is increased or maximized. In one embodiment, at least 92% of the non-spherical particles are aligned in a plane substantially parallel to the direction of flow, so that the image projection of non-spherical particles under imaging conditions in the HORID focal plane is increased or maximized.
[000516] In one embodiment, at least 50% of the spherical particles are aligned, that is, intraparticle structures of the spherical particles are positioned, repositioned and / or better positioned substantially parallel to the flow direction. For example, spherical cells have at least 50% of organelles, nuclear structures, cytosolic structures or granules in the focal plane of the analyzer. In one embodiment, at least 90% of the intraparticle structures of spherical particles, such as cells, are positioned repositioned and / or better positioned substantially parallel to the direction of flow. In one embodiment, at least 92% of the intraparticle structures of spherical particles, such as cells, are positioned repositioned and / or better positioned substantially parallel to the flow direction.
[000517] In one modality, the categorization, subcategorization and particle counting are based on the visual distinctions selected from at least one among size, shape, symmetry and contour. In one embodiment, imaging is digitized imaging. In one embodiment, imaging is performed by microscopy. In one embodiment, imaging is performed manually using conventional microscopy. In one embodiment, imaging is automated. In one embodiment, the particle can include any of the particles disclosed in this document. In one embodiment, imaging is performed using an analyzer in any of the modalities disclosed in this document.
[000518] Each of the calculations or operations described here can be done using a computer or another processor that has hardware, software and / or firmware. The various steps of the method can be performed by modules, and the modules can comprise any of a wide variety of digital and / or analog data processing hardware and / or software arranged to perform the method steps described here. The modules optionally comprise data processing hardware adapted to perform one or more of these steps having appropriate machine programming code associated with it, the modules of two or more steps (or portions of two or more steps) being integrated into a single board or separated on different processor boards on any of a wide variety of integrated and / or distributed processing architectures. These methods and systems will often use a tangible medium including machine-readable code with instructions for performing the steps in the method described above. Suitable tangible media may comprise a memory (including a volatile memory and / or a non-volatile memory), a storage medium (such as a magnetic recording on a floppy disk, a hard disk, a tape, or the like; on an optical memory, such as a CD, CD-R / W, CD-ROM, DVD or the like; or any other digital or analog storage medium), or the like.
[000519] All patents, publications, scientific articles, websites and other documents and materials referred to or mentioned in this document are indicative of the skill levels of those elements versed in the technique to which the invention belongs, and each such document and material referred to it is incorporated herein, by reference, with the same scope as if it had been incorporated herein by reference, in its entirety individually or presented in this document in its entirety. Applicants reserve the right to physically incorporate into this specification any and all material and information from such patents, publications, scientific articles, websites, electronically available information, and other materials or documents referred to.
[000520] The specific methods and compositions described in this document are representative of preferred modalities and are exemplary and are not intended to limit the scope of the invention. Other objectives, aspects and modalities will occur for those elements versed in the technique under the consideration of this specification, and are covered by the spirit of the invention, as defined by the scope of the claims. It will be readily apparent to a person skilled in the art that various substitutions and modifications can be made to the invention disclosed in this document, without departing from the scope and spirit of the invention. The invention illustratively described in the present document can be suitably practiced in the absence of any element or elements, or limitations or limitations, which is not specifically disclosed in the present document as essential. Thus, for example, in each case in the present document, in modalities or examples of the present invention, any of the terms "comprise", "consist essentially of" and "consist of" can be replaced by any one of the other two terms in the specification. In addition, the terms "understand", "include", "contain", etc. should be read in an expansive manner and without limitation. The methods and processes illustratively described in this document can be adequately practiced in different orders of stages, and that they are not necessarily restricted to the orders of stages indicated in this document or in the claims. In addition, for use in the present invention and the appended claims, the singular forms "one" and "o" include the reference of the plural, except where the context clearly determines otherwise. Under no circumstances may the patent be interpreted as limited to the specific examples, modalities or methods specifically disclosed in this document. Under no circumstances may the patent be construed as limited by any statement made by any examiner or any other officer or employee of the trademark and patent office, except where such statement is specifically and without qualification or reservation expressly adopted in a responsive writing by claimants. .
[000521] The terms and expressions that have been used are used as terms of description and not of limitation, and there is no intention in using such terms and expressions to exclude any equivalent of the features shown and described or portions thereof, but it is recognized that several modifications are possible within the scope of the invention, as claimed. Thus, it will be understood that, although the present invention has been specifically revealed by preferential modalities and optional features, the modification and variation of the concepts disclosed herein can be used by those skilled in the art, and that such modifications and variations are considered to be covered by the scope of that invention, as defined by the appended claims.
[000522] The invention has been described in a broad and generic way in this document. Each of the more limited species and subgeneric groupings that are included in the generic disclosure also form part of the invention. This includes the generic description of the invention with a proviso or negative limitation that removes any subject of its kind, regardless of whether or not the material eliminated is specifically mentioned in this document.
[000523] Other modalities are covered by the following claims. In addition, where the features or aspects of the invention are described in terms of Markush groups, those skilled in the art will recognize that the invention is thus described in terms of any individual member or subgroup of members of the Markush group.
[000524] Different dispositions of the components represented in the drawings or described above, as well as the components and steps not shown or described, are possible. Similarly, some features and sub-combinations are useful and can be used without reference to other features and sub-combinations. The modalities of the invention have been described for illustrative and non-restrictive purposes, and alternative modalities will be apparent to readers of this patent. In certain cases, the steps of the method or operations can be performed or performed in different orders, or the operations can be included, deleted or modified. It can be understood that, in certain aspects of the invention, a single component can be replaced by multiple components, and multiple components can be replaced by a single component, to provide an element or structure or to perform a certain function or functions. Except where this substitution is not operational to practice certain modalities of the invention, this substitution is considered to be within the scope of the invention. Consequently, the present invention is not limited to the modalities described above or shown in the drawings, and various modalities and modifications can be made without departing from the scope of the claims below.

权利要求:
Claims (13)
[0001]
1. Method for particle imaging using a particle analysis system configured for geometric hydrofocusing, the particles included within a sample of body fluid (25), the method characterized by the fact that it comprises: injecting a wrapping fluid (426) along a flow path (422) of a flow cell (22, 420) of the particle analyzer; inject the body fluid sample from a sample fluid injection tube (29, 412, 400d) at a flow rate in the circulating envelope fluid (426) within the flow cell (22, 420) in order to supply a sample stream (32, 428) that has a first thickness adjacent to the injection tube (29, 412, 400d), in which the flow path (422) of the flow cell (22, 420) has a decrease in flow path size (21, 419) such that the thickness of the sample stream (32, 428) decreases from the initial thickness to a second thickness adjacent to an image capture site (432); focus on an image capture device (430) by imaging an imaging target (44, 1344, 1470, 1472c, 1476c) that has a fixed position in relation to the flow cell, where the imaging target and the sample stream (32, 428) defines a predetermined displacement distance (52) along the imaging axis (1450a); and acquiring a focused image of a first plurality of particles from the first sample (25) along the geometry axis (1450a) at the image capture site (432) of the flow cell (22, 420), suitable for the characterization and counting of particles, within the stream with the image capture device (430), in which: the image capture device (430) is focused on the sample stream (32, 428) using the imaging step focusing and the predetermined displacement distance (52), the decrease in size of the flow path (21, 419) is defined by a portion of the proximal flow path (21a) that has a proximal thickness and a portion of the distal flow path (21b) which has a distal thickness less than the proximal thickness, a downstream end (427a) of the sample fluid injection tube (29, 412, 400d) is positioned distal to the proximal flow path portion (21a), the wrapping fluid (426) has a first velocity At the downstream end (427a) of the fluid injection tube (29, 412, 400d), the body fluid sample (25) has a second velocity at the downstream end (427a) of the fluid injection tube (29, 412, 400d), and the first speed is greater than the second speed, and the speed difference between the casing (426) and the body fluid samples (25), in combination with the decrease in the size of the flow path and in the sample flow rate, it is effective for releasing cells in the sample (25) from the sample fluid injection tube (29, 412, 400d) to the image capture site (432) in four seconds or less, and in that the body fluid sample (25) has a viscosity of the sample and the wrap fluid (426) has a viscosity of the wrap fluid which is different from the viscosity of the sample.
[0002]
2. Method according to claim 1, characterized by the fact that the body fluid sample (25) is a urine fluid sample.
[0003]
3. Method according to claim 1, characterized by the fact that the sample fluid (25) moves from an outlet port (P, 331, 431) of the sample fluid injection tube (29, 412, 400d) for the geometric imaging axis (1450a) at the image capture site (432) in about 1.5 seconds.
[0004]
4. Method according to claim 1, characterized by the fact that the decrease in size of the flow path is defined by the opposite walls (412a, 423a) of the angulation of the flow path (422) radially inward along the path flow (422) generally symmetrical on a transverse plane (451a) that bisects the first and second thicknesses of the sample fluid stream.
[0005]
5. Method according to claim 1, characterized by the fact that the flow cell (22, 420) is configured to receive the wrapping fluid (426) from a wrapping fluid source in the flow path (422) in a first flow direction that is perpendicular to the second flow direction of the envelope fluid along the flow path at the imaging site (432).
[0006]
6. Method according to claim 1, characterized by the fact that the imaging target (44, 1344, 1470, 1472c, 1476c) is fixed in the flow cell (22, 420).
[0007]
7. Method according to claim 1, characterized by the fact that the sample stream (32, 428) has a third speed of 20 to 200 mm / s at the image capture site.
[0008]
8. Method, according to claim 1, characterized by the fact that the fraction of the second speed to the first speed is in the range of 0.5 to less than 1.
[0009]
9. Method, according to claim 1, characterized by the fact that it also comprises the production of a sample stream in tape format (32, 428) with a width in the range of 500 to 3,000 μm.
[0010]
10. Particle analysis system that performs geometric hydrofocusing for particle imaging in a sample of body fluid, the system characterized by the fact that it comprises: a flow cell (22, 420) that has a flow path (422) configured to transmit a flow of envelope fluid (426); a sample fluid injection system in fluid communication with the flow path (422) and configured to inject the sample into the circulating envelope fluid (426) within the flow cell (22, 420) in order to provide a flow current sample fluid (32, 426) having a first thickness adjacent to the injection tube (29, 412, 400d), where the flow path (422) of the flow cell (22, 420) has a decrease in size flow path (21, 419), so that the thickness of the sample fluid stream decreases from the initial thickness to a second thickness adjacent to an image capture site (432); an image capture device (430) aligned with the image capture site (432) in order to image a plurality of particles from the first sample fluid (426) at the image capture site (432) of the flow cell (22, 420); a focusing mechanism configured to adjust a focal state of the image capture device in relation to the flow cell; an imaging target (44, 1344, 1470, 1472c, 1476c) that has a fixed position relative to the flow cell (22, 420), where the imaging target (44, 1344, 1470, 1472c, 1476c) and the sample stream (32, 426) defines a travel distance (52) along the geometry axis (1450a); a processor (440); and a focusing module comprising a tangible medium that incorporates machine-readable code executed in the processor (440) to operate the focusing mechanism to adjust the focal state of the image capture device (430), suitable for the characterization and counting of images particles, using the displacement distance (52), in which the sample fluid injection system is configured to release the sample fluid (25) in such a way that the sample fluid has a transit time through the cell flow within a range from about 2 to 4 seconds, and where the sample fluid injection system is configured so that the wrapping fluid (426) has a first speed at the downstream end of the injection tube of fluid (9, 412, 400d), the body fluid sample (25) has a second speed at the downstream end (427a) of the fluid injection tube (29, 412, 400d) and the first speed is greater than second speed, and in which the body fluid sample (25) has a sample viscosity and the wrap fluid (426) has a wrap fluid viscosity that is different from the sample viscosity.
[0011]
11. System according to claim 10, characterized by the fact that the body fluid sample (25) is a urine fluid sample.
[0012]
12. System according to claim 10, characterized by the fact that the decrease in flow path size (21, 419) is defined by the opposite walls (412a, 423a) of the flow path angle (422) radially to in along the generally symmetrical flow path over a transverse plane (451a) that bisects the first and second thickness of the sample fluid stream.
[0013]
13. System according to claim 10, characterized by the fact that the flow cell (22, 420) is configured to receive the wrapping fluid (426) from a wrapping fluid source (426) in the flow path (422) in a first flow direction that is perpendicular to the second flow direction of the envelope fluid (426) along the flow path at the imaging site (432).

类似技术:

---

公开号 | 公开日 | 专利标题

---

BR112015020255B1|2021-02-23|method for particle imaging using a particle analysis system configured for geometric hydro-focusing, and particle analysis system that performs geometric hydro-focusing for particle imaging in a body fluid sample

---

US10060846B2|2018-08-28|Hematology systems and methods

---

KR102044593B1|2019-11-13|Hematology systems and methods

---

JP2016520807A5|2019-01-17|

同族专利:

---

公开号 | 公开日

---

WO2014146062A3|2014-12-18|

---

WO2014146062A2|2014-09-18|

---

US9857361B2|2018-01-02|

---

JP2016519760A|2016-07-07|

---

US20140329265A1|2014-11-06|

---

BR112015020255A2|2017-07-18|

---

CN105122034A|2015-12-02|

---

US20180143182A1|2018-05-24|

---

JP6521940B2|2019-05-29|

---

EP2972215A2|2016-01-20|

---

KR20150129707A|2015-11-20|

---

KR102083051B1|2020-02-28|

---

US10794900B2|2020-10-06|

---

CN105122034B|2019-03-29|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

US3822095A|1972-08-14|1974-07-02|Block Engineering|System for differentiating particles|

---

US3894845A|1973-05-24|1975-07-15|Bernard Mcdonald|Urine collection and analysis device|

---

US3988209A|1973-05-24|1976-10-26|Mcdonald Bernard|Microorganism analysis device|

---

GB1471976A|1974-09-20|1977-04-27|Coulter Electronics|Particle sensing apparatus including a device for orientinggenerally flat particles|

---

US4338024A|1980-05-02|1982-07-06|International Remote Imaging Systems, Inc.|Flow analyzer and system for analysis of fluids with particles|

---

US4393466A|1980-09-12|1983-07-12|International Remote Imaging Systems|Method of analyzing particles in a dilute fluid sample|

---

US4612614A|1980-09-12|1986-09-16|International Remote Imaging Systems, Inc.|Method of analyzing particles in a fluid sample|

---

US4473530A|1980-09-24|1984-09-25|Villa Real Antony Euclid C|Compact sanitary urinalysis unit|

---

DE3315195A1|1982-04-29|1983-11-03|International Remote Imaging Systems Inc., 91311 Chatsworth, Calif.|METHOD FOR ALIGNING PARTICLES IN A FLUID SAMPLE|

---

US4622298A|1984-08-09|1986-11-11|Becton, Dickinson And Company|Detection and quantitation of microorganisms, leukocytes and squamous epithelial cells in urine|

---

AU563260B2|1984-11-29|1987-07-02|International Remote Imaging Systems Inc.|Method of operating a microscopic instrument|

---

US5132232A|1985-07-30|1992-07-21|V-Tech, Inc.|Method and apparatus for preparation of liquids for examination|

---

DE3719302C1|1987-06-10|1988-12-29|Hoyer Gmbh & Co|Device for examining urine|

---

US5123055A|1989-08-10|1992-06-16|International Remote Imaging Systems, Inc.|Method and an apparatus for differentiating a sample of biological cells|

---

JP2939647B2|1990-07-24|1999-08-25|シスメックス株式会社|Automatic focus adjustment method for flow imaging cytometer|

---

JP2874746B2|1990-11-22|1999-03-24|シスメックス株式会社|Flow cell mechanism in flow imaging cytometer|

---

JP3111706B2|1992-02-18|2000-11-27|株式会社日立製作所|Particle analyzer and particle analysis method|

---

JP3215175B2|1992-08-10|2001-10-02|シスメックス株式会社|Particle analyzer|

---

JP3052665B2|1993-01-26|2000-06-19|株式会社日立製作所|Flow cell device|

---

JP3290786B2|1993-11-26|2002-06-10|シスメックス株式会社|Particle analyzer|

---

US5457523A|1994-05-27|1995-10-10|Xerox Corporation|Ferrofluid media charging of photoreceptors|

---

US5876697A|1994-08-04|1999-03-02|Gakko Houjin Toin Gakuen|Method for the production of microbubble-type ultrasonic contrast agent using fatty acid surfactants|

---

DE69535413T2|1994-10-20|2007-11-29|Sysmex Corp.|Reagent and method for analyzing solid components in urine|

---

AU4741796A|1994-12-23|1996-07-19|International Remote Imaging Systems Inc.|Method and apparatus of analyzing particles in a fluid sample and displaying same|

---

US5619032A|1995-01-18|1997-04-08|International Remote Imaging Systems, Inc.|Method and apparatus for automatically selecting the best focal position from a plurality of focal positions for a focusing apparatus|

---

JPH08320285A|1995-05-25|1996-12-03|Hitachi Ltd|Particle analyzing device|

---

JPH0989753A|1995-09-25|1997-04-04|Hitachi Ltd|Particle analyzer|

---

US6184978B1|1996-05-15|2001-02-06|International Remote Imaging Systems, Inc.|Method and apparatus for verifying uniform flow of a fluid sample through a flow cell and distribution on a slide|

---

JP3867880B2|1998-04-08|2007-01-17|シスメックス株式会社|Apparatus and method for distinguishing urine red blood cells|

---

US6130745A|1999-01-07|2000-10-10|Biometric Imaging, Inc.|Optical autofocus for use with microtiter plates|

---

US6632676B1|1999-09-24|2003-10-14|Clinical Diagnostic Solutions|Multi-purpose reagent system and method for enumeration of red blood cells, white blood cells and thrombocytes and differential determination of white blood cells|

---

CA2396015A1|1999-12-29|2001-07-05|Union Biometrica, Inc.|High viscosity sheath reagent for flow cytometry|

---

US6974938B1|2000-03-08|2005-12-13|Tibotec Bvba|Microscope having a stable autofocusing apparatus|

---

PT1301894E|2000-04-24|2009-08-21|Iris Int Inc|Multi-neural net imaging apparatus and method|

---

US7236623B2|2000-04-24|2007-06-26|International Remote Imaging Systems, Inc.|Analyte recognition for urinalysis diagnostic system|

---

US6809804B1|2000-05-11|2004-10-26|Becton, Dickinson And Company|System and method for providing improved event reading and data processing capabilities in a flow cytometer|

---

CA2349995A1|2000-06-14|2001-12-14|Lianne Ing|Viewing particles in a relatively translucent medium|

---

JP2003005088A|2001-06-22|2003-01-08|Nikon Corp|Focusing device for microscope and microscope having the same|

---

BR0213520A|2001-10-26|2006-05-23|Immunivest Corp|method for diagnosing the severity of a disease in a test subject; and, testing kit for screening a patient sample for the presence of circulating cancer cells.|

---

JP4021183B2|2001-11-29|2007-12-12|オリンパス株式会社|Focus state signal output device|

---

JP4370554B2|2002-06-14|2009-11-25|株式会社ニコン|Autofocus device and microscope with autofocus|

---

US20060148028A1|2002-09-05|2006-07-06|Naohiro Noda|Method for detecting microbe or cell|

---

JP4754828B2|2002-11-18|2011-08-24|イリスインターナショナルインコーポレイテッド|Multi-level controller system|

---

US6825926B2|2002-11-19|2004-11-30|International Remote Imaging Systems, Inc.|Flow cell for urinalysis diagnostic system and method of making same|

---

GB0228301D0|2002-12-04|2003-01-08|Imp College Innovations Ltd|Engineering redox proteins|

---

DE10308171A1|2003-02-27|2004-09-09|Leica Microsystems Jena Gmbh|Automatic focusing method|

---

DK1608963T3|2003-03-28|2010-04-06|Inguran Llc|Apparatus and methods for providing sex-sorted animal sperm|

---

US7324694B2|2003-05-23|2008-01-29|International Remote Imaging Systems, Inc.|Fluid sample analysis using class weights|

---

US20070292346A1|2004-03-25|2007-12-20|Rong Fan|Lng105 Antibody Composition and Methods of Use, and Use of Lng105 to Assess Lung Cancer Risk|

---

US7394943B2|2004-06-30|2008-07-01|Applera Corporation|Methods, software, and apparatus for focusing an optical system using computer image analysis|

---

JP2006039315A|2004-07-28|2006-02-09|Hamamatsu Photonics Kk|Automatic focusing device and microscope using the same|

---

DE102005034441A1|2005-07-22|2007-02-22|Carl Zeiss Microimaging Gmbh|microscope objective|

---

CN101278190B|2005-09-29|2012-12-19|奥林巴斯株式会社|Focal position determining method, focal position determining apparatus, feeble light detecting apparatus and feeble light detecting method|

---

JPWO2007145091A1|2006-06-15|2009-10-29|株式会社ニコン|Cell culture equipment|

---

DE102006027836B4|2006-06-16|2020-02-20|Carl Zeiss Microscopy Gmbh|Microscope with auto focus device|

---

SE531041C2|2006-07-17|2008-11-25|Hemocue Ab|Platelet count|

---

US7799575B2|2006-11-07|2010-09-21|Genetix Limited|Flow cytometers|

---

JP2008276070A|2007-05-02|2008-11-13|Olympus Corp|Magnifying image pickup apparatus|

---

US9602777B2|2008-04-25|2017-03-21|Roche Diagnostics Hematology, Inc.|Systems and methods for analyzing body fluids|

---

DE102008050347B4|2008-10-02|2011-01-20|Siemens Aktiengesellschaft|Method, magnetic resonance system and data carrier for determining a kidney function parameter|

---

JP2010151566A|2008-12-25|2010-07-08|Hitachi High-Technologies Corp|Particle image analysis method and apparatus|

---

JP2010213598A|2009-03-16|2010-09-30|Kyokuto Seiyaku Kogyo Kk|Method for examining efficacy of antimicrobial agent to microorganism|

---

US8362409B2|2009-10-29|2013-01-29|Applied Precision, Inc.|System and method for continuous, asynchronous autofocus of optical instruments|

---

US9404160B2|2009-12-22|2016-08-02|Becton, Dickinson And Company|Methods for the detection of microorganisms|

---

CA2814552A1|2010-10-27|2012-05-03|Capitalbio Corporation|Luminophore-labeled molecules coupled with particles for microarray-based assays|

---

CA2839542A1|2011-06-17|2012-12-20|Constitution Medical, Inc.|Fixative and staining solutions|

---

KR101849974B1|2011-09-16|2018-04-19|삼성전자주식회사|Numerical aperture controlling unit, variable optic probe and depth scanning method using the same|

---

US9316635B2|2013-03-15|2016-04-19|Iris International, Inc.|Sheath fluid systems and methods for particle analysis in blood samples|

---

EP2972208B1|2013-03-15|2018-06-13|Iris International, Inc.|Method and composition for staining and sample processing|

---

WO2014145989A1|2013-03-15|2014-09-18|Iris International, Inc.|Method and composition for staining and processing a urine sample|

---

JP6112066B2|2014-05-27|2017-04-12|横河電機株式会社|Storage unit for connecting modular electronic devices|US9316635B2|2013-03-15|2016-04-19|Iris International, Inc.|Sheath fluid systems and methods for particle analysis in blood samples|

---

EP2972208B1|2013-03-15|2018-06-13|Iris International, Inc.|Method and composition for staining and sample processing|

---

EP3207358A1|2014-10-17|2017-08-23|Iris International, Inc.|Systems and methods for imaging fluid samples|

---

CN107106095B|2014-12-22|2021-02-05|雷纳尔森瑟公司|Apparatus, system and method for urinalysis|

---

US10761011B2|2015-02-24|2020-09-01|The University Of Tokyo|Dynamic high-speed high-sensitivity imaging device and imaging method|

---

CN105067488A|2015-08-11|2015-11-18|长春瑞克医疗科技有限公司|Particle imaging chamber|

---

WO2017073737A1|2015-10-28|2017-05-04|国立大学法人東京大学|Analysis device|

---

CN105572020B|2016-01-19|2018-05-22|西南交通大学|A kind of nano-particle method of counting|

---

CN105671123B|2016-01-19|2018-11-20|西南交通大学|The method of counting of bacterium in a kind of liquid|

---

WO2017141063A1|2016-02-17|2017-08-24|Waterscope International Zrt.|Digital holographic automatic microscope with through flowing cell|

---

KR20170099737A|2016-02-23|2017-09-01|노을 주식회사|Contact-type staining patch and staining method using the same|

---

EP3220130A1|2016-03-16|2017-09-20|Siemens Healthcare GmbH|High accuracy 5-part differential with digital holographic microscopy and untouched leukocytes from peripheral blood|

---

TWI580963B|2016-04-20|2017-05-01|光寶電子（廣州）有限公司|Biological detecting cartridge and flowing method of detected fluid thereof|

---

WO2018034241A1|2016-08-15|2018-02-22|国立大学法人大阪大学|Electromagnetic wave phase/amplitude generation device, electromagnetic wave phase/amplitude generation method, and electromagnetic wave phase/amplitude generation program|

---

US10705011B2|2016-10-06|2020-07-07|Beckman Coulter, Inc.|Dynamic focus system and methods|

---

CN106501256A|2016-10-25|2017-03-15|许静|A kind of fluid mediaautomatic identification equipment|

---

JP6875930B2|2017-05-31|2021-05-26|シスメックス株式会社|Urinalysis device and urine analysis method|

---

CN107091800A|2017-06-06|2017-08-25|深圳小孚医疗科技有限公司|Focusing system and focus method for micro-imaging particle analysis|

---

CN107402212A|2017-08-28|2017-11-28|深圳小孚医疗科技有限公司|A kind of excrement application liquid detection means|

---

US10585028B2|2017-10-20|2020-03-10|Charted Scientific, Inc.|Method and apparatus for optical analysis|

---

AU2018385767A1|2017-12-15|2020-06-11|Gastroklenz Inc.|Sensor monitoring system for in-dwelling catheter based treatments|

---

JP2019154339A|2018-03-14|2019-09-19|株式会社リコー|Droplet formation head, droplet formation device and droplet formation method|

---

US10761007B2|2018-05-31|2020-09-01|Yokogawa Fluid Imaging Technologies, Inc.|System and method for light obscuration enhanced imaging flow cytometry|

---

CN110118717A|2019-05-28|2019-08-13|北京唯公医疗技术有限公司|The liquid channel system and its application method and flow cytometer of flow cytometer|

---

CN110118718A|2019-05-28|2019-08-13|深圳唯公生物科技有限公司|Liquid fluid system, test method, the regulation method of negative pressure device and flow cytometer|

---

USD903126S1|2019-06-26|2020-11-24|Gastroklenz Inc.|Monitoring device|

---

WO2020264422A1|2019-06-26|2020-12-30|Gastroklenz Inc.|Systems, devices, and methods for fluid monitoring|

---

US10620104B1|2019-10-17|2020-04-14|Horiba Instruments Incorporated|Apparatus and method for observation of microscopic movements and counting of particles in colloids|

---

RU2747790C1|2020-01-30|2021-05-14|Сергей Анатольевич Жданов|Flowing microscope for measuring particle size distribution of liquid-suspended particles|

---

WO2021247918A1|2020-06-03|2021-12-09|Kinetic River Corp.|Configurable particle analyzer apparatuses and methods|

法律状态:
2018-11-13| B06F| Objections, documents and/or translations needed after an examination request according art. 34 industrial property law|

---

2020-01-21| B06U| Preliminary requirement: requests with searches performed by other patent offices: suspension of the patent application procedure|

---

2020-11-17| B09A| Decision: intention to grant|

---

2021-02-23| B16A| Patent or certificate of addition of invention granted|Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/03/2014, OBSERVADAS AS CONDICOES LEGAIS. |

优先权:

---

申请号 | 申请日 | 专利标题

---

US201361799014P| true| 2013-03-15|2013-03-15|

---

US61/799,014|2013-03-15|

---

US14/217,228|2014-03-17|

---

US14/217,228|US9857361B2|2013-03-15|2014-03-17|Flowcell, sheath fluid, and autofocus systems and methods for particle analysis in urine samples|

---

PCT/US2014/030940|WO2014146062A2|2013-03-15|2014-03-18|Flowcell, sheath fluid, and autofocus systems and methods for particle analysis in urine samples|

---